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1 Summary
Summary
Alveolar echinococcosis (AE), a severe and life-threatening disease is caused by
the small fox tapeworm Echinococcus multilocularis. Currently, the options of
chemotherapeutic treatment are very limited and are based on benzimidazole com-
pounds, which act merely parasitostatic in vivo and often display strong side ef-
fects. Therefore, new therapeutic drugs and targets are urgently needed.
Evolutionarily conserved signaling systems of E. multilocularis were suggested to
be involved in host-parasite cross-communication and the development of the par-
asite larvae in the course of the disease. In the present work the role of two evo-
lutionarily conserved signalling pathways in E. multilocularis has been studied
in regard to host-parasite interaction and the possible use in anti-AE chemother-
apy.
Previously, two insulin receptors, EmIR1 and EmIR2 were described in E. mul-
tilocularis and preliminary results indicated that host insulin plays a role in the
larval development of this cestode. In this work the influence of host insulin on
the parasite development was further studied. Host insulin significantly increased
parasite metacestode vesicle formation from primary cell cultures and protoscole-
ces. Furthermore, DNA de novo synthesis and glucose uptake in metacestode vesi-
cles were increased by insulin. Further study of the signalling processes revealed
that EmIR2 is able to bind insulin, IGF-I and Echinococcus insulin-like peptides
in vitro and is phosphorylated in the parasite in vivo upon stimulation with ex-
ogenous insulin. Additionally, I could show that insulin stimulation activates the
parasite PI3K/ Akt signalling. Inhibition of the Echinococcus insulin receptors and
PI3K led to a significant decrease in survival and development of parasite larvae
and blocked signal transduction via the PI3K/Akt pathway.
Taken together, these results showed that host-parasite cross-communication via
the E. multilocularis insulin signalling pathway is possible and that host insulin
has an important influence on Echinococcus survival and development. Conse-
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quently, insulin signalling pathway might be a promising target for anti-AE chemother-
apy.
As additional possible drug targets, ˝extitEchinococcus Abl kinases were charac-
terised for the first time in the present work. Two Abl kinase and one Src-Abl
hybrid kinase are expressed in the E. multilocularis larval stages. The anti-cancer
drug Imatinib, directed against human Abl-kinases, proved to be very effective
also against E. multilocularis larvae. Imatinib drastically decreased the survival
of Echinococcus larvae in vitro and had severe influence on parasite morphology
after short term treatment.
To complement this work, further inhibitors were tested in the E. multilocularis
in vitro cultivation systems. Among these was the JNK inhibitor AS601245, which
showed highly synergistic effects in combination with Imatinib. Additionally, pre-
liminary results indicated the cystein protease inhibitor K11777 as an effective
compound in the culture system.
Taken together, this work yielded important insights into host-parasite commu-
nication during echinococcosis and several promising targets for future anti AE-
chemotherapy development.
Zusammenfassung
Die alveola¨re Echinokokkose ist eine ernste und lebensgefa¨hrliche Erkrankung,
die durch den kleinen Fuchsbandwurm ausgelo¨st wird. Die gegenwa¨rtigen chemo-
therapeutischen Behandlungsmo¨glichkeiten beschra¨nken sich auf die Behandlung
mit Benzimidazolen, die in vivo nur parasitostatische Wirkung besitzen und ha¨ufig
sehr starke Nebenwirkungen aufweisen. Aus diesem Grund besteht ein dringen-
des Bedu¨rfnis nach neuen Medikamenten und Angriffszielen fu¨r diese.
Es wird angenommen, dass evolutionsgeschichtlich konservierte Signalsysteme an
der Wirt-Parasit Kreuzkommunikation und der Entwicklung des Parasiten im Ver-
lauf der Erkrankung beteiligt sind. In der vorliegenden Arbeit wurde die Rolle
zweier evolutionsgeschichtlich konservierter Signalsysteme in E. multilocularis in
Hinblick auf die Wirt-Parasiten Interaktion und dem mo¨glichen Nutzen in der AE
Chemotherapie untersucht.
In fru¨heren Arbeiten konnten zwei Insulin Rezeptoren in E. multilocularis beschrieben
werde und vorla¨ufige Ergebnisse deuten darauf hin, dass Wirtsinsulin eine Rolle in
10
1 Summary
der Larvenentwicklung dieses Cestoden spielt. In dieser Arbeit wurde wurde der
Einfluss von Wirtsinsulin auf die Parasiten Entwicklung weiter studiert. Wirtsin-
sulin stimulierte die Vesikelbildung aus Prima¨rzellen und Protoscolizes signifikant.
Weiterhin wurde die DNA de novo Synthese und die Glucose Aufnahme in Metaces-
toden Vesikeln versta¨rkt. Zusa¨tzliche Untersuchungen der Signal-Prozesse er-
gaben, dass EmIR2 in der Lage ist, Insulin, IGF-I und die Echinococcus Insulin-
a¨hnlichen Peptide zu binden und dass EmIR2 in Antwort auf die Stimulation mit
Insulin phosphoryliert wird. Zusa¨tzlich konnte ich zeigen, dass diese Stimula-
tion die PI3K/Akt Kaskade des Parasiten aktiviert. Die Inhibition der Echinococ-
cus Insulin Rezeptoren und der PI3K fu¨hrte zu einer signifikanten Reduktion des
U¨berlebens und der Entwicklung der Parasitenlarven und blockierte die Signal-
transduktion u¨ber den PI3K/Akt Signalweg.
Zusammengefasst zeigen diese Ergebnisse, dass eine Wirt-Parasiten Kreuzkom-
munikation u¨ber den E. multilocularis Insulin Signalweg mo¨glich ist und das Wirtsin-
sulin einen wichtigen Einfluss auf das U¨berleben und die Entwicklung des Para-
siten hat. Folglich ko¨nnte der Insulin Signalweg ein vielversprechender Angriff-
spunkt fu¨r die anti-AE Chemotherapie sein.
In dieser Arbeit wurden zum ersten Mal Abl Kinasen in E. multilocularis beschrieben.
Zwei Abl Kinasen und eine Src-Abl Hybridkinase werden in den E. multilocularis
Larvenstadien exprimiert. Das Krebsmedikament Imatinib hat sich als sehr ef-
fektiv gegen E. multilocularis erwiesen. Imatinib verringerte das U¨berleben von
Echinococcus Larven in vitro drastisch und hatte starken Einfluss auf die Mor-
phologie des Parasiten nach kurzzeitiger Behandlung.
Um diese Arbeit zu vervollsta¨ndigen wurden weitere Inhibitoren in den E. mul-
tilocularis in vitro Kultivierungssystemen getestet. Unter diesen war der JNK
Inhibitor AS601245, der stark synergistische Effekte in Kombination mit Ima-
tinib zeigte. Zusa¨tzlich deuten vorla¨ufige Ergebnisse darauf hin, dass der Cys-
tein Protease Inhibitor K11777 eine effektive Substanz in den Kultursystemen
darstellt.
Zusammengefasst brachte diese Arbeit wichtige Erkenntnisse u¨ber die Wirts-Parasiten
Interaktion in E. multilocularis und einige vielversprechende Angriffspunkte fu¨r
zuku¨nftige anti-AE Chemotherapie konnten identifiziert werden.
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2 Introduction
2.1 The small fox tapeworm Echinococcus multilocularis
2.1.1 Phylogeny and epidemiology of E. multilocularis
The small fox tape worm Echinococcus multilocularis belongs to the class Ces-
toda in the phylum of Platyhelminthes (flatworms). The Platyhelminthes is com-
prised of the classes cestoda, trematoda and turbellarians. All Platyhelminthes
have a parasitic life-cycle with exeption of turbellarians and can be allocated to
the Bilaterata (Bilateria) and Protostoma. The protostomes can furthermore be
divided into the Ecdysozoa, which include the Nematoda and Arthropoda and the
Lophotrochozoa that consists of Platyhelminthes, Annelida and Mollusca and sev-
eral other phyla [1]. Important model organisms from Ecdysozoa for genetics and
developmental biology are the nematode Caenorhabditis elegans and the arthro-
pod Drosophila melanogaster. The parasitic worms of the Nematoda and Platy-
helminthes are combined in the historic term ”helminths”. In Fig. 2.1 a summary of
the phylogenetic organization of the helminths is depicted.
Bilaterata
Protostomia
Deuterostomia Vertebrata
Ecdysozoa
Arthropoda
Nematoda Cenorhabditis elegans
Lophotrochazoa
Platyhelminthes
Trematoda Schistosoma ssp.
Cestoda
Echinococcus ssp.
Taenia ssp.
Hymenolepis ssp.
Turbellaria Planaria
Mollusca
Annelida
Fig. 2.1: Phylogenetic organisation of helminths within the Bilaterata [1]. The classification of ces-
toda is marked by boxes, example species are printed in italics
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Echinococcus species are found in a variety of final and intermediate hosts and
the genus Echinococcus contains at least eight species. The small fox tapeworm
E.multilocularis and the dog tapeworm E. granulosus have the highest impact on
human and animal health issues and cause severe diseases in humans, the alveolar
(AE) and cystic echinococcosis (CE), respectively [2]. Further members of the genus
are E. oligarthus [3], E. vogeli [3], E. shiquicus [4], E. equinus [5], E. ortleppi [5]
and E. felidis [6], many of which were previously repositioned from E.granulosus
strains [6,7].
E. multilocularis is endemic worldwide in the Northern Hemisphere (Fig. 2.2) [2].
In recent years an increase in AE and a spread of E. multilocularis from south-
central europe to neighbouring countries like France, Italy and the Balkan states
was observed [8, 9]. This expansion of endemic areas is most likely caused by an
increase in the fox population due to rabies vaccination and urbanisation, resulting
in a higher infestation rate with E. multilocularis [10,11].
Previous surveys of endoparasites of canids and rodents in the
NCR had failed to reveal E. multilocularis (180).
Recent surveys in central Europe have revealed that E. mul-
tilocularis has a much wider geographical distribution than
previously thought. By the end of the 1980s, areas of endemic
infection with E. multilocularis were known to exist in only four
countries (Austria, France, Germany, and Switzerland), but by
the end of 2001 the parasite was known to occur in red foxes in
at least nine further central European countries (Belgium,
Czech Republic, Denmark, Italy, Liechtenstein, Luxembourg,
Poland, Slovak Republic, and The Netherlands) (references
51, 58, and 173 and references therein). Findings of E. mul-
tilocularis metacestodes in rodents have been reported from
several countries (Slovenia, Bulgaria, Romania, etc.) and more
recently from Spitsbergen (Norwegian Svalbard Island group
in the Barents Sea). Since surveys were not conducted in pre-
vious years, it cannot be determined if the new records reflect
a recent extension of the parasite’s range or only the first
identification of hitherto unnoticed areas of endemic infection.
(ii) AE in humans as a risk indicator. The real infection risk
for humans in areas of endemic infection is reflected by AE
cases in the human population. Such cases have been diag-
nosed in many Eurasian areas and in Alaska, but only two cases
are known from the NTZ in North America (58, 180). Appar-
ently, the infection risk can differ considerably between and
within various regions. For example, since the middle of the
19th century, most AE cases in central Europe have been
recorded from regions in western Austria, southwestern Ger-
many, eastern France, and northern Switzerland, where recent
surveys have revealed high prevalences of E. multilocularis in
foxes (58, 66, 110). Since 1993, human cases of AE have been
recorded from at least 8 (61%) of 13 countries with endemic
infection, namely, from Austria, Belgium, France, Germany,
Slovak Republic, Switzerland, Liechtenstein, and Poland (51,
119) but most of the human cases have been reported so far
from Switzerland, France, Germany, and Austria (58, 110).
Between 1982 and 2000, 559 human cases of AE were reported
on a voluntary basis from nine European countries to the
European Echinococcosis Registry (110) and 202 new cases
were diagnosed in Turkey between 1980 and 1998 (1). These
data probably do not include all cases, but they do indicate a
considerable and persistent infection risk for humans in certain
Europen regions. In France, cases of human AE are found
predominantly in areas of intermediate altitudes (600 to
900 m) where grassland is dominant and the E. multilocularis
prevalence in foxes is high (40 to 60% in winter) (79). In Japan,
with the spread of E. multilocularis in Hokkaido, the number of
human cases of AE had increased in that area from only 6 new
cases between 1937 and 1964 to a total of 110 cases between
1985 and 1994 (118).
(iii) Increasing fox populations and parasite prevalences.
Evidence is accumulating that in parts of Europe the fox pop-
ulation densities have increased in recent years (23), possibly
due to reduced fox mortality after the introduction of anti-
rabies vaccination. For example, in Baden-Wu¨rttemberg,
southwestern Germany, the number of foxes sampled by hunt-
ing has increased approximately 2.7-fold between 1975/1976
and 1997 (data extracted from a graph) (170). In several other
Federal States of Germany, increasing fox populations have
FIG. 9. Approximate global distribution of E. multilocularis (as of 2002). Exact identification of areas of normal and high endemicity is difficult
becaue of incomplete or lacking data. Modified from WHO/OIE 2001 (223) with permission.
VOL. 17, 2004 BIOLOGY AND EPIDEMIOLOGY OF ECHINOCOCCOSIS 125
Fig. 2.2: Global distribution of E. multilocularis [2].
2.1.2 Biology and life cycle
The life cycle of E.multilocularis is characterised by two host changes, one adult
stage and three larval stages, namely the met cestode st ge, the pr toscolex and
the oncosphere (Fig. 2.3). The adult worm is found in the intestine of its final host,
mostly the red-fox (V lpes vulpes) and the polar fox (Alopex lagopus), but also other
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carnivores can serve as definite host [2, 12]. Small rodents serve as intermediate
hosts, however also primates and humans can be infected [8, 13]. When parasite
material in ingested by the final host, the 2 to 4 mm long adult worm develops
in a period of 28 to 35 days [8] and then starts to produce large amounts of eggs.
The head region (scolex) of the adult worm is comprised of the rostellum and four
suckers to attach itself to the intestine wall. The scolex is followed by the pro-
liferative zone (strobila), which contains the proliferative segments (proglottids).
In the terminal proglottid the eggs are formed. Each egg contains a multicellular
oncosphere of 25 to 30 µm in diameter and are very resistant towards low temper-
atures and humidity [2]. With the feces, the oncospheres together with the gravid
proglottid are shed to the environment from where they are then taken up by the
intermediate host through their food source. During the stomach and the intes-
tine passage the oncosphere hatches and becomes activated, most likely by the
involvement of the acidic pH and bile salts. The oncosphere then penetrates the
intestine wall and is transported to the liver via the blood stream,where it settles
and forms the metacestode stage [8,14,15]. The metacestode stage is an infiltrative
growing, tumour-like tissue consisting of mother and daughter vesicles. A single
metacestode vesicles consists of a cellular and an acellular layer surrounding the
hydatid fluid. The cellular layer of the metacestode vesicle is subdivided into the
syncytial tegument and the underlying germinal layer, that contains several cell
types, including the undifferentiated germinal cells that are responsible for asex-
ual reproduction and metastasis formation [16]. The laminated layer (acellular) is
highly glycosylated and has immune-evasive attributes [17]. Furthermore it gives
the parasite tissue structural integrity and stability [18,19]. In the further course
of the infection the germinal layer forms brood capsules, in which the protoscoleces
develop [5]. This larval stages already formed the scolex of the adult worm, but
does not contain the proglottids. The infiltration of the liver with parasite tissue
gradually weakens the intermediate host, which falls finally prey to the final host.
By the stomach/intestine passage the protoscolex is activated, evaginates and de-
velops into the adult stage [8,19].
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tigen (EG95) induces high degrees of protection, reducing the
cyst numbers in vaccinated animals by approximately 90 to
100% (93, 95, 107, 129, 130). A high degree of immunity (about
80%) persists for 6 months (in the absence of reinfection), and
pregnant ewes vaccinated before lambing transfer high levels
of antibody to their lambs (94).
A recent mathematical simulation suggests that a combina-
tion of regular dosing of dogs with praziquantel and vaccina-
tion of intermediate hosts would destabilize the system more
rapidly than other control options (200). Regrettably, the vac-
cine is not yet commercially available.
Problems of safety precautions and disinfection have been
neglected in research. A review of the current state of art has
been published in the WHO/OIE Manual on Echinococcosis
(55). Essential precautions are summarized as follows. (i) Per-
sonnel involved in handling animals infected with mature in-
testinal stages of Echinococcus spp. or egg-contaminated ma-
terials should weare protective clothing (cap, face mask, safety
glasses, single-use overall, plastic apron, rubber gloves, and
boots). (ii) For work with infected definitive hosts (for exam-
ple, treatment of dogs), their intestines, fecal matter, or other
materials possibly containing infective Echinococcus eggs, spe-
cial rooms or sterile bench systems should be used. In some
countries, a BL-3 biohazard safety level is required. (iii)
Whole carcasses of carnivores, intestines, or fecal sample
possibly containing infective Echinococcus eggs can be de-
contaminated by deep-freezing at !70 to !80°C. Care
should be taken that the effective temperature reaches all
parts of the material and is maintained for at least 96 or
48 h, respectively. The temperatures of household deep-
freezers are too high to inactivate eggs. Echinococcus eggs
are killed within 5 min at "60 to 80°C and instantly at "
100°C. (iv) Persons who have had a single exposure to in-
fected final hosts or egg-contaminated materials or who
have ingested apparently contaminated food should receive
serological screening for specific antibodies at the following
intervals after the suspected contact: 4 weeks and 6, 12, and
24 months. Individuals with repeated infection risk (for ex-
ample, laboratory personnel, field workers in echinococcosis
control) should be serologically examined twice a year.
In areas which are free of E. granulosus or have only spo-
radic occurrence of the parasite, special measures should be
taken in order to prevent the introduction of the parasite by
living definitive or intermediate host animals.
E. MULTILOCULARIS AND ALVEOLAR
ECHINOCOCCOSIS
The Parasite and Its Life Cycle
The adult stage of E. multilocularis is characterized by its
small size (length of up to 4.5 mm), a mean number of five
segments, a sack-like uterus, and other morphological features,
allowing its differentiation from E. granulosus and other Echi-
nococcus species (193, 223) (Table 1). Transmission of E. mul-
tilocularis occurs in a sylvatic cycle, which is sometimes linked
via infected small mammals to domestic dogs and cats (Fig. 6).
In the sylvatic cycle, foxes (mainly the Arctic fox [Alopex lago-
pus] and the red fox [Vulpes vulpes]) play a key role as definitive
hosts and small mammals, mainly rodents, are the intermediate
hosts. In some areas, other wild canids, such as coyotes (Canis
latrans), raccoon dogs (Nyctereutes procyonoides), and wolves
(Canis lupus f. familiaris), or wild felidae (wild cats) can also
serve as definitive hosts. Among the many species (#40 spe-
cies) of small mammals that are susceptible to E. multilocularis
under natural conditions, members of the family Arvicolidae
(voles and lemmings) and Cricetidae (hamsters, gerbils, and
related rodents) are most important (79, 155, 165). Aberrant
host animals and humans can also become infected with the
metacestode stage, which has the potential to cause AE, one of
the most lethal helminthic infection in humans. Although some
variation between E. multiolocularis isolates from North Amer-
ica and Eurasia has been described, there is no evidence for
distinct genetic strain differences (91). This is in accordance
with the fact that E. multilocularis in various regions, including
large areas of the northern hemisphere (Asia, Europe, and
North America), is infective to humans.
Alveolar Echinococcosis in Humans
Course of infection. The metacestode stage of E. multilocu-
laris in natural intermediate hosts or aberrant hosts is charac-
terized by an alveolar structure, composed of numerous small
vesicles ($1 mm to 3 cm in diameter). A characteristic feature
of this stage is its exogenous tumour-like proliferation, which
leads to infiltration of the affected organs and, in progressive
cases, to severe disease and even death (Fig. 7). The single
vesicle has a wall structure similar to that of the metacestode of
E. granulosus (germinal and laminated layer) (48). In interme-
diate or aberrant hosts, the metacestodes can proliferate from
FIG. 6. Life cycle of E. multilocularis. (A) Adult parasite. (B) Foxes
(left, red fox; right, Arctic fox) as principal definitive hosts; dogs, other
canids, and cats can be involved in the cycle. (C) Proglottid with eggs.
(D) Egg with oncosphere. (E) Infection of humans. (F) Rodent in-
fected with metacestodes. (G) Rodent liver with metacestodes.
(H) single metacestode cyst with protoscoleces.
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Fig. 2.3: The life cycle of E.multilocularis [2]. (A) Adult worm. (B) Final hosts: foxes, dogs, other
canids and cats. (C) Proglottid with eggs. (D) Egg with oncosphere. (E) Infection of hu-
mans. (F) Intermediate host: Rodents. (G) Rodent liver with metacestodes. (H) Single
metacestode cyst with developing protoscoleces.
2.1.3 Alveolar Echinococcosis, clinical manifestation and
therapy
Infective eggs can be taken up by humans, in which case the natural passage be-
tween intermediate and fin l hos is broke . However, a in the natural inter-
mediate hosts the oncosphere is activated and transported to the liver, where the
etacestode stage develops. The infiltrative, tumour-like growth of the parasite
tissue in the liver imp irs the liver function, the clinical m ifestation accompa-
nied by lesion formation is referred to as alveolar echinococcosis [20]. By metasta-
sis formation the parasite can also spread to organs like lung, bones and the brain
[8, 21]. Early symptoms are abdominal pain, jaundice, hepatomegaly, sometimes
fever and anaemia, weight loss, and pleural pain and end in dysfunction of the
affected organs resulting in the death of th patient [2]. P rsons with high risk of
infection are pet owners and in that regard especially those of dogs, but also farm-
er , hunters and gardeners [15,22]. Exact AE rates are difficult to estimate due to
a low prevalence and a large ti e span between infection and the first symptoms,
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which can be up to 15 years [2]. In high endemic areas in central Europe between 2
and 40 cases per 100.000 inhabitants were reported [9].
For diagnosis of AE imaging techniques based on ultrasonography, computed to-
mography (CT), magnetic resonance tomography (MRT) and serology are used
[23]. In serological tests a wide range of antigens are available which allow de-
tection with a diagnostic sensitivity of 90–100 % and a specificity of 95–100 %
[8,23].
Treatment options are currently very limited. Radical surgery is useful, when the
lesions are detected in an early stage of infection. Due to the infiltrative growth
of the parasite the complete removal is only possible in 20 to 40 % of the cases
[2, 24]. Liver transplantation is not recommended, because the required immuno-
suppression can cause massive growth of residual and metastasize parasite mate-
rial [8,25,26]. The current standard of therapy is chemotherapy, in somecases com-
bined with surgery [8]. For therapy benzimidazoles, like Albendazole or Mebenda-
zole are recommended [23]. These compounds bind to the parasitic β -tubulins and
inhibit the formation of microtubuli [27, 28]. However, these drugs have severe
side-effects, like fever, urticaria, neurological deficits, gastrointestinal disorders,
decreased numbers of leukocytes and thrombocytes and bone marrow toxicity as
they also bind the human protein [29]. Furthermore they act merely parasitostatic
and therefore require lifelong treatment [29].
2.2 The study of host-parasite interplay during Alveolar
Echinococcosis
2.2.1 Molecular and biochemical approaches
In the last decades studies of E. multilocularis were mostly aimed at the identi-
fication of antigens for diagnostic purposes [30] or the investigation of epidemio-
logical and phylogenetic patterns [31, 32]. Emelp was the first chromosomal locus
described for E. multilocularis, which encodes a errin-radixin-moesin (ERM)- like
protein [33]. Trans-splicing was first reported in trypanosomes [34] and was sub-
sequently studied in the cestodes E. multilocularis and T. solium [35, 36]. Trans-
splicing involves the transfer of an exon derived from a small nucleolar pre-mRNA,
the so called spliced leader (SL) to the 5’ end exon of a different mRNA [37]. In
E.multilocularis 30 % of transcripts seem to undergo this process [38]. The first
16
2 Introduction
cDNA libraries of E. multilocularis were produced on the basis of trans-splicing.
Primers against the 36 bp SL sequence and the poly-A tail were used to to am-
plify the complete subset of trans-spliced cDNAs [35, 37]. After that further SL-
independent cDNA libraries were produced [39], including a Y2H library [40]. In
2003 the whole genome sequence project for E. multilocularis by the Wellcome
Trust Sanger Institute (Hinxton, Cambridge, UK) was started in cooperation with
the groups of Klaus Brehm (Wuerzburg) and Cecilia Fernandez (Montevideo). The
genomic sequence data is now available under http://www.sanger.ac.uk/resources/
downloads/helminths/echinococcus-multilocularis.html. The publication of the an-
notated genome data is currently in preparation. Furthermore, the Sanger in-
stitute in cooperation Klaus Brehm (Wuerzburg) is presently working on a tran-
scriptome project of distinct E. multilocularis larval stages. The access to genomic
and transcriptomic data will considerably facilitate the work with E. multilocularis
with respect to developmental and immunological questions of the parasite and will
facilitate the identification of new possible drug targets.
2.2.2 In vitro cultivation systems
Elaborate cultivation systems have been developed in recent years that allow the
investigation of E. multilocularis under defined, laboratory conditions. The influ-
ence of host factors as well as the effect of parasite factors on host systems can now
be studied in vitro. The first long term cultivation systems for E. multilocularis
were developed in the mid 90ties. 1995 Hemphill and Gottstein [41] introduced
the tissue block system, in which tissue blocks from secondary infected rodents
were incubated in serum containing medium. Metacestode vesicles emerged from
the tissue block that were morphologically similar to the vesicles from the liver or
peritoneum of infected mice. The system developed by Jura et al. [42] relied on
the co-incubation of homogenised parasite tissue with primary rat hepatocytes em-
bedded in a collagen layer. A disadvantage of both systems was the low amount of
vesicles that could be gained. Therefore the large scale liquid culture systems was
established [43]. Homogenised parasite material was incubated in the presence of
actively dividing rat hepatoma feeder cells. Like in the other systems metacestode
vesicles developed and subsequently produced protoscoleces. The removal of the
feeder cells lead to a fast degeneration of the parasite material, indicating that
the system relies on soluble factors secreted by the feeder cells. Large amounts of
vesicles with comparable sizes and developmental stages were produced with this
system. However, the investigation of the influence of host factors on the parasite
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was hindered by the continuous presence of feeder cells in the cultivation system.
It was not possible to distinguish between a direct effect on the parasite or an indi-
rect effect mediated by the feeder cells. This lead to the development of the axenic
system [44]. In this systems anaerobic growth conditions and the presence of re-
ducing agents were required for the larval development and survival, indicating
that the larval material is sensitive to reactive oxygen species produced during
culture. Medium containing serum was pre-conditioned with rat hepatoma cells,
supplemented with reducing agents and then used for the cultivation of metaces-
tode vesicles grown in the large scale liquid culture system. The next achievement
in the cultivation of E. multilocularis was the development of primary cell isola-
tion and cultivation [45]. Primary cells were isolated from metacestode vesicles
and were cultivated in axenic or co-culture conditions. The isolated cells consisted
of approximately 30 % undifferentiated cells. After a period of 3 to 6 weeks these
cultures formed new metacestode vesicles, which were infected when injected into
the peritoneum of rodents. Recently gene knock-down in primary cell cultures was
successful [46]. The current cell culture methods make it possible to produce large
amounts of metacestode vesicles. They are useful tools to investigate the develop-
ment of the parasite in response to cytokines and culture conditions as well as the
effect of novel, alternative chemotherapeutics.
2.2.3 Evolutionary conserved signalling in E. multilocularis
Cell-cell communication and signalling systems have arisen very early in the meta-
zoan development. They are therefore well conserved between vertebrate and in-
vertebrate organisms [47,48] and are already present in the most basal phyla like
sponges [49,50]. It was demonstrated that due to the high conservation of the sig-
nalling molecules, mammalian insulin and BMP-like factors were able to stimulate
the respective receptors of D. melanogaster and C. elegans [51, 52]. In E. multiloc-
ularis many factors of evolutionary conserved signalling pathways were already
identified by our group. Among these are the epidermal growth factor receptor
(EGFR), the insulin receptor family, the MAP kinase cascade, and receptors of the
TGF-β and BMP family [16, 53–58]. Thanks to the E. multilocularis genome se-
quencing project many other factors were identified in the genome.
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2.3 The insulin signalling cascade
2.3.1 The insulin and insulin/ IGF-I receptor family
The insulin superfamily in mammals contains insulin, IGF-I (insulin like growth
factor) and IGF-II. Insulin regulates the glucose and fatty-acid metabolism [59,60],
while IGF-I is involved in proliferation processes and has anti-apoptotic activi-
tiy [61]. Additionally, it has also been reported that IGF-I is involved in cancer
development [62, 63]. Insulin and IGF-I are expressed as pro-peptides. Insulin
consist of a signal peptide followed by the B, C and A chains. During processing
the B chain is cleaved out and the C and A peptides are connected by disulphide
bonds [59,60]. IGF-I additionally contains the C-terminal D and E chains, but only
the E chain is cleaved [59]. Therefore, although the structure between insulin and
IGF-I is very similar the later is significantly larger. In mammals insulin is ex-
pressed in the pancreas within the β-cells of the islets of Langerhans [59, 60], but
reaches its highest concentration in the portal vein and the adjacent peripheral
liver tissue [64,65]. IGF-I is synthesised primarily in the liver and to lesser extend
in peripheral tissue [66].
The insulin receptor superfamily consists of the insulin receptor [67], the IGF-I
receptor [61] and the orphan insulin-related receptor constitutive [68]. The ma-
ture receptor forms an constitutive heterotetramer on the cell surface [67, 69].
Insulin receptors are expressed as a pro-receptor with an N-terminal signal pep-
tide, a ligand binding domain, a transmembrane domain and the intracellular ty-
rosine kinase domain. The pro-peptide is processed into an α chain containing
the ligand binding site and a β chain with the transmembrane and kinase do-
mains. The chains are connected by disulphide bonds, which also link two αβ
dimers to form the mature tetramer [70, 71]. Alternative splicing occurs in the
ligand binding domain of the human insulin receptor, resulting in an A and B
form, which have distinct ligand binding and signalling properties [72–74]. Fur-
thermore the ligands show a high cross-reactivity with the insulin and IGF-I re-
ceptors, which can also hybrid-receptors in cells where they are expressed together
[74–77].
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2.3.2 The insulin signalling pathways
The binding of the ligand to the receptors activates the autophosphorylation ac-
tivity of the receptor. Tyrosine residues in the kinase domain are phosphorylated,
which activated the kinase and form binding sites for adaptor proteins [78–80].
Among the direct interactors with the receptors are the IRS proteins and SHC that
get phosphorylated themselves and recruit other effector molecules to the recep-
tor complex [81, 82]. The most important signalling cascades activated by insulin
and IGF-I are the mitogen activated protein kinase (MAPK) cascade and the phos-
phatidylinositol 3-kinase (PI3K)/ Akt pathway [83] (see. Fig. 2.4).
Fig. 2.4: Insulin signalling pathways. Binding of the ligand induces the intrinsic kinase activity
of the kinase domain, leading to auto-phosphorylation of the kinase at crucial tyrosine
residues. that form the docking sites for downstream effectors. The MAPK cascade and the
PI3K/ Akt pathways are the main mediators of insulin signals. Insulin signalling regu-
lates the glucose and lipid metabolism, cell growth and differentiation, protein synthesis
and gene expression [83].
The MAPK cascade is activated by the recruitment of GrB2 to the receptor complex.
GrB2 binds mSos, which catalyses the substitution of GDP to GTP of Ras [84, 85].
Subsequently Raf-1, MEK and Erk1/2 are activated. Erk1/2 dimerises and is trans-
ported to the nucleus, where it serves as a transcription factor. The protein synthe-
sis is regulated by the subsequent activation of Mnk-1 and eIF-4G that phospho-
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rylates eIF-4E [86]. The MAPK pathway in mammals is primarily associated with
growth and differentiation processes [87].
The second pathway activated by insulin signalling is the PI3K/Akt pathway. The
regulatory subunit of the PI3K binds to IRS-1 associated with the receptor, which
activates the catalytic subunit. The PI3K catalyses the formation of phosphatidyl
inositol triphosphate, which recruits the Akt kinase to the membrane [88,89]. The
glucose uptake is regulated by inducing the translocation of Glut4 to the cell sur-
face [90]. Protein synthesis is regulated by the sequential activation of mTor, 4E-
BP and eIF-4E [89,91].
2.3.3 Insulin signalling in Platyhelminthes and nematodes
Several insulin-like (ILP) peptides were identified in invertebrates. D. melano-
gaster expresses seven ILPs (DILP 1 to 7) [92], while in C. elegans genome analysis
revealed the presence of 37 distinct members of the insulin superfamily. Among
these, Ins-1 and Ins-18 show the highest homologies to the human insulin [93].
Finally, in the E. multilocularis genome two genes coding for ILPs were identi-
fied. However, for all these peptides a processing similar to the human insulin is
still unclear. Next to the ILPs insulin receptors and their intracellular signalling
cascades were identified in invertebrates. The best characterised insulin receptor
homologues are DIR from D. melanogaster and DAF-2 in C. elegans [94–96]. DIR
is involved in the regulation of body and cell size, longevity, embryonal differenti-
ation and lipid metabolism [59, 92, 97]. In C. elegans insulin signalling regulates
entry and exit of the dauer larval stage [98].
Still very little is known about the role of insulin signalling in parasitic helminths.
In E. multilocularis, Schistosoma mansoni, Schistosoma japonicum and Mesoces-
toides vogae insulin receptor orthologues have been identified [53, 99–101] and
Yeast two hybrid studies on the Echinococcus and Schistosoma receptors homo-
logues showed that they interacted with human pro-insulin. Additionally, it was
shown that the Schistosoma receptors are involved in the insulin mediated glucose
uptake [100, 102]. However, the maximum insulin concentration used by Ahier
et al. [102] was unphysiologiycally high, while You et al. [100] only gave an indi-
rect prove of insulin action by blocking the S. japonicum insulin receptors. For M.
vogae, an influence of human insulin on glucose uptake, survival and asexual re-
production was shown [101] and Escobedo et al. [103] gave evidence that insulin
promotes the budding of Taenia crassiceps significantly, indicating the presence
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of an insulin receptor in this organism. A major drawback of this study was the
high insulin concentration used to stimulate Taenia larvae. The concentrations
ranged from 3.45 to 13.8 µM while the physiological systemic insulin concentra-
tion reaches a maximum of 100 pM [64]. Furthermore, budding in T. crassiceps
measures asexual reproduction and is therefore not directly linked larvae develop-
ment.
2.4 Abl tyrosine kinases
2.4.1 Abl kinases
The Abl kinases were first reported in form of the virally transduced oncogene of
the Abelson murine lymphosarcoma virus (v-abl) [104] and the BCR-Abl fusion
protein in chronic myeloid leukemia (CML) patients [105]. Abl genes are found in
all metazoans [106]. In vertebrates two genes, Abl1 [107] and the closely related
Abl2 [108] were identified, while in invertebrates normally only one abl gene is
present [106]. Both, the oncogenic properties and the high conservation indicate
an important role for endogenous Abl kinases. Among the various functions of en-
dogenous Abl kinases are actin remodelling, cell adhesion and motility, DNA dam-
age response, and microbial pathogen response [106]. Abl kinases have a modular
structure. At the N-terminus SH3 and SH2 domains are located that are important
for protein interaction and substrate specificity [106]. The SH domains are followed
by the tyrosine kinase domain and at the C-terminal part of the protein, domains
for the interaction with cytoskeletal components and DNA are found [106]. In the
cytoplasm Abl localises with F-actin [109], where it is suggested to be involved
in the signal transduction for the regulation of mitogenesis. The cytoplasmatic
functions seem to be associated with the oncogenic properties of Abl kinases [109].
Nuclear Abl seems to be regulated in a cell-cycle dependent manner and is im-
plicated to be involved in the regulation of transcription and the suppression of
cell growth [110, 111]. Due to its role in cancer development the interactions and
functions of Abl proteins were researched most thoroughly in BCR-Abl and are
summarized in Fig. 2.5.
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gether with an invariant aspartic acid residue (part of 
the DFG triad) that deprotonates the phosphoacceptor hy- 
droxy group, are involved in the catalytic process. The 
adenosine binding interactions are less conserved, and 
apart from a bidentate donor-acceptor H-bonding motif 
involving the N-1 of the adenine ring and its N-7 amino 
group with the backbone NH and carbonyl groups of 
residues in the hinge region, the interactions with the 
nucleoside are of a lipophilic/van der Waals nature. Be- 
cause highly polar molecules would be required to target 
the triphosphate/catalytic site, which would have poor 
oral absorption, cellular permeability and pharmacokinetic 
properties, almost all ATP-competitive kinase inhibitors 
target the adenosine recognition motif of the ATP-binding 
site. However, while the ATP-binding site is highly con- 
served throughout kinases, the architecture of these pro- 
teins in the regions proximal to the ATP-binding pocket 
does afford some key diversity. The case of the tyrosine 
kinase inhibitor imatinib (Glivec ®, formerly STI571, No- 
vartis Pharma AG, Basel, Switzerland) provides a good 
example to illustrate these points. 
3.1. Discovery of  imatinib as an inhibitor of  Bcr-Abl 
In chronic myelogenous leukemia (CML), a recipro- 
cal balanced chromosomal translocation in hematopoietic 
stem cells (HSCs) produces the BCR-ABL hybrid gene, 
which encodes the oncogenic Bcr-Abl fusion protein. The 
ABL gene encodes the tightly regulated non-receptor pro- 
tein tyrosine kinase cAbl, which plays a fundamental role 
in regulating cell proliferation, adherence and apoptosis. 
In contrast, the BCR-ABL fusion gene encodes a constitu- 
tively activated kinase. This transforms HSCs to produce a 
phenotype exhibiting deregulated clonal proliferation, re- 
duced capacity to adhere to the bone marrow stroma and 
a reduced apoptotic response to mutagenic stimuli, which 
enable them to accumulate progressively more malignant 
transformations. The resulting granulocytes fail to develop 
into mature lymphocytes and are released into the circu- 
lation, leading to a deficiency in the mature cells and an 
increased susceptibility to infection. This etiology renders 
Bcr-Abl as a highly attractive target for drug intervention 
in CML. Unlike the membrane-bound receptor tyrosine 
kinases, such as those of the platelet-derived growth factor 
receptor (PDGFR) family, Bcr-Abl is a cytosolic kinase 
that is constitutively active and does not depend upon 
ligand binding and subsequent receptor dimerization for 
activation. Consequently, Bcr-Abl activity cannot be mod- 
ulated by means of receptor-based inhibitors. Furthermore, 
since Bcr-Abl phosphorylates a large number of substrates, 
thereby upregulating several intracellular signaling path- 
ways (Fig. 2), the most obvious approach to blocking 
the activation of this enzyme cascade is by means of an 
ATP-competitive inhibitor of the Bcr-Abl kinase activity. 
The value of large, diverse compound archives was il- 
lustrated when screening at Novartis resulted in the identi- 
fication of the pyrimidine A as a structurally attractive lead 
molecule for optimization against cAbl (Fig. 3, Table 1) 
[6]. Structure-activity studies led to N-acyl and N-aroyl 
amide derivatives, such as B in which replacement of the 
imidazole with a benzamido group maintained the activity 
of the compound as a kinase inhibitor. Subsequently, intro- 
ducing a methyl substituent ortho to the pyrimidinyl-ami- 
no group abrogated PKC-c~ and CDK1 serine/threonine 
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Fig. 2.5: Schematic representation of key pathways in the Bcr-Abl signalling cascade [112]. The
oncogenic BCR-Abl is involved in proliferation, survival and cell mobility.
2.4.2 Abl kinases in invertebrates
D. melanogaster has a single Abl kinase (D-Abl) that is important for viability,
the development of the central nervous system and dentritic morphogenesis [113–
115]. Furthermore D-Abl was shown to have a critical role in the morphogenesis
of epithelial tissues during early embryonic development [116]. In C. elegans Abl
controls epithelial morphogenesis [117]. Furthermore, in eggs of the sea urchin
Strongylocentrotus purpuratus an Abl kinase homologue was identified, which was
suggested to play a role in fertilisation [118]. In the trematode S. mansoni two
genes for Abl kinases and a unique Abl-Src hybrid kinase, SmTK6 were reported
[119, 120]. Beckman and Grevelding [119] showed that that the Abl kinases are
expressed in both genders in the reproductive system and weakly in some cells of
the parenchyma and the gastrodermis, indicating a role in reproduction. Similarly,
SmTK6 was mainly expressed within the testes of the male and the ovary of the
female [121].
2.4.3 The Abl inhibitor Imatinib
Imatinib (Glevec, STI-571) is an ATP-competitive kinase inhibitor specifically de-
signed against Abl kinases and other type III tyrosine kinases, like c-Kit and the
platelet-derived growth factor receptor (PDGFR) [122]. Imatinib is currently used
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in cancer therapy against CML, which is caused by the constitutively active BCR-
Abl fusion protein [112,123] and gastrointestinal stromal tumours (GIST) that are
mostly caused by constitutive activation of the receptor tyrosine kinase c-Kit [112].
Recently the effect of Imatinib on the trematode S. mansoni was published, show-
ing that Imatinib has a drastic effect on the survival and morphology of this para-
site [119].
2.5 Objectives
In the past, studies of E. multilocularis were mostly focused on diagnostic, epi-
demiological and phylogenetic questions [30–32]. Only in recent years the inves-
tigation of conserved signalling systems and developmental processes was taken
up [16, 48]. Therefore, the developmental mechanisms that E. multilocularis uses
to thrive and to establish itself in the liver are poorly understood. Insulin reaches
its highest concentration in the portal vein and IGF-I is expressed highly in the
liver [64–66]. Previous works have shown the presence of insulin receptors that
are expressed by E. multilocularis and preliminary investigations indicate an im-
portant role of insulin signalling in the development of this parasite [53,124,125].
The elucidation of the function of insulin signalling in E. multilocularis is an im-
portant step to understanding the development of AE and is therefore one major
focus of this work.
Furthermore, current chemotherapeutic anti-AE treatment is based mostly on ben-
zimidazoles (BZ) which target the parasite β-tubulin [20]. However, due to an affin-
ity of the drugs to host β-tubulin, BZ treatment is often associated with severe side-
effects and acts merely parasitostatic,which therefore makes life-long treatment
necessary [126, 127]. Therefore new therapeutic drugs and targets are urgently
needed. Four major pathways for the development of new anti-parasitic drugs are
currently employed [29]: conventional drug screening, the testing of established
anti cancer drugs, the study of similarities between parasite and mammalian cells
for the identification of suitable drug targets and in silico analysis on genomic
data.
Among these, targeting the cellular signalling components seems to be a promis-
ing approach, due to their important role in the development and survival of all
metazoan organisms including parasitic helminths [56,128]. Additionally, the bio-
chemistry of these signalling components have been researched very thoroughly,
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due to their important role in cancer chemotherapy and a broad range of molecules
is therefore available to target these components [16].
Another useful approach for identification of new anti-parasitic therapies is the
testing of compounds that showed promising effects in related parasites [129]. In
the drug testing metacestodes are major targets of anti-parasitic chemotherapy
due to their role as the disease causing stage [16, 29]. However, the newly de-
veloped primary cell cultivation system can give important insights on the effect
of the tested compounds on stem cell viability and regeneration [45]. Therefore
the second part of this work focuses on the identification of new possible drug tar-
gets and components and the characterisation of the involved E. multilocularis
molecules.
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3.1 Material
3.1.1 Equipment
Developer for radiographic films (Agfa Graphics Germany, Duesseldorf)
ELISA reader Multiscan Ex Primary EIA V.2.1-0 (Thermo)
Gel documentation system: MidiDoc (Herolab, Wiesloch)
Gelelectrophoresis camber (Bio-Rad, Muenchen)
Heating block: DB-3 (Techne, Cambridge, UK), Heizblock (Liebisch, Bielefeld)
Heating stirrer: Typ RCT (Jahnke & Kunkel, Staufen i. Br.)
HERA safe (Heraeus, Thermo Electron, Langenselbold)
Incubator: Heraeus (Thermo Electron, Langenselbold)
Leica IRB (Leica Microsystems, Wetzlar)
Mikro 200 table centrifuge (Hettich, Tuttlingen)
Micro scales: R160P (Sartorius, Goettingen)
Microtom 2065 (Leica Microsystems, Wetzlar )
Mini-PROTEAN II System (BioRad, Muenchen)
MSC advantage laminar flow (Thermo Scientific, Braunschweig)
NanoDrop 1000 (PeqLab Biotechnologie, Erlangen)
Neubauer chamber ( 0.1 mm, 0.0025 mm2; (Hartenstein, Wuerzburg)
Nuaire laminar flow (Nuaire)
Power Pack P24 and P25 (Biometra, Goettingen)
Refrigerated Centrifuge 3K30 (Sigma-Aldrich, Muenchen)
Research Plus pipette set (Eppendorf, Hamburg)
Scale: 10-1000 g (Sartorius, Goettingen)
Selectomat S2000 autoclave (Muenchner Medizin Mechanik, Muenchen)
G24 shaking incubator(New Brunswick Scientic, Edison, N.J., USA)
Spectrophotometer U-2000 (Hitachi, NY, USA)
Tecan ELISA reader (Tecan Group, Crailsheim)
T-Gradient Thermocycler (Biometra, Goettingen)
TH30 shaking incubator (Hartensein, Wuerzburg)
Tricarb scintillation counter (Packard)
Trio-ThermoblockTM heated lid (Biometra, Goettingen)
Trio-ThermoblockTM oil(Biometra, Goettingen)
Vacuum pump (ILMVAC, Ilmenau)
Vortex mixer: L46 (Gesellschaft fuer Laborbedarf, Wuerzburg)
26
3 Material and Methods
3.1.2 Consumables
96-well plates (Sarstedt, Nuembrecht)
12-well plates (Nunc, Roskilde, Denmark)
24-well plates (Nunc, Roskilde, Denmark)
96-well plates (Sarstedt, Nuembrecht)
25 cm2(Sarstedt, Nuembrecht)
75 cm2(Sarstedt, Nuembrecht)
175 cm2 (Sarstedt, Nuembrecht)
Microtom sample adapter (Rudens Plastinindusti, Hestra, Sweden)
Nitrocellulose membran (GE Healthcare, Muenchen)
PD-10 column (GE Healthcare, Muenchen)
Radiographic film (Fujifilm Europe, Duesseldorf)
Safe-Lock Tubes 0,5, 1,5 and 2 ml (Eppendorf, Hamburg)
Semi-micro cuvettes (Sarstedt, Nuembrecht)
Sterilfilter (Nalgene, New York, USA)
Sterile tubes, 15 and 50 ml (Greiner, Nuertingen)
Superfrost Plus slides (Thermo Scientific, Braunschweig)
Syringes and canula, sterile (Braun Melsungen AG, Melsungen)
Whatman blotting paper (GE Healthcare, Muenchen)
X-Ray film HyperfimTM -MP (Amersham, Braunschweig)
3.1.3 Chemicals, media, commercially available kits and
enzymes
[14C]-D-Glucose (Hartmann Analytic, Braunschweig)
2’,5’-Dideoxyadenosine (Sigma-Aldrich, Muenchen)
3,3 Diaminobenzidine 4 Hydrochloride (Serva, Heidelberg)
5-Bromo-2-Deoxyuridine (AppliChem, Darmstadt)
Adenine hemisulfate (Sigma-Aldrich, Muenchen)
Agarose (ROTH, Karlsruhe)
Aladin1 (By courtesy of ...)
Albumin fraction V (pH 7) Blotting grade (BSA) (AppliChem, Darmstadt)
Ammonium peroxodisulfate (APS), (Carl Roth, Karlsruhe)
Aqua demin. (VE-water)
Ampuwa (Fresenius, Bad Homburg)
Ampicillin (Sigma-Aldrich, Muenchen)
Antarctic Phosphatase (New England Biolabs Inc., Schwalbach)
AS601245 (Calbiochem, Merck, Darmstadt)
Bacto agar (Difco Laboratories, Augsburg)
Bathocuproine disulfonic acid (Sigma-Aldrich, Muenchen)
β -Mercaptoethanol (Sigma-Aldrich, Muenchen)
CIP (New England Biolabs Inc., Schwalbach)
Chloroform (Merck, Darmstadt)
CloneJETTM (Fermentas, St. Leon-Rot)
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Color Plus Prestained Protein Marker (10- 230 kDa) (NEB, Schwalbach)
Colorimetric Cell Proliferation ELISA BrdU (Roche, Grenzach)
Complete Mini phosphatase inhibitor Mix (Roche, Grenzach)
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Muenchen)
dNTP lyophilised (ROTH, Heidelberg)
DMEM- glucose free (Biochrom, Berlin)
DMEM- GlutaMAXTM (DMEM) (Invitrogen, Darmstadt)
DMEM- no phenolred (Invitrogen, Darmstadt)
DO Supplement –Ade/–His/–Leu/–Trp (Clontech, Heidelberg)
DO Supplement –Leu/–Trp (Clontech, Heidelberg)
Entellan (Merck, Darmstadt)
Eosine (Roche, Mannheim)
Fetal Calf Serum (FCS) (Invitrogen, Darmstadt)
Haemalaun (Roche, Mannheim)
HNMPA(AM)3 (Enzo Life Sciences, Loerrach)
Hystidine HCL mono-hydrate (Sigma Aldrich, Muenchen)
Imatinib- mesylate (Enzo Life Sciences, Loerrach)
Insulin, recombinant human (Sigma Aldrich, Muenchen)
K11777 (By courtesy of Caffrey Conor, UCSF, USA)
Luria-Broth (LB; Invitrogen, Darmstadt)
L-Cystein (Sigma Aldrich, Muenchen)
LY294002 (Biozol, Eching)
Matchmaker Two Hybrid System 3 (Clontech, Heidelberg)
NucleoSpin R© Extract II (Macherey-Nagel, Dueren)
NucleoSpin R© PC100 (Macherey-Nagel, Dueren)
NucleoSpin R© Plasmid Kit (Macherey-Nagel, Dueren)
Oligonucleotides (Sigma, Muenchen)
Omniscript R© RT Kit (Qiagen, Hilden)
pBAD/TOPO R© ThioFusionTM Expression Kit (Invitrogen, Darmstadt)
PCR Cloning Kits (Qiagen, Hilden)
Penicillin/Streptomycin (Invitrogen, Darmstadt)
Pepsin (Sigma-Aldrich, Muenchen)
Pierce R© BCA Protein Assay Kit (Thermo Scientific, Braunschweig)
Pierce R© ECL westen blot substrate (Thermo Scientific, Braunschweig)
Pierce ReactBind R© (Thermo Scientific, Braunschweig)
ProBondTM Nickel-Chelating Resin (Invitrogen, Darmstadt)
Proteinase K (AppliChem, Darmstadt)
RNAse A (Roche, Grenzach)
RNAseOut (Invitrogen, Darmstadt)
Peptone (Difco Laboratories, Augsburg)
Phospho DetectTM Phosphoserine Detection kit (Calbiochem, Merck, Darmstadt)
PhosStop (Roche, Grenzach)
Polyethylene glycol (PEG 3350, Sigma-Aldrich, Muenchen)
PrimeScript RNA Polymerase (Takara, Verviers, Belgium )
Rapamycin (Cell Signalling, NEB, Schwalbach)
Resazurin (Sigma-Aldrich, Muenchen)
Restriction enzymes (New England Biolabs Inc., Schwalbach)
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Rotiphorese R© Gel 30 (37,5:1) (Carl Roth, Karlsruhe)
Rotiphorese R© Gel 40 (Carl Roth, Karlsruhe)
RQ1 RNase-Free DNase (Promega, Mannheim)
SmartLadder (Eurogentec, Koeln)
SMARTTM RACE cDNA Amplification kit (Clontech, Heidelberg)
SOC (Invitrogen, Darmstadt)
Sodium taurocholat (Sigma-Aldrich, Muenchen)
SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific, Braunschweig)
T4 DNA Ligase (New England Biolabs Inc., Schwalbach)
Taq-Polymerase (New England Biolabs Inc., Schwalbach)
Tavanic R© (Tava, active component levofloxacin, 5mg/ml) (Aventis)
Technovit 8100 (Heraeus Kulzer, Wehrheim)
TEMED (N,N,N’,N’-Tetramethylethylendiamin) (Merck, Darmstadt)
TNFα, recombinant human (Invitrogen, Darmstadt)
Triton R© X-100 (Sigma-Aldrich, Muenchen)
Trizol R© Reagent (Invitrogen, Darmstadt)
TOPO-TA Cloning R©KIT (Invitrogen, Darmstadt)
Trypsin/EDTA (0,05%/0,02% (w/v)/ PBS w/o Ca2+, Mg2+) (Biochrom, Berlin)
Tween R© 20 (Merck, Darmstadt)
UlitmaGoldTM (Perkin Elmer, Rodgau)
Yeast extract (Difco Laboratories, Augsburg)
Yeast nitrogen base w/o amino acids (Difco Laboratories, Augsburg)
All buffers and solutions were made with distilled water, autoclaved and sterile filtrated. For RNA, either
DEPC-treated or commercially available RNase-free water was used. For enzymatic reactions, double distilled
and autoclaved water was used.
29
3 Material and Methods
3.2 Oligonucleotides
cDNA, Race:
Name Sequence
CD3RT TCTCTTGAAAGGATCCTGCAGGT26V; V= G, C, A
CD3 CTTGAAAGGATCCTGCAGGACT
CD3nested ATCTCTTGAAAGGATCCTGCAGG
Em10 15 AATAAGGTCAGGGTGACTAC
Em1016 TTGCTGGTAATCAGTCGATC
pJG 4-5 5´ GCCTCCTACCCTTATGATGTG
pJG 4-5 SPR CTTATGATGTGCCAGATTATG
pJG 4-3 up TGGAGACTTGACCAAACCTCTG
pJG 4-3 nested CTGGCGAAGAAGTCCAAAG
RandomOct NNNNNNNN
SmartI AAGCAGTGGTAACAACGCAGAGTACGCGGGGGGGG
SmartII AAGCAGTGGTAACAACGCAGAGTACGCGGG
UPM long CTAATACGACTCACTATAGGGCAAGC-
AGTGGTATCAACGCAGAG
UPM short CTAATACGACTCACTATAGGGC
NUP AAGCAGTGGTATCAACGCAGAGT
Plasmids:
Plasmid Name Sequence
pDrive T7 GTAATACGACTCACTATAG
SP6 CATTTAGGTGACACTATAG
pBad/Thio-Topo R© pBad fw GCTATGCCATAGCATTTTTATCC
pBad rev GACTAAATTAGACATAGTCCG
pJet (Clonejet) pJetfw CGACTCACTATAGGGAGAGCGGC
pJetrev AAGAACATCGATTTTCCATGGCA
pGADT7 Y2H T7 TAATACGACTCACTATAGGGC
Y2H AD AGATGGTGCACGATGCACAG
pGBTK7 Y2H T7 TAATACGACTCACTATAGGGC
Y2H BD TTTTCGTTTTAAAACCTAAGAGTC
pSec-Hygro psecfw CTAGTTATTGCTCAGCGGTGG
psecrev TAATACGACTCACTATAGGG
pcDNA3.1 pcDNA3.1rev CTAGAAGGCACAGTCGAGGC
T7 GTAATACGACTCACTATAG
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Genespecific primers:
Name Sequence
abl1dw1 CACCCCACCCATTCTCCTCTAC
abl1up1 CAGCCATGAGGACGTTGC
abl2dw CCGGAGCTATGCAGAATATCTTC
abl2up-II CACAGCCACAGTAACGTCATAGG
emil11 BamH1 up GCGATGGATCCGCCTTTTGCACAGAAC
emilp1 EcoR1dw GTCACGAATTCTTTGAGATGGATAAACG
emilp2 BamHI GCGATGGATCCAACAACAGCATTGAG
emilp2 ecoRI GTCACGAATTCGTATCACCTCTTCATG
emir2adw CCCTCGAGTGATGCAGTGC
emir2bdw GGAGCCTATGGATGCAGTGC
emir2cdw CCCTCGAGTCCTCCTTGAGTTC
emir2ex EcoRI GTCACGAATTCACAGACAATGAATGTGC
emir2ex SacI up GTTGAGAGCTCCCATTCGTAAAAACCAC
emir2ex XhoI GTTGACTCGAGGTCCTTCACAGAAGC
emir2intra up CTCAGAATTCATGTGAGAGTGGAAG
emirbdw3 GGACGAGTGGGAGGTGG
emirbdw5 GAGCCTATGCCTCCTTGAGTTCG
emirbF3dw GCAACCACCTTCGCTAATG
emirbup3 GAACTGTTTCATGTGGGAGG
emirbup4 GGAAACTCAATTTCGCCG
ilp1HindIII dw GCATAAGCTTGTCGCCTCTGGCCCAAG
ilP1NotI Stop GCATGCGGCCGCTCAGCCTTTTGCACA
ilp2HindIII dw GCATAAGCTTGGTATCACCTCTTCAT
ilp2NotI Stop GCATGCGGCCGCCTAAACAACAGCATT
ins1dw3 GACCTTTTCACTAGTGAATTCC
ins2dw2 GCAATGTCTTCCCCAAGTC
ins1 upnested GGTGTAAGGCTCGTAGCG
ins2 upnested GTACAGCCTAAACAACAGCATTG
RC19 GATGATTCCTTCGATTTGCA
RC21 TAAACGAGACGTTCCCAACATG
tk6dw CTTCGAGCCGCCAACATCC
tk6up GATGTACTGACCCTCCGTCTGG
3.3 Antibodies
Primary antibodies:
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Antibody Dilution Source Company
β-Actin 1: 1000 5 % BSA TBST Rabbit Cell Sig.
Elp 1: 1000 5 % skim milk TBST Mouse Cell Sig.
EmIR1 purified 1:300 5 % skim milk TBST Rabbit Immunoglobe
EmIR2 purified 1:300 5 % skim milk TBST Rabbit Immunoglobe
1:30 (IP)
1:10 (IHC)
P-Akt substrate 1: 1000 5 % BSA TBST Rabbit Cell Sig.
P-4E-BP 1: 1000 5 % BSA TBST Rabbit Cell Sig.
Secondary antibodies:
Antibody Dilution Company
anti-mouse IgG–HRP 1: 10.000 5 % skim milk TBST Jackson,
ImmunoResearch
anti–rabbit IgG–HRP 1: 5.000 5 % skim milk TBST Jackson,
ImmunoResearch
3.4 Working with RNA
3.4.1 Isolation of RNA
For the isolation of RNA, parasite material was resuspended in 1 ml Trizol and lysed for
5 min. Then 200 µl Chloroform was added. The suspension was shaken vigorously for 15
s and subsequently centrifuged at 12000 g for 15 min at 4◦C. The upper water-phase was
transferred into a new Cap and the RNA was precipitated over night at -20◦C by adding
0,25 Vol precipitation buffer (1.2 M NaCl, 0.8 M Sodium citrate) and 0,25 Vol isopropanol.
The samples were then centrifuged at 12000 g for 30 min and 4◦C and the pellet was
washed with 70 % ethanol. The pellet was then air-dried and resuspended in 17 µl DEPC-
water.
3.4.2 DNAse treatment of isolated RNA
For DNA digestion the RNA was heated for 15 min at 95◦C,then the RNA was supple-
mented with DNAse (2 U/ µg RNA; RQ1 DNAse, Promega) and 10 x DNAse buffer and
incubated at 37◦C for 1 h. 1 µl stop-solution was added and the DNAse was inactivated at
65◦C for 15 min.
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3.4.3 Determination of RNA concentration
The RNA concentration was photometrically measured at a wavelength of 260 nm using
the NanoDrop 1000. The purity of the nucleic acids was analysed on the basis of the ratios
of 260 nm/ 280 nm (for protein impurity ≥ 2.0).
3.4.4 Synthesis of cDNA
Omniscript RT-PCR kit (Qiagen)
The reverse transcription of total RNA into the first strand of cDNA was done using the
oligo-dT-primer CD3RT and the Reverse Transcriptase from the Omniscript RT-PCR kit
(Qiagen) according to the manual instructions. 2 µg RNA were incubated with CD3RT at
a final concentration of 1 µM at 65◦C for 10 min to allow better annealing of the oligonu-
cleotide. After cooling to RT, all remaining components, including 1 U RNAseOut (Invitro-
gen), were added. The reaction was incubated at 37◦C for 90 min.
PrimeScript
Reverse transcription with the PrimeScript was carried out according to the product man-
ual. 1- 2 µg RNA was incubated with a random-octamer oligonucleotide for 5 min at 65◦C.
Subsequently, all remaining components were added, including 1 U RNAseOut (Invitro-
gen) and the reaction was incubated for 10 min at 30◦C and then 90 min at 42◦C. The
reaction was terminated by incubating for 15 min at 70◦C.
Smart cDNA synthesis
Synthesis of smart cDNA is based on the SMARTTM RACE cDNA Amplification kit (Clon-
tech). Reverse transcription was carried out using the PrimeScript polymerase and the
primers CD3RT, SmartI and SmartII. CD3RT was incorporated during first strand synthe-
sis, while SmartI and SmartII bind to the 5´cystidine overhangs created by the polymerase.
This approach allows amplification of unknown 5´and 3´ends via PCR.
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3.5 Working with DNA
3.5.1 Isolation of chromosomal DNA
For the isolation of genomic DNA, in vitro cultivated metacestode vesicles were washed
with 1x PBS, disrupted by pipetting and pelleted by a centrifugation step at 800 g for 3
min. The supernatant was removed and the pellet was dissolved in gDNA lysis buffer (100
mM NaCl, 10 mM Tris-HCl, pH8.0, 50 mM EDTA, pH8.0, 0.5 % SDS) supplemented with
20 µg/ml RNase A and 100 µg/ml Proteinase K. 1.2 ml buffer per 100 mg pellet was used.
For total digestion of Echinococcus cells, the samples were incubated 4- 5 h at 50◦C and
agitated. The DNA extraction was carried out as follows. One volume of phenol-chloroform-
isoamyl-alcohol (25:24:1) was added to the samples and centrifuged for 25 minutes at 2000
g and room temperature, the upper aqueous phase was transferred into a new tube and the
extraction step was repeated one to two times. The DNA was precipitated by adding 0.1
Vol LiCl (stock 5 M; pH 4.5) and 2 Vol 96 % ethanol. The precipitation mix was incubated
over night at -20◦C. The samples were then centrifuged at 20,000 g for 30 min at 4◦C and
the pellet was washed with 70 % ethanol and air-dried. The pellet was resuspended in 1x
TE buffer (10 mM Tris, 1 mM EDTA pH 8.0).
Isolation of plasmid DNA from E. coli
The isolation of plasmid DNA from E. coli strains was performed with the NucleoSpin R©
Plasmid Kit (Macherey-Nagel).
3.5.2 Determination of DNA concentration
DNA concentration was photometrically measured at a wavelength of 260 nm using the
NanoDrop 1000. The purity of the nucleic acids was analysed on the basis of the ra-
tios of 260 nm/ 280 nm (for protein impurity; 1.8- 2.0) and 260 nm/ 230 nm (for salt
impurity, above 2.0). A method to measure DNA concentration of PCR products was
the comparison of the band intensity with the defined SmartLadder (Eurogentec) DNA-
standard.
3.5.3 Polymerase-Chain Reaction (PCR)
PCR reactions were carried out with custom-made oligonucleotides (Sigma-Aldrich). The
annealing temperature was calculated with the equation Ta[◦C]= 4x (G+C)+ 2x (A+T).
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The elongation time (te) was calculated with 1 min per 1000 nt for TaqPolymerase (NEB).
The elongation temperature was 72◦C. Therefore, the cycling parameters were generally
as follows: an initial denaturation for 1 min at 94◦C, 30- 35 cycles of a denaturation
(30 s), primer annealing (30 s) and a elongation step (te) and with a final elongation
for 10 min at 72◦C. The PCR mix included 1- 5 µl template, 2 µl 10x buffer, 0.2 µl of
dNTPs (10 mM), oligonucleotides (50 µM) and Taq DNA polymerase (2 U/ µl) at a final
volume of 20 µl. Other polymerases were used according to the manufacturer’s instruc-
tions.
Semi-quantitative RT-PCR
Total RNA was isolated from in vitro cultivated metacestode vesicles, primary cells, as
well as activated or non-activated protoscoleces isolated from gerbil material. cDNA was
produced using the Omniscript RT-PCR kit (Qiagen) and oligonucleotide CD3RT according
to the manufacturer’s instructions. The original cDNA was diluted 1:2 and ten-fold serial
dilutions of the cDNA were used as template for PCR. Normalisation of the cDNA amount
was carried out by comparison of the band intensity of the constitutively expressed emelp
using the primer pair Em10 15 and Em10 16 at 35 cycles. For the studied genes, oligonu-
cleotides were designed amplifying fragments of 300- 500 nt.
Colony-PCR
To test the successful integration of fragments into the target plasmids the colony PCR was
used. Colonies were picked from the agar plate and transferred separately into 30 µl sterile
water. For PCR 3 µl of this bacteria-suspension were used. The PCR reaction was carried
out with the Taq-Polymerase under standard conditions.
3.5.4 Rapid amplification of cDNA ends (RACE)
The 5´ and 3´ RACE experiments were carried out on either smart cDNA or the Y2H
cDNA library in the pJG4-5 plasmid [40]. For the first PCR a primer complementary to
the 5 or 3´end of the template and a gene specific primer was chosen. For nested PCR
primers within the amplified fragment close to the first primer binding sites were cho-
sen.
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3.5.5 Sequencing
DNA was sequenced in an ABI PrismTM Sequencer 377 (Perkin Elmer), according to the
dideoxy method (Sanger, 1977). 300 ng plasmid or 1 µl PCR-product was mixed with 5 nM
oligonucleotide and 5x sequencing buffer to a final volume of 9 µl. Polymerase was added
directly before the PCR-reaction. From march 2012 onwards sequencing was carried out at
GATC (Konstanz, Germany). The DNA (plasmid 400-500 ng and PCR-product 100- 200 ng)
was mixed with the oligonucleotide at a final volume of 10 µl.
3.5.6 Agarose gel-electrophoreses
1- 2 % agarose gels were prepared according to the size of the DNA-fragments. The agarose
was dissolved by heating in 1x TAE buffer (40 mM Tris, 1 mM EDTA, pH8.0, 0.11 % glacial
acetic acid ad 1 l H2O, pH8.5). At 50◦C, the agarose-TAE solution was poured into a hor-
izontal gel sleigh, where loading wells were left by inserting combs. The samples were
mixed with 6x agarose buffer (0.25 % bromophenol blue, 0.25 % xylene cyanol, 40 % sac-
charose and 30 % glycerol) and the separation was carried out at a voltage of 100- 120 V
for 20- 30 minutes. The separation was estimated by running of the two dyes included
in the loading buffer. In a 1 % agarose gel, the bromophenol blue band and the xylene
cyanol correspond to a 0.3 kb and 3 kb fragments, respectively. The DNA was visualised
by staining with ethidium bromide (0.2 mg/ml in 1x TAE) and UV light. The SmartLadder
(Eurogentec) was used as DNA standard.
3.5.7 TA-cloning
The Taq-Polymerase automatically adds A-overhangs to the 3´ end of the synthesised frag-
ments. These fragments can be ligated into plasmids supporting the TA cloning e.g. PCR-
cloning kit (Qiagen) or the TOPO-TA Cloning R©KIT (Invitrogen), which possesses corre-
sponding 5´T overhangs. The reaction was carried out according to manufacturer´s in-
structions. Selection of the positive colonies was done by blue-white selection and colony-
PCR.
3.5.8 Addition of A-overhangs
PCR products without the 3’ A-overhangs were incubated with Taq DNA polymerase and
dATP for 10- 30 min at 72◦C and subsequently ligated into pDrive or pBad.
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3.5.9 Blunt-end ligation
For ligation of blunt-end fragments the CloneJETTM kit (Fermentas) was used according
to the manual.
3.5.10 Purification of DNA from agarose gels, PCR and enzyme
reactions
Purification of fragments was from agarose gels carried out by excising the band of in-
terest and purification with the NucleoSpin R© (Macherey-Nagel), according to the manual.
PCR products and enzyme reactions were purified with the same kit, without the agarose
melting step.
3.5.11 Restriction digestion
Restriction digestion was carried out with enzymes purchased from NEB. With the optimal
buffer and temperature for every enzyme according to the instructions. The reaction was
incubated for 15 min to 2 h depending on the enzyme.
3.5.12 Dephosphorylation of plasmid DNA
To avoid re-ligation, plasmids were dephosphorylated subsequently to restriction diges-
tion. CIP or antarctic phosphatase (NEB) were added according to the manufacturer´s
specification and incubated for 30 min at 37◦C.
3.5.13 Ligation
Inserts and plasmids resulting from restriction digestion were ligated with the T4 DNA
ligase (NEB). The amount of insert DNA was calculated with the following formula. Ide-
ally, a ratio between 3:1 and 5:1 was used.
ngInsert =
ngV ector ∗ kbInsert
kbV ector
∗Ratio
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3.6 Working with proteins
3.6.1 Preparation of protein samples
Crude lysates were prepared by adding 5x sample buffer to a final concentration of 1x.
The samples were boiled for 10 min and centrifuged for 1 min with 11.000 g. The su-
pernatant was transferred to a fresh cap. For subsequent protein determination sample
buffer without bromophenol blue was used. Membrane fractions were won by lysis of para-
site material for 1-2 h in lysis buffer (20 mM Tris-HCl,pH 8.0; 150 mM NaCl; 1 mM EDTA
pH 8, 0;1 %TritonX-100 ; 2 % Sodiumdeoxycholate; 1 mM Na3VO4; 10 mM NaF) sup-
plemented with 1x protease inhibitor (Complete Mini phosphatase inhibitor Mix, Roche).
The lysis was carried out at 4◦C on a rotor. The samples were centrifuged for 1 min at
11.000 g and the supernatant was transferred into a new cap. After determination of the
protein concentration, the samples were diluted with 5x sample buffer and boiled for 10
min.
3.6.2 Quantification of protein concentration
The protein concentration was measured with the BCA protein assay (Pierce). The solution
A and B were mixed with the ratio 50:1 and 200 µl were added to 10 µl protein solution in
a 96 well plate. The following standard samples were prepared with BSA: Blank, 25 µg/ml,
125 µg/ml, 250 µg/ml, 500 µg/ml, 750 µg/ml, 1000 µg/ml, 1500 µg/ml. The reaction was
incubated for 30 min at 37◦C and measured at 540 nm.
3.6.3 SDS-PAGE
For the SDS-PAGE the Biorad Mini- Protean system was used. Separation gels were pre-
pared in 8 10 or 15%, the stacking gel was 4%. Combs with 9, 10 or 15 pockets were
inserted into the gel directly after filling the gel solution into the polymerisation chamber.
The indicated amounts were calculated for 2 Mini-gels.
Solutions:
4 x Lower-Tris 1.5 M Tris-HCl pH 8.8; 0.4% SDS
4 x Upper- Tris 0.5 M Tris-HCl pH 6.8; 0.4% SDS
5x Sample buffer 15% Tris-HCl (250 mM pH6.8);50 % Glycerol;
10 % SDS, 25 % ß-MerOH,bromophenol blue
TEMED (N, N, N’, N’-Tetramethylethylendiamin)
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16% Ammonium-Persulfat (APS)
PAA
Running buffer 25 mM Tris pH 8.3; 192 mM Glycin, 0.1% SDS
Pipetting scheme for 2 gels:
15 % 10 % 4 %
H2O [ml] 3 5 3.2
Lower-Tris [ml] 3 3 -
Upper-Tris [ml] - - 1.6
PAA 30% [ml] 6 4 0.75
APS 16[µl] % 60 60 35
TEMED [µl] % 20 20 10
3.6.4 Coomassie
The protein gels were stained for 20- 30 min with staining solution on the seesaw. For
destaining, the destaining buffer was changed several times until the desired band in-
tensity was reached. Bands were visualised by destaining the unspecifically stained gel
areas. To dry the gels cell glass was wetted in water with glycerol. The gel was completely
covered with the foil and fixed in a dry-frame. The gels were dried for approximately 3
days.
Solutions:
Staining solution 1 g Coomassie Blue R-250, 450 ml Methanol,
450 ml H2O, 100 ml acetic acid
Destaining solution 100 ml Methanol, 100 ml acetic acid, 800 ml H2O
3.6.5 Western blot
For the transfer of the separated proteins onto a nitrocellulose membrane the Biorad Mini
Trans-Blot Cell system was used. The transfer was carried out for 1 h at 350 mA. Sub-
sequently, the membrane was blocked for 1 h at room temperature in blocking buffer The
corresponding antibody was incubated over night at 4◦C on a seesaw. The membrane was
washed 3x for 10 min at room temperature, after which the membrane was incubated
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with the secondary antibody for 1 h at RT on the seesaw. The three washing steps were
repeated and the proteins were visualised by chemiluminescence (ECL, Pierce) and ex-
posing to X-ray-films. The films were developed with a Curix 60 automated developer
(Agfa).
Solutions:
Running buffer 25 mM Tris pH 8.3; 192 mM Glycin; 5% Methanol
Blocking buffer 5 % skim milk in TBST
5 % BSA in TBST
TBST 20 mM Tris pH 7.5; 150 mM NaCl; 0.1 % Tween-20
Stripping buffer 20 mM Tris pH 6.8; 2 % SDS; 0.7 % β-Mercaptoethanol
ECL- Western Blot Substrate (Pierce)
3.6.6 Ponceau-red staining
Nitrocellulose membranes were stained with Ponceau-red solution (2 % Ponceau-red in 30
% trichlor acetic acid) for 1- 2 min prior to blocking. The dye was washed out by rinsing
with desalted water until the protein bands were visible.
3.6.7 Purification of polyclonal antibodies
To purify polyclonal antibodies the corresponding, heterologous expressed protein was sep-
arated on a 10 % SDS gel prepared with a 2- pocket comb. After western blot, the protein
band was detected by Ponceau-staining and cut out. The nitrocellulose membrane was
transferred to a 2 ml Eppendorf cap and blocked with 5 % BSA in PBS for 4 h at 4◦C
on a rotor. 2 ml immune-serum was added and incubated over night at 4◦C on a rotor.
The supernatant was transferred to a new cap for repeated use and the membrane was
washed first with 0.15 M NaCl for 20 min at room temperature and then with 1x PBS.
Subsequently, the membrane was incubated with 300 µl elution buffer (0.2 M Glycin; 1
mM EGTA pH 2.5) for 20 min at room temperature. The supernatant was transferred into
a fresh cap and neutralised with 00 µl 1 M Tris pH 8. The membrane was washed with 1x
PBS and stored at -20◦C.
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3.6.8 IHC
Samples embedded in Technovit 8100 were cut in 4 µm sections and taken up on a glass
slide. The sections were dried for 2 h at 37◦C and cauterised for 4 min with acetone. A de-
creasing ethanol series was used to rehydrate the sections (5 min 100 % ethanol; 5 min 96
% ethanol; 5 min 70 % ethanol; 5 min 1 x PBS). The samples were then permeabilised for
7 min with 1 % Triton in PBS and rinsed 3 x with PBS. To block endogenous peroxydases
the slides were incubated for 10 min with 0.3 % H2O2 in methanol and washed 2x 5- 10
min with PBS. Blocking was carried out for 60 min with 2 % BSA in PBS. The first anti-
body was used at a dilution of 1:10 in blocking buffer and incubated over night at 4◦C in a
humid chamber. The samples were washed 3x for 5 min with PBS and the second antibody
(POX-anti-rabbit 1:50 in blocking buffer) was incubated for 3 h at room temperature in a
humid chamber. The samples were washed again and substrate solution (2 mg DAB; 2 ml
PBS; 2 ml H2O; 1.34 µl 30% H2O2) was added and incubated at room temperature until the
desired intensity was reached. To stop the reaction the slides were rinsed with H2O. Coun-
terstaining with Haematoxylin was carried out by a 6 min incubation with Haemalaun
(Roche) and rinsing in H2O. The slides were then washed for 15 min in running tab water.
The slides were then dehydrated by passing through an increasing ethanol series (5 min
70 % ethanol; 5 min 96 % ethanol; 5 min 100 % ethanol; 5 min xylol) and then mounted
with Entellan (Merck).
3.6.9 Immuno precipitation
Metacestode vesicles were stimulated and prepared according to protocol. The vesicles
were disrupted and 1 ml IP buffer (20 mM Tris-HCl,pH 8.0; 150 mM NaCl; 1 mM EDTA pH
8, 0;1 %TritonX-100 ; 1 mM Na3VO4; 10 mM NaF) supplemented with 1x protease inhibitor
was added. The samples were rotated for 2 h at 4◦C and then centrifuged for 15 min at
13.000 g and 4◦C. The supernatand was transferred to a fresh cap and supplemented with
purified immune-serum in the dilution of 1:50. The samples were incubated over night
at 4◦C on a rotor. 60 µl Agarose-G beads were washed 3x with TBST (centrifugation at
2500 rpm for 1 min) and added to the protein-antibody solution. The samples were rotated
for 4-5 h at 4◦C and subsequently washed 3x with IP buffer (2500 rpm 1 min). 100 µl
2x sample buffer was added and the samples were boiled for 10 min. Technical controls
were included to check for unspecific binding: First, protein samples without antibody and
second, antibody without protein.
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3.7 Working with bacteria
3.7.1 Chemically competent E. coli
E. coli strains Top10 or Bl21 were made chemically competent with the CaCl2 method as
follows. 1 ml LB- medium was inoculated with the E. coli strain and grown over night at
37 ◦C and 225 rpm. This culture was transferred into 50 50 ml of fresh LB and the bacteria
were left to grow to an OD600 of 0,5- 0.7 (app. 2- 3 h). The culture was centrifuged at 4000
rpm at 4◦C for 10 min. The supernatant was discarded and the pellet was resuspended in
12 ml ice cold 100 mM CaCl2 and again centrifuged. The pellet was carefully resuspended
in 1 ml 100 mM CaCl2 and incubated on ice for 30 to 60 min. Glycerol was added in a final
concentration of 20 %. The bacteria were frozen on dry-ice in 50 µl aliquots and stored at
-80◦C.
3.7.2 Transformation of E.coli
Aliquots of competent E. coli aliquots were melted on ice and 2- 5 µl ligation reaction was
added. The transformation reactions were incubated on ice for 30 to 60 min, followed by
a heat-shock for 1 min at 42◦C and additional 2 min on ice. 125 µl of Soc or LB medium
were added and the reactions were incubated at 37◦C and 225 rpm for 45 min to 1 h.
Afterwards the bacteria were plated on LB- agar plates (LB, 15 % agar) supplemented
with antibiotics (100 µg/ml ampicillin or 50 µg/ml kanamycin) and incubated at 37◦C over
night. Additionally, for blue-white selection of the pDrive plasmid (PCR cloning kit, Quia-
gen) 40 µl X-Gal (40 mg/ml in DMSF) was plated before adding the transformation reac-
tion.
3.7.3 Liquid culture of E.coli
4 ml to 1 l LB-medium supplemented with the corresponding antibiotics was inoculated
with transformed E. coli. The culture was incubated over night at 37◦C and 225 rpm.
3.7.4 Glycerin stocks
600 µl liquid solution were mixed with 400 µl 85 % glycerol and transferred to a cryo-cap.
The glycerol stock was stored immediately at - 80◦C. For inoculation of liquid cultures
from the stocks small portions were scraped of the frozen culture and transferred to the
LB-medium.
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3.7.5 Recombinant expression of E. multilocularis proteins in E.
coli
For expression of E. multilocularis proteins the pBAD/TOPO R© ThioFusionTM Expression
Kit (Invitrogen) was chosen. The cloning of PCR products into the pBAD/thio plasmid is
based on TA-cloning and was carried out according to manufacturer´s instructions. The
expression was tested in a pilot experiment for testing the expression conditions. Based
on these experiment the expression was carried out using 1 l final volume of LB medium.
Therefore 10 ml over night culture of E.coli transfected with the respective plasmid were
transferred to 1 l LB-Amp. The culture was incubated at 37◦C and 125 rpm until an
OD600 of 0.4- 0,5 was reached. The expression was induced by adding arabinose to a final
concentration of 0.002 % and the culture was incubated for another 4 h. The cells were
pelleted at 3000 rpm for 10 min at 4◦C and the purification was carried out according to
the ProBondTM Purification System (Invitrogen) manual. The cell pellet was resuspended
in 20 ml Guanidinium lysis buffer and incubated at room temperature for 10 min and
gentle shaking. The samples were sonicated with 5 30 s pulses and centrifuged at 12.000
rpm for 20 min. The pellet was lysed a second time with 5 ml fresh lysis buffer and after
centrifugation the supernatants were combined. The ProBondTM Nickel-Chelating Beads
(Invitrogen) were equilibrated by washing three times with guanidinium lysis buffer. 2 ml
beads were added to the lysis supernatant and the samples were incubated over night at
4◦C on a rotor. The mixture was then decanted into a PD-10 column (GE Healthcare) and
the flow was set to 30- 40 drops/ min. The beads were washed with 150 ml Denaturing
wash buffer. Elution was carried out two times for each buffer by incubation of the beads
for 10 min with 1 ml elution buffer and collection of the elution fraction. Elution was done
with Denaturing elution buffer, followed by Imidazole elution buffer and a third elution
with 0.5 M EDTA. The beads were regenerated by washing with 15 ml of the following: 50
mM EDTA, 0.5 M NaOH, H2O, 5 mg/ml Ni(II)Cl2 and H2O. The beads were stored at 4◦C
in 20 % EtOH.
Samples for SDS-PAGE were collected before and after induction, from the washing frac-
tion and the elution fractions.
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Buffers and solutions
Guanidinium Lysis buffer 6 M Guanidine-HCl, 20 mM Na3PO4, 0.5 M NaCl, pH 7.8
Denaturing wash buffer 8 M Urea, 20 mM NaH2PO4, 0.5 M NaCl, pH 5.8
Denaturing elution buffer 8 M Urea, 20 mM NaH2PO4, 0.5 M NaCl, pH 3.8
Imidazole elution buffer 250 mM Imidazole, 50 mM Na2HPO4, 300 mM NaCl, pH
8
0.5 M EDTA, pH8
0.5 M NaOH
5 mg/ml Ni(II)Cl2 and H2O
20 % EtOH
3.8 Working with E. multilocularis
Media and solutions Preparation
MEM DMEM without FCS and PST
Culture medium DMEM, 10 % FCS, 1 % PST, 4 µl/ml Tavanic
Starvation medium DMEM, 0.2 % FCS, 1 % PST, 4 µl/ml Tavanic
A4 pre-incubation of 100 ml culture medium for 7 d with 106
Rh-, sterile filtration, storage at -20◦C
B2 pre-incubation of 100 ml culture medium for 3 d with 2x
107 Rh-, sterile filtration, storage at -20◦C
cMEM undefined conditioned medium (filtered supernatant of
Rh- from co-culture)
Reducing agents 100 µM L-Cystein , 10 µM Bathocuproine disulfonic acid,
0.01 % β-mercaptoethanol
3.8.1 Isolates and maintenance of parasite material
The long-term maintenance of E. multilocularis metacestodes is ensured by passages in
the peritoneum of Mongolian jirds (Meriones unguiculatus). The jirds were infected with
homogenised larval material by intraperitoneal injection. The animals that developed a
secondary alveolar echinococcosis (app after two months) were sacrificed with CO2 and the
larval material was isolated under sterile conditions. The isolated parasite tissue was cut
into small pieces and passed through a metallic tea sieve. The sedimented material was
washed with sterile PBS until the majority of red blood cells was removed. For reinfection
of jirds the parasite material was treated with Tava (4 µl/ml parasite suspension) at 4◦C
over night. Then the material was washed again and the PBS was carefully decanted. Sub-
sequently syringes with 0.3- 0.5 ml were prepared from the sediment and used for infection
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of jirds. The Tava treated material was also used to set up metacestode in vitro cultures.
For the isolation of protoscoleces the material was used without the antibiotic over night
treatment [42,43].
Isolate Source
H95 primary infection of M. unguiculatus by oncosphere uptake
Java, 7030, J31 Java monkey as intermediate host
GH09 Java monkey as intermediate host, 2009
G8065, GT10 Java monkey as intermediate host, 2010
Ingrid Java monkey as intermediate host, 2011
MS10 dog as intermediate host, 2010
3.8.2 In vitro cultivation
For in vitro cultivation of E. multilocularis Tava- treated parasite material was used to
set up co-cultures. The material was passed through a plastic tea sieve and transferred
to a 50 ml greiner. Different fractions could be used to set up the culture: Crude material
from the top of the sieve, liquid from the 20 ml mark after 10-30 s of sedimentation and
the sediment in the greiner.1 ml material was seeded into a 75 cm2 bottle and 50 ml of 10
% FCS/ DMEM/ PST (100 U/ml penicillin G/ streptomycin) was added. Additionally 107
trypsinised Rh- cells were added. Medium change was carried out once a week and new
Rh- cells were added during each change. The parasite material was split after reaching
5, 10 and 20 ml of volume [42,43].
3.8.3 Axenic culture
For axenic cultivation 15- 20 ml metacestode vesicles were washed with PBS. CMEM sup-
plemented with L-Cystein (100 µM), Bathocuproine disulfonic acid (10 µM) and β- mercap-
toethanol (0.01 %) was added to 50 ml. The culture was transferred to a 75 cm2 sterile cel
culture bottle and a nitrogen atmosphere was applied. The culture was incubated for 2- 3
d prior to experiments [43,44].
3.8.4 Isolation and cultivation of primary cells
Axenic metacestode vesicles of a milky-white appearance with a thick laminar layer were
washed with PBS until the supernatant was colourless. The vesicles were destroyed with a
10 ml pipette and washed again for two more times. Centrifugation for 3 min at 800 g could
be included for better pelleting. The PBS was removed and 4 volumes of trypsin (0.05 %
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trypsin, 0.02 % EDTA in PBS) was added and the vesicles were incubated for 15- 20 min at
37 ◦C. During the incubation the vesicles were shaken at regular intervals. The trypsiniza-
tion was ready when the majority of vesicles were floating at the surface of the liquid. The
suspension was then shaken vigorously for 2 min and filtered over a 150 µm gauze filter
fixed to a glass beaker. The filter was rinsed with PBS and the flow-through was again
filtered over a 30 µm gauze filter. this flow-through was decanted into a 50 ml greiner tube
and centrifuged for 1 min at 100 g to remove calcium bodies. The supernatant was trans-
ferred to a fresh greiner and centrifugation to pellet the cells was carried out at 300- 500 g
for 15 min [45]. The cells were resuspended in PBS corresponding to a volume of 1/2 of the
original metacestode vesicle pellet. Subsequently the cell density was measured at OD600.
For that 12.5 µl of the cell suspension was mixed with 1 ml. An OD600 of 0.02 corresponds
to 1 Unit of cells in the cuvette (Markus Spiliotis personal communication). The following
amounts of cells were used for ideal growing conditions:
Plate Units
6 well 500
12 well 150-200
24 well 100- 150
96 well 50
3.8.5 Isolation of protoscoleces
To isolate parasite material from jirds PBS was added to a volume of 25 ml. The material
was vigorously shaken for 10 min and the filtered first over a 150 µm gauze filter fixed to a
glass beaker and then the flow-through with a 30 µm gauze filter. The protoscoleces were
collected from the surface of the 30 µm gauze filter by pipetting and rinsing with PBS. The
protoscoleces were transferred to a petri dish. Circular movement of the dish resulted in
a concentration of pure protoscoleces in the middle of the dish, where they were collected
with a pipette and transferred to a Eppendorf cap.
3.8.6 In vitro activation of protoscoleces
Isolated protoscoleces were activated by mimicking the gastrointestinal passage. They
were incubated in 30 ml MEM supplemented 0.05 % pepsin pH2 (200 µl 25 % HCL) for
30 min at 37◦C and 125 rpm. After washing with PBS until the supernatant was colour-
less the protoscoleces were transferred to 30 ml MEM supplemented with 0.2 % sodium
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taurocholate and were incubated for another 3 h at 37◦C and 125 rpm. The protoscole-
ces were washed again with PBS. Both activation media were sterile filtered prior to
use [54].
3.8.7 Cultivation of protoscoleces
Non-activated or activated protoscoleces were ideally cultivated in A4 or B2 supplemented
with reducing agents and a nitrogen phase. The amount of seeded protoscoleces was ap-
proximately 200- 400 protoscoleces per well of a 12 well plate [38].
3.8.8 Life-dead staining of protoscoleces
Protoscoleces were transferred to a Eppendorf cap washed 1x with PBS. The PBS was re-
moved and 0.03 % methylene blue was added. After 1 min the samples were washed again.
The protoscoleces were counted under a light microscope. Dead protoscoleces appeared
blue, while healthy protoscoleces were not stained.
3.8.9 In vitro stimulation of metacestode vesicles
Metacestode vesicles were collected in a 50 ml Greiner tube and washed with PBS. Depend-
ing of the size of the vesicles 10 to 12 axenic vesicles of 3- 5 mm or 0.5 ml of smaller vesicles
were used per sample. For starvation the vesicles were incubated with starvation medium
(0.2 % FCS) and reducing agents for 16 h to 4 days. After starvation the medium was
changed to pre-warmed fresh starvation medium and cytokines or inhibitors were added.
For terminating the reaction, the samples were put on ice and washed 1x with cold PBS
supplemented with 1 mM Na3VO4 and 10 mM NaF. The vesicles were destroyed by pipet-
ting and centrifuged for 3 min at 800 g and 4◦C. The PBS was removed and the samples
prepared for SDS-PAGE (see section 3.6.3).
3.8.10 BrdU incorporation
Axenic metacestode vesicles were starved over night in starvation medium supplemented
with reducing agents and nitrogen phase. The medium was removed and fresh medium
was added. BrdU (final concentration: 1 mM) and insulin (1- 100 nM) were added and
the samples were incubated for 2 d followed by isolation of chromosomal DNA (see section
3.5.1). A 96 well plate was coated with cDNA as follows. 0.5- 1 µg were mixed in a glass
tube with the same volume of TE buffer. One volume of Reactibind (Pierce) was added. 96
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well plates were loaded with 200 µl of the coating solution and incubated over night at room
temperature and gentle shaking. The plate was washed 3x with PBS and blocked with 2%
skim milk in PBS for 1 h. After washing the BrdU incorporation was determinated with
the colorimetric cell proliferation BrdU ELISA kit (Roche), continuing with step 6 (Manual
version: august 2007). The substrate reaction was stopped by adding 25 µl of H2SO4 and
the absorption was measured at 450 nm (reference wavelength 690 nm) on a Tecan ELISA
reader.
For detection of BrdU incorporation in primary cell cultures, 10 U/ well of freshly isolated
primary cells were seeded in a 96 well plate with 200 µl of 2 % FCS/DMEM supplemented
with reducing agents. Insulin was added and the cells were incubated for 24 h at 37◦C
and nitrogen phase. BrdU was added to a final concentration of 1 mM and incubated for
another 4 h. The plate was centrifuged for 10 min at 4◦C and 400 g followed by a washing
step with PBS. Subsequently, the PBS was removed and the plate was dried for 1 h at
60◦C, after which the plate could be stored at 4◦C. The colorimetric cell proliferation BrdU
ELISA kit (Roche) was used to measure the brdU incorporation. Lysis of the samples was
carried out according to the manufacturer´s instructions. After washing with PBS and a
blocking step (2 % skim milk/ PBS 1h, RT) was included followed by washing 3 x with PBS.
The protocol was continued at step 6.
3.8.11 Glucose uptake
Axenic metacestode vesicles were starved over night in 0.2 % FCS/ DMEM (glucose free)
supplemented with 2.5 mM D-glucose. For the stimulation with insulin 5 vesicles (3- 4
mm) were transferred to a 15 ml Greiner tube, washed with PBS and 1.5 ml pre-warmed
medium supplemented with 30 nM insulin or insulin and 30 nM Na3VO4 was added. All
samples were prepared as triplets. The stimulation was carried out for 5 min and 0.1 µCi/
µl (Hartmann Analytic) was added to each sample. The samples were carefully mixed
and incubated for 1 h at 37◦C. Subsequently, the vesicles were destroyed and washed 2x
with PBS. The samples were centrifuged for 1 min at 2000 rpm and the supernatant was
discarded. The pellet was lysed in 300 µl 0.15 M NaOH for 5 min at room temperature.
The samples were then centrifuged for 3 min at 10.000 rpm and 150 µl of the sample was
mixed with 1.5 ml UltimaGoldTM (Perkin Elmer). The C14 content was measured in a
scintillation counter.
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3.8.12 Resazurin assay in primary cells
Primary cells were isolated according to protocol (see section 3.8.4) and seeded with 10
U/ well to a 96 well plate. DMEM (10 % FCS, without phenol-red) was supplemented
with the inhibitor in question and 100 µl medium were added to the cells. A dead-control
was prepared with 1 % Triton. The plate was incubated for 2- 6 d at 37◦C and nitrogen
atmosphere. Subsequently, the resazurin stock solution (2 mg/ml in H2O, stored at 4◦C,
Sigma) was diluted 1: 100 in PBS and 100 µl of the dilution was added to each well. The
fluorescence was directly measured at 540 nm (reference wavelength 595 nm) with the
Tecan reader to normalise the samples. The plate was then incubated for 3 h at culture
conditions and the final fluorescence was measured (Markus Spiliotis personal communi-
cation).
3.8.13 Embedding of E. multilocularis material
Parasite larval stages were transferred from culture to 2 ml caps and washed with PBS.
Metacestode vesicles were disrupted by pipetting or pricking with a needle. Subsequently,
the samples were fixed for 1 h in 4 % PFA in PBS, followed by a over night with incubation
acetone at -20◦C. Technovit 8100 (Heraeus Kulzer) was used for embedding. First the
samples were incubated with Technovit 8100 solution supplemented with hardener I for 6
h at 4◦C, then the solution was changed to Technovit 8100 supplemented with hardener
I and II. The samples were directly transferred to block forms and a Microtome plastic
block was added on top. The hardening of the plastic was carried out at 4◦C with a N2
atmosphere.
3.9 Working with eukaryotic cell lines
3.9.1 Cultivation
In this work the cell lines Rh- (Reuber hepatoma cells; ATCC No. CRL-1600) was main-
tained for the co-cultivation system. The cells were once a week trypsinized and approx-
imately 106 cells were seeded in a 75 cm2 with 50 ml culture medium. Hek293T cells
(ATCC No. CRL-11268) were seeded with 5x 104 to 105 and medium was changed accord-
ingly.
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3.9.2 Freezing stocks
Freezing stocks were prepared from all cell lines. For that the medium of a cell culture
flask grown to 80 % density was transferred to a Greiner tube (conditioned medium) and
the cells were trypsinized. The cells were also transferred to a greiner tube and centrifuged
for 15 min at 400 g. The supernatant was discarded and the cells were resuspended in 2 ml
conditioned medium, 1.2 ml fresh culture medium and 0.8 ml DMSO. The cell suspension
was aliquoted at 1 ml per cryo-cap and immediately stored in the liquid nitrogen tank.
For setting up new cultures from frozen stocks, the cell aliquots were melted on ice and
transferred to a cell culture flask with 20 ml culture medium. The medium was changed to
remove the DMSO as soon as the cells were adherent.
3.9.3 Transfection of Hek293T cells with the PEI method
Actively dividing Hek293T cells were seeded into wells of a 12 Ell plate with 0.3x 106 cells
per well and incubated over night in 10 % FCS/DMEM For the transfection 100x PEI was
diluted to 1x in MEM. 2 µg plasmid with 50 µl MEM and 2 µl 1x PEI with 50 µl MEM per
transfection reaction were prepared separately. The suspensions were carefully mixed and
incubated for 30 min at room temperature. The medium of the Hek cells was removed and
400 µl fresh medium was carefully added. The transfection mixture was added to the cells
and incubated for 4-6 h, after which it was removed and 2 ml fresh 10 % FCS/DMEM was
added. The expression was carried out for 24 h.
3.10 Working with yeast cells
3.10.1 Yeast strains and media
The S. cerevisiae strain AH109 (BD, Buosciences, Clontech), which was used for yeast two
hybrid (Y2H) experiments has the following specifications:
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal44, gal804, LYS2::GAL1UAS-GAL1TATA-
HIS3, GAL2UAS-GAL2TATA-ADE2, URA3::MEL1UAS-MEL1TATA-lacZ
Media:
YPDA:
20 g/l Difco Peptone
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10 g/l yeast extract
20 g/l Bacto agar (for plates)
H20 ad 950 ml
pH was adjusted to 6.5 by titration of 25 % HCl. After autoclavation 50 ml of 40 % glucose
and 3 ml of 1 % adenine-hemisulfate solution were added. Both solution were sterile fil-
tered.
SD:
6.5 g/l DifcoTM Yeast Nitrogen Base, w/o Amino Acids
20 g/l DifcoTM Bacto Agar
X g of the corresponding drop out supplement (DOS) (Clontech)
H20 ad 950 ml
pH was adjusted to 6.5 by titration of 25 % HCl. After autoclavation 50 ml of 40 % glucose
was added.
SD - Trp:
SD supplemented with 0.64 g/ll Leu/- Trp DOS and 20 ml 50x Leu (5 mg/ml).
SD - Leu:
SD supplemented with 0.64 g/l Leu/- Trp DOS and 20 ml 50x Trp (1 mg/ml).
SD - Leu/- Trp:
SD supplemented with 0.64 g/ll Leu/- Trp DOS
SD - Leu/- Trp/ -His:
0.6 g/l Ade/- His/- Leu/-Trp DOS and 0.64 mg/l histidine HCl mono-hydrate (Sigma-Aldrich).
SD - Leu/- Trp/ -His/-Ade:
0.6 g/l Ade/ - His/ - Leu/ - Trp DOS
3.10.2 Liquid culture
AH109 from freezing stocks or a YPDA plate were transferred into YPDA liquid medium
and incubated over night at 30◦C and 200 rpm.
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3.10.3 Yeast two hybrid (Y2H)
Protein-protein interactions were analysed using the Gal4-based MATCHMAKER system
(Clontech). The proteins of interest were expressed as fusion proteins either with the DNA-
binding domain or the activation domain of the Gal4 transcription factor, that are encoded
on the plasmids pGBKT7 and pGADT7, respectively. The plasmids containing the ORFs
of the respective genes were co-transfected into AH109, grown over night in liquid culture.
10 ml of culture was needed for 10 reactions. The culture was centrifuged for 5 min at 750g
and the pellet was resuspended in transformation buffer (40 % PEG 3350, 200 mM lithium
acetate, 100 mM DTT). 500 ng of each plasmids were prepared in an Eppendorf cap and
mixed with 100 µl of the transformation suspension. The samples were incubated for 30
min at 45◦C. Then the transformation reactions were plated on -Leu/-Trp SD plates for
double transformants. Controls included were the co-transfection of the large T- antigen
(pGADT7: TAG-AD) with tumour suppressor p53 (pGBKT7; p53-BD) as positive control
and the T-Antigen with lamin C (pGBKT7; LamC-BD) as negative control. Furthermore,
the constructs of interest were co-transfected with the respective ”empty” Gal4 plasmid.
Expression of each construct was tested by western blot analysis. For that clones were
picked and transferred to liquid culture with SD medium - Leu (pGADT7) or -Trp (pG-
BKT7). The cells were pelleted and prepared for SDS- PAGE. For the analysis of protein-
interactions the double-transformants were transferred to selection plates. For high strin-
gency selection, SD plates missing leucin, tryptophan, histidin and adenin were used. SD
-Leu/ -Trp/ -His plates were used for medium stringency. The growth was assessed after 3
days of incubation.
3.11 Computer analysis and statistics
Amino acid comparisons were performed using the basic local alignment search tool (BLAST)
available under http://blast.genome.jp. CLUSTAL W alignments were constructed em-
ploying the software BioEdit Sequence Alignment Editor (version 7.0.0) using the BLO-
SUM62 matrix. Alignments were manually modified as needed. Domain predictions were
performed using the simple modular architecture research tool (SMART) available under
http:// smart.emblheidelberg.de. Genomic analyses and BLAST searches against the cur-
rent assembly version of the E. multilocularis genome were done using the respective re-
sources of the Sanger Institute (Hinxton, UK) available under http://www.sanger.ac.uk/cgi-
bin/ blast/submitblast/Echinococcus and the gene annotation available under http://www.
genedb.org/Homepage.
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4.1 The insulin signalling cascade as a possible target for anti-echinococcosis
chemotherapy
4.1.1 Insulin affects the larval development of E. multilocularis
It was recently shown, that insulin positively affects growth and survival of E. multiloc-
ularis metacestode vesicles in vitro [124, 130]. To study this further we employed the
above described culture methods for primary cells, metacestode vesicles and protoscole-
ces.
Development of primary stem cell cultures was shown to mimic oncosphere- metacestode
transition in vitro, which is one of the earliest events during establishment of the dis-
ease [45]. Freshly isolated primary cells first form aggregates, which grow in size and
develop internal cavities and then develop into new metacestode vesicles. In primary
cell experiments morphological appearance, vesicle formation and proliferation of the cul-
tures were investigated. In the primary cell system vesicle formation was significantly
increased at host insulin concentrations of 10 and 100 nM (Fig.4.1A). Aggregates appeared
larger and cavities were more pronounced (Fig. 4.1B). Furthermore, cell density and or-
ganisation of the cellular layer surrounding the cavities appeared healthier and more
structured than in the samples without insulin. In a next experiment proliferation was
measured by BrdU incorporation. Insulin stimulation with 10 nM lead to a significant
increase of BrdU incorporation, whereas 1 nM only slightly increased proliferation (Fig.
4.1C).
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Fig. 4.1: Effects of recombinant host insulin on primary cell cultures. (A) Primary cells were culti-
vated in conditioned medium supplemented with human insulin for 3 weeks after which
the formed vesicles were counted. Results were normalised against the control. (B) Pri-
mary cells were cultivated in 2 % FCS/DMEM with or without 10 nM human insulin for
1 week. Then the aggregates were fixed and embedded in Technovit 8100 and sections were
stained with haematoxylin/eosin. (C) Primary cells were isolated form axenic vesicles and
cultivated for 24 h with or without insulin. BrdU incorporation was measured with col-
orimetric BrdU ELISA kit (Roche). (*) p values below 0.05 (**) p between 0.001 and 0.01,
(***) for p below 0.001
In metacestode vesicles a general increase in growth was observed when insulin was in-
cluded in the culture [124], but due to a high variance no significance could be gained for
theses experiments. Therefore, DNA de novo synthesis was used as a indicator for insulin
action. In these experiments the BrdU incorporation was significantly increased with 10
nM recombinant insulin, but 100 nM insulin lead to a strong inhibition of proliferation
even below the control value (Fig. 4.2).
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Fig. 4.2: Effects of insulin on BrdU incorporation
in metacestode vesicles. Axenic metaces-
tode vesicles were incubated for 2 days
in the presence or absence of insulin in
0.2 % FCS/DMEM supplemented with
BrdU. BrdU uptake was measured after
chromosomal DNA isolation with colori-
metric BrdU ELISA kit (Roche). (*) p be-
low 0.05 and (**) p between 0.001 and
0.01
It was shown for protoscoleces of E. granulosus and E. multilocularis that they have the
ability to develop into microcysts, that add to the pool of metacestode vesicles [131, 132].
We therefore studied the development of microcysts from protoscoleces in our cell culture
system and showed that under axenic conditions microcysts form (Fig. 4.3A). Host insulin
significantly increased the number of microcysts at concentrations of 1 and 10 nM human
insulin (Fig. 4.3B). 100 nM insulin increased dedifferentiation, although no significance
could be achieved. The amount of protoscoleces undergoing dedifferentiation was very low,
between 2 and 4 % (data not shown).
Fig. 4.3: Effect of insulin on dedifferentiation of protoscoleces. (A) Dedifferentiation of protoscoleces
is characterised by a rounding up of the whole protoscolex. Suckers and hooks degener-
ate. The protoscolex appears transparent and vesicle-like. Muscle fibers, retained from the
apical-basal organisation of the protoscolex are still visible in the microcyst (B) Protoscole-
ces were isolated from infected jird material and cultivated for three weeks in conditioned
medium with or without insulin, after which dedifferentiated protoscoleces were counted
(see A below). (*) p values below 0.05 (**) p between 0.001 and 0.01, (***) for p below 0.001.
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Taken together these data showed that insulin clearly stimulated development of metaces-
tode vesicles and promoted the development of E. multilocularis in vitro, where 10 nM
insulin had the strongest effect on the parasite.
4.1.2 Effect of host insulin on glucose uptake
For EmIR1 a high expression in glycogen storage cells was detected [53], indicating an
involvement of this receptor in glucose metabolism. Therefore, uptake of radioactively la-
belled glucose by metacestode vesicles in response to insulin was measured. At a concentra-
tion of 10 nM human insulin glucose uptake was stimulated significantly (Fig. 4.4). This
effect was even more pronounced adding the phosphatase inhibitor Na3VO4, which was
previously used to stimulate insulin dependent glucose uptake [102]. These data suggest
that host insulin, next to mitogenic effects, shown by proliferation and growth experiments
also has metabolic effects on E. multilocularis.
Fig. 4.4: Glucose uptake of metacestode vesi-
cles. Axenic metacestode vesicles
were incubated with C14-D-glucose
with or without 10 nM insulin and
100 µM Na3VO4. Control was set
to 1 and results were normalised
against the control. (*) p below 0.05
4.1.3 RT-PCR analysis of emir1 and emir2
Previously two insulin receptor orthologues, EmIR1 [53] and EmIR2 [125] were identified,
which are likely candidates to transmit insulin signals in E. multilocularis. EmIR2 is
expressed in four isoforms that vary in the presence of two small alternative exons in the
ligand binding domain [125].
New RT-PCR experiments for emir1 and emir2 were carried out to complete expression
analysis with data from primary cell cultures. For these experiments protoscoleces were
isolated from secondary infected jirds and part of the material was activated. Primary cells
were isolated from axenic metacestode vesicles and harvested at day 3. Further, intact
axenic metacestode vesicles of 3 to 5 mm were collected. RT-PCR experiments showed that
emir1 and emir2 transcripts were present in all stages at nearly equal amounts (Fig. 4.5A).
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Comparison of emir2 isoforms [125] showed that emir2a and b are expressed equally in all
stages, while emir2c was stronger expressed in non-activated protoscoleces and primary
cell cultures (Fig. 4.5B). Emir2d could not be detected.
emir1
emir2
elp
Ps- Ps+ McPcA
B
Fig. 4.5: Expression analysis of emir1 and emir2 in Echinococcus multilocularis larval stages by
semi-quantitative RT-PCR. (A) Emir1 was amplified with gene specific primers RC19 and
RC21, emir2 with EmIRb dw3 and EmIRb up3 was used. (B) Semi-quantitative RT-
PCR of emir2 isoforms. RT-PCR was carried out with the following primer combinations.
Emir2adw and emirbup4 for emir2a, emir2bdw and emirbup4 for emir2b, emir2cdw and
emirbup4 for emir2c and primers emirbdw5 and emirbup4 to amplify emir2d. Elp was
used as a cDNA control and amplified with Em10 15 and Em10 16. Triangles indicate
serial 10 times serial dilution of cDNA. PCR products were separated on a 1 % agarose
gel and stained with ethidium bromide. (Ps-) non-activated protoscoleces, (Ps+) activated
protoscoleces, (Pc) primary cells, (Mc) metacestode vesicles
4.1.4 Production of an anti-EmIR2 immunserum
The intracellular domain of EmIR2 was amplified via primers emirbF3dw and emir2intra
up and cloned into pBAD/TOPO R© ThioFusionTM expression plasmid (Invitrogen). The
EmIR2-Thio construct was expressed in E. coli analogous to the production of EmIR1 im-
munserum [124] and the protein was purified via the HIS-Tag. Elution fractions containing
the protein were dialysed and used for immunisation of a rabbit (Fig. 4.6A). The immun-
serum was purified against EmIR2-GST by western blot. In subsequent western blot analy-
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sis the purified immunserum detected only EmIR2-Thio and EmIR2-GST at 52 kDa and 75
kDa, respectively, but not EmIR1-GST (Fig. 4.6B). Expression of EmIR1 and EmIR2-GST
constructs was proved using anti-GST antibody (Fig. 4.6C).
Fig. 4.6: Production of EmIR2 immunserum. (A) Purification of EmIR2-Thio expressed in E. coli.
Protein samples were separated on a 10 % SDS gel and stained with Coomassie. EmIR2-
Thio fusion protein was detected at 52 kDa. b.I.: before induction, I: after induction, L:
lysate, WF: washing fraction, 1,2: Denaturing elution buffer, 3,4: Imidazole elution buffer,
5,6: 0.5 M EDTA, R: regeneration. (B) Test of the purified EmIR2 immunserum. Purified
protein samples of EmIR2-Thio, EmIR2-GST and EmIR1-GST were separated on a 10 %
SDS gel and a western blot was carried out with the purified EmIR2 immunserum. (C)
Detection of EmIR2-GST and EmIR1-GST with anti-GST antibody.
4.1.5 Analysis of EmIR1 and EmIR2 expression on protein level
The purified immunserum of EmIR2 was used to analyse expression in different larval
stages. Protein samples of axenic metacestode vesicles, primary cells and non-activated
and activated protoscoleces were prepared. The EmIR2 serum detected a band at 87
kDa, corresponding to EmIR2 β subunit (Fig. 4.7A). A second band at 60 kDa was also
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recognised by the serum most likely presented the IgG fraction or a degradation prod-
uct of EmIR2. In contrast to RT-PCR analysis EmIR2 was highest expressed in primary
cells and activated protoscoleces and to a lower extend in non-activated protoscoleces. No
protein was detected in metacestode vesicles. To investigate expression of EmIR1 in pri-
mary cells the EmIR1 immunserum was purified and used to analyse EmIR1 expression
in protein samples. Corresponding to the analysis of Konrad [124] EmIR1 was detected in
metacestode vesicles and protoscoleces. New analysis revealed that EmIR1 is not present
in primary cell cultures (Fig. 4.7B). The discrepancy in the results between protein and
cDNA levels of EmIR1 and EmIR2 indicated a post-transcriptional expression regulation.
In a next experiment the EmIR2 immunserum was used to precipitate EmIR2 to anal-
yse processing of the receptor. For human insulin- and IGF-receptor it is known that
they form heterotetramers consisting of two α and β chains that are linked via disulphide
bonds [67,69]. Therefore, EmIR2 immunoprecipitation samples were supplemented with 1
or 10 % β-Mercaptoethanol (β-ME) to allow incomplete and complete denaturation of the
assembled receptor. With 10 % β-ME the β- subunit of EmIR2 was detected at 87 kDa and a
fainter band at 211 kDa that could correspond to the αβ dimer (Fig. 4.7C). Both bands were
not present in samples containing 1 % β-ME. However a significantly larger band visible
could indicate presence of assembled α2β2 heterotetramer.
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Fig. 4.7: Analysis of EmIR2 and EmIR1 protein expression. (A) Expression of EmIR2 in larval
stages. The purified immunserum of EmIR2 (1:300 in 5 % skim milk/ TBS-T) recognised
the EmIR2 β subunit at 87 kDa and a second band at 60 kDa. Mc: metacestode vesicles,
Pc: primary cell cultures, PS-: non-activated protoscoleces, PS+: activated protoscoleces.
(B) The purified EmIR1 serum (1:300 in 5 % skim milk/ TBS-T) was used to detect EmIR1
expression in metacestode vesicles, primary cells and nonactivated and activated proto-
scoleces. (C) Assembly of EmIR2. Immunoprecipitation of EmIR2 from protoscoleces was
carried out with the EmIR2 immunserum. Samples were supplemented with 1 or 10 %
β-Mercaptoethanol (β-ME) and separated on a 10 % SDS gel. Western blot was carried
out with the EmIR2 serum (1:30 in 5 % skim milk/ TBS-T).The antibody recognised the β
subunit and bands corresponding to the αβ dimer and α2 β2 heterotetramer.
4.1.6 Immunohistochemical analysis of EmIR2 expression in E. multilocularis larval
stages
The EmIR2 immunserum was employed to investigate the presence of EmIR2 on sections
of parasite material. In primary cells expression can be seen throughout the aggregate,
with a denser stained layer at the cavity borders (Fig. 4.8A). In protoscoleces expression
was found near the scolex and the tegumental layer (Fig. 4.8B). Interestingly, although no
expression of EmIR2 could be seen in western blot analysis of in vitro cultures, in infected
liver material a specific staining of metacestode vesicles embedded in liver tissue was visi-
ble (Fig. 4.8D). The control without serum did not show any staining (Fig. 4.8C). Detection
of EmIR2 in liver material indicated a low expression level that could not be detected in
western blot.
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Fig. 4.8: Imunnohistochemical expression analysis of EmIR2. (A) Primary cell aggregates were em-
bedded in Technovit 8100 and sections were incubated with the EmIR2 immunserum (1:10
in 5 % skim milk/ TBS-T) as first antibody. (B) Protoscoleces were embedded in Technovit
8100 and 4 µm sections were stained with the EmIR2 immunserum. The figure depicts an
invaginated protoscolex. (C) Infected liver tissue of Mongolian jirds was used as a control
by omitting incubation with the EmIR2 immunserum; (D) EmIR2 expression in infected
liver. CA: cavity; Ps: Protoscolex; HC: host cells; Mc: metacestode vesicle
4.1.7 The activation of EmIR2 by host insulin
Binding of insulin to the insulin receptor is the first step of the signalling process. Binding
induces a conformational change in the receptor, which triggers autophosphorylation activ-
ity of the intracellular kinase domain [79]. The binding of insulin and IGF-I to EmIR2 was
studied in Yeast two Hybrid experiments (Y2H) analogous to analysis of EmIR1 [53]. For
EmIR2 constructs the ligand binding domain (Thr23- Asp281) including leucine and cys-
teine rich regions (L1-CR-L2) was amplified with the primers emir2ex EcoRI and emirex
XhoI and subsequently cloned into the vector pGADT7 (AD) via the restriction sites incor-
porated into the primer sequences. Furthermore constructs for EmIR2 isoforms (a, b and c),
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containing the full extracellular domain were produced (Thr23- Trp1141) using the primer
combination emir2ex EcoRI and emirex SacI up. Due to a low expression the EmIR2d
extracellular domain could not be amplified. Pro-insulin and pro-IGFI constructs were ex-
pressed as fusion proteins with the Gal4 binding domain (BD) [124]. All constructs were
tested for expression by western blot prior to Y2H interaction experiments. For Y2H, yeast
cells of the strain AH109 were co-transfected with the respective plasmids and double-
transfectants were selected on leucine and tryptophan deficient agar plates (see section
3.10.3). The interaction assay was carried out on high and medium stringency plates. The
plasmids pGADT7 and pBKT7 were used as negative controls control in combination with
the respective fusion-proteins.
Y2H analysis showed that the N-terminal part of the ligand binding domain (EmIR2-
LBD) interacted with pro-insulin as well as with pro-IGF-I (Tab. 4.1). In contrast, HIR
and EmIR1 only bound to pro-insulin in Y2H experiments [124]. Binding of complete ex-
tracellular domains showed an overall weaker binding without differences between iso-
forms. The weaker binding is probably a consequence of the large size of the fusion-
protein.
Tab. 4.1: Interaction studies of EmIR2 with insulin and IGF-I in Y2H assay. EmIR2 ligand binding
domain (LBD) and full-length extracellular domain (ex) were expressed with the activa-
tion domain of Gal4 (pGADT7). Insulin and IGF-I were expressed as pro-peptides with
the Gal4 binding domain (pBKT7). Co-transfection with pGADT7 or pBKT7 was used
as negative control. (-) no growth, (+) weak growth, (++) moderate growth, (+++) strong
growth
pBKT7 pro-Insulin pro-IGFI
pGADT7 - - -
EmIR2-LBD - ++ +
EmIR2a-ex - + -
EmIR2b-ex - + -
EmIR2c-ex - + -
Having shown binding of insulin to the receptor in the Y2H system, activation by autophos-
phorylation of the intracellular domain was investigated. For EmIR1 it was observed, that
the TK domain is tyrosine phosphorylated upon stimulation with insulin indicating acti-
vation of the receptor [124]. Unfortunately, tyrosine phosphorylation could not be detected
for EmIR2. However, serine phosphorylation was reported to occur subsequent to tyro-
sine phosphorylation in the mammalian receptor [133]. Therefore it served as an indirect
proof of EmIR2 activation. For the experiments primary cell cultures were stimulated with
host insulin and the β subunit of EmIR2 was immuno-precipitated using specific serum.
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Stimulated samples showed a slightly increased serine phosphorylation compared to the
unstimulated control (Fig. 4.9).
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EmIR2
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Fig. 4.9: Primary cells were grown for 5 days in conditioned medium
under axenic conditions. Subsequently, cultures were starved
for 5 h in 0,2 % FCS/DEMEM supplemented with reducing
agents and stimulated with 10 nM insulin for 5 min. The
EmIR2 β subunit was purified by immunoprecipitation with
the EmIR2 immunserum. Samples were normalised by the
amount of EmIR2 and phosphorylation was detected with
Phospho-serine sampler kit (Calbiochem).
4.1.8 Characterisation of the insulin receptor downstream signalling molecules PI3K, Akt and
4E-BP
With data from the whole genome sequencing project [134], molecules that are involved
in insulin signal transmission in the mammalian signalling system were identified on ge-
nomic level (Tab. 4.2). Investigation of MAPK pathway involvement in insulin signalling
only resulted in slight activation of EmMPK1 [124]. Therefore we investigated PI3K/Akt
signalling in that respect. On the basis of genome data and BlastX analysis complete
cDNAs of empi3k, emakt and em4e-bp were amplified and sequenced. RACE experiments
were carried out to identify 5 and 3 prime ends of the cDNAs.
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Tab. 4.2: Homologues of PI3K pathway molecules were identified in the E. multilocularis genome.
Name Systematic name Location Product
EmPI3K EmW 000526100 supercontig pathogen EMU phosphatidylinositol 3-kinase
scaffold 007636 : 1191161-1207682 catalytic, alpha
EmAkt EmW 000979200 supercontig pathogen EMU akt-like serine/threonine
scaffold 007780 : 4083862-4092994 protein kinase
Em4E-BP EmW 000044600 contig pathogen EMU contig eukaryotic initiation factor
60709 : 459698-462653 4e binding protein 1
EmIF-4E EmW 000044600 contig pathogen EMU contig eukaryotic initiation
60709 : 459698-462653 factor 4E
EmIRS EmW 000848300 supercontig pathogen EMU insulin receptor substrate
scaffold 007768 : 10045618-10058030
EmmTor EmW 000787900 supercontig pathogen EMU target of rapamycin
scaffold 007768 : 5264722-5284913
EmFKBP12 EmW 000787900 supercontig pathogen EMU rapamycin complex
scaffold 007768 : 5264722-5284913 associated protein
EmPDK1 EmW 000723900 supercontig pathogen EMU phosphoinositide-dependent
scaffold 007765 : 22476-24029 protein kinase I
EmGSK3 EmW 000980300 supercontig pathogen EMU glycogen synthase kinase 3
scaffold 007780 : 4164112-4186701
EmRps6 EmW 000877900 supercontig pathogen EMU ribosomal protein S6 kinase
scaffold 007768 : 12109605-12110518
EmPKC EmW 000455600 supercontig pathogen EMU protein kinase c iota type
scaffold 007614 : 3119007-3125424
The E. multilocularis PI3 kinase orthologue
The cDNA of empi3k contained a single open reading frame (ORF) of 3582 bp coding for
a protein of 1194 amino acids with a deduced weight of 134 kDa. In EmPI3K the char-
acteristic domains were present [135]. The N-terminal p85 binding domain (30- 108), the
ras binding domain (rbd, 183- 294), the C2 domain (411- 526), the PI3K accessory do-
main (PI3Ka, 611- 832) and the catalytic domain (PI3Kc, 923- 1193) were identified by
Smart analysis (Fig. 4.10). Alignment with HsPI3Ka indicated the presence of three in-
serts of unknown function spanning amino acids 310- 369 in the rbd, 393- 423 in the C2
domain and 703- 732 in the PI3Ka domain. Homology between EmPI3Ka and HsPI3Ka
was 32 % with the highest conservation in the catalytic domain and an overall 40 % with
SmPI3K. The active center motives DRHNSN and DFG were conserved. The p85 binding
domain mediates binding to the regulatory subunit [135]. Although no regulatory sub-
unit was yet identified, the p85 binding domain shows an overall conservation, indicating
presence of a binding partner, which could regulate PI3K activity. Before LY294002, an
ATP-competitive PI3K inhibitor was tested in cell culture an analysis of the binding site
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conservation was carried out. Three out of four residues that were reported to mediate
binding of LY294002 [136] were found in EmPI3K, therefore binding of the inhibitor was
assumed.
1    MPPTTLESSDHMFQHCSSMKHDFLMPNGIVLTLKPDPDISLADLKAHLWDLASAEPLYECLGPPNDYLFQGISSPKAEEE  
 
81   EFYDEQCKFAGLQLFLPFMRLEKVSDDAQIIEQKRNAMIAKISTISQAHLKAAEGGNPELAWARQCLLEMSEANMRRLEA  
 
161  GGPVSMAHYLTAASLQPKLNTALQRRLQRLPYLTISAVCVDCYSPPTQHLLKLNLPKSITVAAAIKEIIDEQRRLVQGDV  
 
241  SCHDVDPAPQYLLKVCCSQEYLFEQESALVHYAYVQECLQRDDIPRLTPVLLKDVLECLGLPVPEVVNCEGCTPAYPSPA  
 
321  VVSNAAPLPSVIDLYGVKEEDEDEGDEAMEASVDLWDLRDYFSLTVRAAQKLTTLTQNPSTEQLDTGLFFTGSSSFSDLT  
 
401  TDVTSSLGGSESSGSGGGGGASASTTPLSASSASSLDASSGSVVNYIVRVGLAHGGQLLAKYQNTRGAIIVMGGNSALQW  
 
481  NQSLNFRLIYSNLPLATRVCVVLLQVKRRPGRIMEFPVGWANMNLFDERGYLVTGRRSLPLWRSSFTSPETETTHQLNLA  
 
561  GTVAENPDPEFTLVLNFCHPSNQKARIRFPISRFITTVRGASPNTPTATIVPSLHSSDSDIRVIRDLIHRDPFYELSEQD  
 
641  KALLWRIRDSCCRRLYPAESLPWLVQAVAWERRELVEEFYRLLAVWPRPLPVETCLQLLGVAGLAGSAAAEGTFGEGGGG  
 
721  SYVMAGGRTTGVADPLVRDIAVQGLQARLSNADLADYLLQLVQVVRTEAFLVNPLTCFLLQRALDCPTLIGVRLCWHLRS  
 
801  QLDNPDARLRFGLILDALCRGFGPRLLLFVHEQVNALHRLTDLAISVKRIAEDEEQRARFKFELHRSEVRRDLEGILSPL  
 
881  RFSIKLGPVVEQQCTVKRSKKRPLWIVWANPDNLGFHHHKIHQLLFKHGDDLRQDMLTLQILKVMDHIWKDEGLNLDLTT  
                             *                     * 
961  YDCLATGDEMGLIEVVRNSQTIMSIQGQRVRSAMQIDSSQLHKWFLQKKAPPLGSEEAYESAIRRFTNSCAGYCVATFVL  
 
1041 GIRDRHNDNIMVDDSGRLFHIDFGHILNNKKKKFGITRERVPFVLTSDFACVIARGEEKPYRSKGFMDFTRLCEDAYRIL  
               * 
1121 RRHSNLLLTLLAMMVPSGLPELTCASDLEYVRKTLAVELRDEEEALNYFNAKFNEAYNGAWTTKIDWFAHWVRR  
 
 
PI3Kc&
PI3Ka&
C2&
rbd&
p85B&
Fig. 4.10: Deduced amino acid sequence of EmPI3K. Domains are underlined and indicated at the
side. Insert regions are indicated by dotted lines and activation loop motifs are high-
lighted in bold. Asterics mark residues important for binding of the PI3K inhibitor
LY294002.
The E. multilocularis Akt kinase
Only a single akt gene was identified using BlastX search on genome data. The emakt
cDNA contained a single ORF of 2136 bp coding for a peptide of 712 amino acids with a de-
duced weight of 81 kDa. EmAkt displayed the characteristic structure of Akt kinases [88]
with an N-terminal pleckstrin homology domain (PH, 124- 226), the serine/ threonin kinase
domain (S/TKc, 262- 519) and an C-terminal regulatory domain (S/TKr, 520-587). The reg-
ulatory domain also contained a hydrophobic motif F-X-X-F/Y-S/T-Y/F specific for kinases
of the AGC family. The homology between EmAkt and HsAkt1 lied at 39 % with very
high conservation in the characteristic domains (Fig. 4.11). However EmAkt contained N-
and C-terminal extensions, explaining the low overall conservation. In mammals Thr308
and Ser473 are phosphorylated in response to insulin or IGF-I [88]. Both residues were
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present in EmAkt, corresponding to Thr419 and Ser584 , which lied in the hydrophobic
motif. In EmAkt the motif was not conserved, containing only the central residues F583
and S584.
1   MQVDESLNCSTPMGTLTPTSAPMAVDPLSSFVQFQSASMSQIPCNTPQFSNPSTVSSLVPGAGTPCAGLSQEHFVPHAPV  
 
81  SMPHLTGGLPGSTDLLGHQQALAINPTSLMQYFRIRTLPLTRKVIREGWLMKRGEHIKTWRRRYFILREDGTFYGYKNIP  
 
161 RDNLEQPLNNFTVRDCQIICLNKPKPYTILMRGLQWTTVVERLFFVEHEVERDEWISAIQMVANRLRSENEAPTSVFKVD  
 
241 FAEDVVIDFPQRPPKRYSTDDFELLKVLGKGTFGKVVLCKEKESGCFYAMKILKKTVLIEKEEVGHTQTEHRVLQLNHHP  
 
321 FMTQLKYSFTTRDHIFFVMEYCNGGELFYHLSREHVFSESRTQFYAAEITSALGYLHSQNIVYRDLKLENLLLDKDGHIK  
 
401 ITDFGLCKEDIGFGSTTKTFCGTPEYLAPELLLDNDYGLSVDWWSLGVVMYEMMCGRLPFYSNEHEILFELILQESVKVP  
                      * 
481 DNLSPVARDILIRLLMKDPAERLGGGKADAIEVMVHPFFESISWDKLIRKDIIPPWKPDVNGDMDTKYIPEEFQRENVAV  
 
561 TPPEKSVASAIMAADRVSVVKVFSASETMALYLKAPFPTDSPTLSSAKAQSLTVYIRGTFGGSFPVDVITVRRIQPNSPS  
                           * 
641 LRRIFGHAYFSPRGQLFDSCLRVSFVEIMVISHCVSLCLFISLSIPATWHFSCTIADAVVRPLLSSLPLWDV  
 
S/TKr&
S/TKc&
PH&
Fig. 4.11: Deduced amino acid sequence of EmAkt. Domains are underlined and indicated at the
side. The activation loop motifs are highlighted in bold. Asterics mark phosphorylation
sites and the hydrophobic motif is indicated by a box.
The E. multilocularis 4E binding protein
The cDNA of em4e-bp was identified by BlastX analysis and fully sequenced. The ORF
was 351 bp in length, with only one exon. The deduced peptide was 117 aa in length and
had a calculated molecular weight of 12.6 kDa. The Em4E-Bp was well conserved with
39.5 % identity to the human protein. In the mammalian homologue the residues Thr37,
Thr46, Ser65 and Thr70 are phosphorylated after stimulation [137]. These residues were
found to be conserved in Em4E-BP and correspond to the residues Thr30, Thr39, Ser58
and Ser63 in Em4E-BP (Fig. 4.12). For further analysis of the protein, a phospho specific
antibody was used directed against the phosphorylated peptide surrounding the residues
Thr37/46.
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                  10        20        30        40        50        60        70        80                
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
Em4E_BP  -----MASNRGPDGIP-FRRLKVTDPSQIP-NDYSTTPGGSIFSTTPGGTRIFYDRDTMLMCKNSPIARSPPTDMVCRPG 73   
Hs4E-BP  MSGGSSCSQTPSRAIPATRRVVLGDGVQLPPGDYSTTPGGTLFSTTPGGTRIIYDRKFLMECRNSPVTKTPPRDLPTIPG 80   
DrE4-BP  MS--TNTQQSKSCPIP-TRVLHLKDWSQLP-DCYSQTPGGTLFSTTPGGTRIIYDRKFLLDCRNSPIARTPPCCLPQIPG 76   
                                             *        *                  *    * 
                  90       100       110       120     
         ....|....|....|....|....|....|....|....|.... 
Em4E_BP  ITCPATCAGECRLPAATAQKPAKNTRQEHASVQKSDEGPFDIDL 117  
Hs4E-BP  VTSPSSDE----PPMEASQSHLRNSPEDKRAG--GEESQFEMDI 118  
DrE4-BP  VTIPSLH------PVSKLQELKEELEEEKELA--ADDSQFEMDI 112  
 
Fig. 4.12: Alignment of Em4E-BP with the Homo sapiens and Danio rerio homologues. Identical
residues are highlighted in black, similar in grey. Asterics mark phosphorylated serine
and threonin residues.
4.1.9 Activation of the PI3K/ Akt pathway is involved in insulin
signalling
To investigate activation of the PI3K/ Akt pathway, anti-phospho antibodies specific for
phosphorylated Akt substrate motif RXRXXS/T [88] and phosphorylated 4E-BP (Thr37/ 46)
were selected. Metacestode vesicles were stimulated with 10 nM insulin for 5 min to 1 h.
The strongest increase in phosphorylation was observed after 5 min of stimulation for Akt
substrate and 4E-BP (Fig. 4.13). At 30 and 60 min no significantly higher phosphorylation
was observed, indicating a fast activation of the pathway followed by termination of the
signalling.
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Fig. 4.13: Insulin triggers phosphorylation
of PI3K/ Akt pathway molecules.
Metacestode vesicles were starved
in 0.2 % FCS/DMEM for 16 hours,
followed by stimulation with 10 nM
insulin for the indicated time. Detec-
tion of phosphorylated proteins was
carried out using antibodies against
phosphorylated Akt substrate motif
and 4E-BP. Actin was used as loading
control.
To verify direkt activation of the PI3K/ Akt pathway by Echinococcus insulin receptor and
PI3K, specific inhibitors were used to block insulin induced signalling. HNMPA(AM)3 is
an ATP-competitive insulin inhibitor designed against the human insulin receptor [138].
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Due to high conservation of the ATP binding domain in helmintic insulin receptors, the
inhibitor was used previously to block Schistosoma insulin receptors [100]. LY294002 was
used to block EmPI3K [139]. Both inhibitors were added in concentrations of 100 µM 2 h
prior to insulin stimulation to ensure uptake into the cells. Insulin stimulation was carried
out for 5 min with 10 nM recombinant human insulin and activation of the signalling cas-
cade was tested using the phospho-E4-BP antibody. In this experiment insulin only slightly
increased phosphorylation of 4E-BP, which is probably a consequence of short activation
of the signalling as seen in Fig. 4.13. However, the inhibitor HNMPA(AM)3 completely
abolished phosphorylation, while LY294002 was less effective, but still reducing phospho-
rylation below the level of the control (Fig. 4.14)
Fig. 4.14: The inhibitors HNMPA(AM)3 and LY294002 blocked phosphorylation of 4E-BP. Metaces-
tode vesicles were starved in 0.2 % FCS/DMEM for 16 hours. The inhibitors were added
2 h prior to insulin stimulation. Ten nM insulin were added and samples were incubated
for 5 min. Protein samples were separated on a 15 % SDS PAGE and a western blot was
carried out. Detection of phosphorylated proteins was carried out using the phospho-4E-
BP antibody. Actin was used as loading control.
4.1.10 Effect of HNMPA(AM)3 on E. multilocularis development
HNMPA(AM)3 showed promising results in blocking insulin signalling. Therefore it was
tested in the cell culture system on primary cells, metacestode vesicles and protoscoleces
to investigate the importance of insulin signalling on survival and development of parasite
material.
In the Resazurin cell health assay, 25 µM and 50 µM HNMPA(AM)3 reduced viability of
primary cell cultures to 75 and 50 %, respectively (Fig. 4.15).
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Fig. 4.15: Cell viability assay of HNMPA(AM)3
treated primary cell cultures. Freshly
isolated primary cells were incubated
for 2 d with the indicated concentration
of HNMPA(AM)3 or DMSO. Resazurin
was added for 3 h after which the flu-
orescence was measured. (***) p below
0.001
To analyse morphological changes induced by HNMPA(AM)3, primary cells were incu-
bated with the inhibitor for 7 days, followed by staining of aggregate sections with haema-
toxylin/eosin. Aggregates treated with 25 µM showed a loss of tissue integrity, while ag-
gregates treated with 50 µM were completely dead (Fig. 4.16). Untreated aggregates
appeared healthy, with large cavities and a good organization with a clear cavity bor-
der.
Fig. 4.16: HNMPA(AM)3 induced morphological changes in primary cell aggregates. Primary cells
were cultivated in conditioned medium supplemented with DMSO or HNMPA(AM)3 for 7
days. Samples were embedded in Technovit 8100 and sections of 4 µm were stained with
haematoxylin/ eosin.
The effect of HNMPA(AM)3 was more pronounced on vesicle formation of primary cell ag-
gregates (Fig. 4.17A). Vesicle formation was increased two fold when insulin was included
in the culture medium. In samples treated with 25 µM and 50 µM HNMPA(AM)3 no sig-
nificant vesicle formation took place. This finding corresponded with the observed growth
of the cultures (Fig. 4.17B). Both the control and the insulin treated samples showed
strong aggregation and regeneration, while in 25 µM inhibitor treated samples aggregation
was strongly impaired and no aggregation was observed in cultures treated with 50 µM
HNMPA(AM)3 (see also [140]).
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Fig. 4.17: HNMPA(AM)3 impaired vesicle regeneration in primary cell cultures. (A) Freshly isolated
primary cells were incubated with conditioned medium supplemented with insulin and
HNMPA(AM)3 or DMSO for one week. (B) Aggregation in 7 day old primary cell cultures
treated with or without HNMPA(AM)3 and host insulin. (*) p values below 0.05 (**) p
between 0.001 and 0.01, (***) for p below 0.001
HNMPA(AM)3 at a concentration of 100 µM HNMPA(AM)3 severely decreased survival
in metacestode vesicles (Fig. 4.18A). In protoscoleces 50 µM inhibitor reduced survival
significantly, while 25 µM HNMPA(AM)3 only had a slight effect (Fig. 4.18B). Further-
more, HNMPA(AM)3 had a even more pronounced effect on dedifferentiation of proto-
scoleces in vitro cultures. 25 µM reduced the number of microcysts by more than 50
% and only few microcysts formed in samples treated with 50 µM HNMPA(AM)3 (Fig.
4.18C).
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A B C
Fig. 4.18: Effect of HNMPA(AM)3 on metacestode vesicles and protoscoleces. (A) Metacestode vesi-
cles were cultured in conditioned medium supplemented with DMSO or HNMPA(AM)3
for 7 days. (B) Protoscoleces were isolated from infected jird material and cultured un-
der axenic conditions with DMSO or HNMPA(AM)3 for three weeks, after which living
and dead protoscoleces were counted. (C) After three weeks of incubation in conditioned
medium supplemented with inhibitor round, transparent microcysts were counted. (*) p
values below 0.05 (**) p between 0.001 and 0.01, (***) for p below 0.001.
4.1.11 Effect of the PI3 kinase inhibitor LY294002 on E. multilocularis
development
LY294002 was tested in cell culture on metacestode vesicles and primary cells. Metaces-
tode vesicles were susceptible to LY294002 treatment at a concentration of 50 and 100 µM
(Fig.4.19A). After 14 days nearly all of the vesicles appeared to be dead. At day 7 only
50 % of the vesicles were killed. The inhibitor therefore exhibits a weaker effect than
HNMPA(AM)3. Primary cell cultures, measured with the Resazurin health assay 100 µM
showed a 50 % reduced viability (Fig.4.19B). In the Resazurin assay, the weak effect is
probably caused by the short treatment period and would be more pronounced at a longer
treatment. Therefore, primary cells were treated for two weeks with LY294002 (Fig.4.19C).
Cultures treated with 50 µM LY294002 showed reduced aggregation compared to the con-
trol. However, the aggregates had an overall healthy appearance with well formed cavities.
In cultures incubated with 100 µM LY294002 initially aggregates formed (data not shown),
but disintegrated after two weeks of incubation with the inhibitor (Fig.4.19C).
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Fig. 4.19: Effect of LY294002 on in vitro cultivated metacestode vesicles and primary cell cultures.
(A) Metacestode vesicles were cultured in conditioned medium supplemented with DMSO
or LY294002 for 14 days. Survival was measured by counting damaged vesicles. p below
0.001. (B) Primary cells were cultivated with DMSO or LY294002 for 2 days and the
Resazurin assay was performed. ***: p below 0.001. (C) Freshly isolated primary cells
were cultivated in the presence or absence of LY294002 for 14 days in conditioned medium.
4.1.12 Insulin sensitivity in old and new isolates
Larval cestode material is routinely kept in peritoneal culture [43]. In the cause of the ex-
periments, isolates that were kept in culture for several years lost their ability to respond
to insulin. In regeneration experiments old isolates still aggregated and regenerated nor-
mally (data not shown). To investigate insulin responsiveness further, the isolates H95 and
Ingrid, that represent an old and new isolate, respectively, were tested in phosphorylation
and BrdU incorporation experiments. In Ingrid, 4E-BP was phosphorylated in response to
insulin, although basal phosphorylation in the control was very high in these experiments.
H95 did not show any insulin stimulated phosphorylation (Fig. 4.20A). Incorporation of
BrdU in primary cell cultures showed that basal proliferation rate is approximately the
same between H95 and Ingrid. However, 10 nM of insulin strongly stimulated DNA de
novo synthesis in Ingrid, while H95 did not react to insulin stimulation (Fig. 4.20B). The
range of 1 nM to 100 nM of insulin also excluded the possibility, that H95 differs only in its
ligand concentration optimum from Ingrid. A similar low reaction to insulin in different
experiments was also observed for J31 and Java (data not shown). Taken together these
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data indicated that the capacity to react to insulin is lost during prolonged passages in
peritoneal culture, while isolates freshly isolated from natural hosts still reacted in the
investigated manner. Insulin insensitivity was observed for old isolates (H95, J31, Java),
while the isolates GH09, GT10, G8065 and Ingrid that were recently isolated from pri-
mates, were still responsive to host insulin.
H95 Ingrid- +-+ Ins
Phospho-
4E-BP
beta Actin
A B
Fig. 4.20: Comparison of insulin responsiveness in old and new isolates. (A) Metacestode vesicles
of H95 (old isolate) and Ingrid (new isolate) were starved in 0.2 % FCS/DMEM for 16
hour, followed by stimulation with 10 nM insulin for 10 min. Detection of phosphory-
lated proteins was carried out using the anti-phospho 4E-BP antibody. Actin was used as
loading control. (B) Primary cells were incubated for 24 h with the indicated amount of
insulin and subsequently incubated with BrdU for 4h. BrdU uptake was measured with
the colorimetric BrdU ELISA kit (Roche).
4.1.13 Insulin-like peptides in E. multilocularis
Previously, two insulin like peptides (ILP) were identified that were termed EmIns1 and
EmIns2 [125]. According to current terminology these genes were renamed ilp1a and ilp2a.
Additionally for each gene an alternative splice variant was detected (Fig. 4.21). In the
emilp1 gene two ORFs of 366 bp and 510 bp, respectively, which differ in their 5´ ends.
EmIlp1a is composed of 122 amino acids, while the newly described EmIlp1b is 170 amino
acids in length. Only EmIlp1b is expressed with an N-terminal signal peptide and is there-
fore expected to be the active, secreted form of EmIlp1. The previously described EmIlp2a
and the newly identified EmIlp2b have the same N-terminus containing a signal peptide,
but differ in their C-terminus. Both are likely to be secreted, active peptides. The emilp2b
ORF is comprised of 465 bp, coding for a peptide of 155 aa.
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                  10        20        30        40        50        60        70        80                
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmIlp1a  ---------------MCERGFTCSPSS----------------SS----------------LLFSP-FEMDKRNNFSDPR 32   
EmIlp1b  MHSPFHPSVADPPTIFPHSTVTTNPASPHLLILAMLMTFSLVNSSPLPSDLESGVNYVDQKTIFVPSFEMDKRNNFSDPR 80   
EmIlp2a  ----MSSPSHYIPVFLLLNIFFLISGG--------------CAVSPLHDWEEEGDALSEDSLSMMKRANTEYATTEVDRP 62   
EmIlp2b  ----MSSPSHYIPVFLLLNIFFLISGG--------------CAVSPLHDWEEEGDALSEDSLSMMKRANTEYATTEVDRP 62   
HsIns    -------------MALWMRLLPL--------------------------------------LALLALWGPDPAAAFVN-- 27   
                                                                                        >< 
                  90       100       110       120       130       140       150       160         
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmIlp1a  RIMCGYQLIVNLKMQCGDRGTYSPYERGPRIKRGLRLGRPAPLYSPLKSRG----RKHDDFCSIYLRYEPYTIVTECCCR 108  
EmIlp1b  RIMCGYQLIVNLKMQCGDRGTYSPYERGPRIKRGLRLGRPAPLYSPLKSRG----RKHDDFCSIYLRYEPYTIVTECCCR 156  
EmIlp2a  RILCGQSLIHTLKEQCGQRGTFSPYHKR-AVRELIRVARGLPVKSTCTN---------------------DTTISVKCT- 119  
EmIlp2b  RILCGQSLIHTLKEQCGQRGTFSPYHKR-AVRELIRVARGLPDISDFVDSQIHLHKRYDDICEVYLRYEPDSPLSQCCCL 141  
HsIns    QHLCGSHLVEALYLVCGERGFFYTPKTR-REAEDLQVGQVELGGGPGAGSLQP--------LALEGSLQKRGIVEQCCTS 98   
            *           *       A     ><                          B            ><     * 
                 170       
         ....|....|....| 
EmIlp1a  GCTRRFLEQFCAKG- 122  
EmIlp1b  GCTRRFLEQFCAKG- 170  
EmIlp2a  -CDTNPIVHFLNAVV 133  
EmIlp2b  GCTRAYLENFCAEA- 155  
HsIns    ICSLYQLENYCN--- 110  
          *   C    * 
Fig. 4.21: Alignment of EmIlp1 and EmIlp2 orthologues with human insulin. Identical residues are
highlighted in black, similar in grey. Beginning and end of A, B and C chains are marked
by brackets and cysteine residues important for folding are indicated by asterics.
A genome wide search was performed on S. mansoni, Hymenolepis microstoma (available
under GeneDB.org), E. granulosus (http://www.sanger.ac.uk/resources/downloads/helminths
/echinococcus-granulosus.html) and Taenia solium (labintern data) genomic data with EmILP1
and EmILP2 sequences to identify insulin like peptides in these helminth (Fig. 4.22 and
Tab A.1). In E. granulosus homologues of both sequences were identified, which are fully
identical to E. multilocularis sequences. Each two ILPs were found in H. microstoma and
T. solium genome which are over 70 % identical to EmILP1 and EmILP2. No sequence
homologies to ILPs were found in S. mansoni. However, an insulin homologue seems to
be present in S. japonicum, although no distinct homologues could be found in S. mansoni
genome.
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                  10        20        30        40        50        60        70        80                
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmIlp1b  MHSPFHPSVADPPTIFPHSTVTTNPASPHLLILAMLMTFSLVNSSPLPSDLESGVN-----YVDQKTIFVPSFEMDKRNN 75   
EmIlp2a  -------------------MSSPSHYIPVFLLLNIFFLISGGCAVSPLHDWEEEGD----ALSEDSLSMMKRANTEYATT 57   
HmILP1   MSR-VNRLVDTAPFPCDNLWISSNRLT-ILLLLPPLFTLLFITPMASSTELDT--------EEYRNTNISLSQEAEKRAN 70   
HmILP2   -------------------MFPLEHYIPIFLVFNIFFLVSGACGVTPFEQWNHELEPVITTTTEEPVNVARREEQPIVPT 61   
EgILP1   MHSPFHPSVADPPTIFPHSTVTTNPASPHLLILAMLMTFSLVNSSPLPSDLESGVN-----YVDQKTIFVPSFEMDKRNN 75   
EgILP2   -------------------MSSPSHYIPVFLLLNIFFLISGGCAVSPLHDWEEEGD----ALSEDSLSMMKRANTEYATT 57   
TsILP1   MPRPFHPAVADSPTAFPNPIVITNTASSHRFILAMLMTLSLVNSSPLLGSLNGGVS-----SVDQRTTYVPNSEMEKQNN 75   
TsILP2   -------------------MSSPGHYIPVFLLLNIFFLISGGCAVSPFNDWEEEGE----SPSEETLSMSKRATNAYTTT 57   
SjIns    --------------------------------MRILFWLMLTILTLYLCILESSLE-----IEMKYTTHSLPELQTDYTP 43   
 
                  90       100       110       120       130       140       150       160         
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmIlp1b  FSDPRRIMCGYQLIVNLKMQCGDRGTYSPYERGPRIKRGLRLGRPAPLYS------PLKSRGRKHDDFCSIYLRYEPYTI 149  
EmIlp2a  EVDRPRILCGQSLIHTLKEQCGQRGTFSPYH--KRAVRELIRVARG---------LPVK----------STCTNDTTIS- 115  
HmILP1   ISDPRRIMCGYQLIVNLKQQCGDRGTYSPYAESGRVRRGLRLHRATQLYK------PGKVRRRKHDEFCALYLRYEPYTI 144  
HmILP2   FEDRPRILCGQAMINALKEQCGPRGTYSPYK--KRMARDLIALTRGIYGPDLTDSLPRRRLRKRFDDYCQVYLRYEPESP 139  
EgILP1   FSDPRRIMCGYQLIVNLKMQCGDRGTYSPYERGPRIKRGLRLGRPAPLYS------PLKSRGRKHDDFCSIYLRYEPYTI 149  
EgILP2   EVDRPRILCGQSLIHTLKEQCGQRGTFSPYH--KRAVRELIRVARG---------LPVK----------STCTNDTTIS- 115  
TsILP1   VSDPRRIMCGYQLIINLKMQCGDRGTFSPYERGPRIKRGLRLGRPGSLYS------PLKSRGRKHDDFCSIYLRYEPYTI 149  
TsILP2   EEDRPRILCGQALIHTLKEQCGQRGTFSPYQ--KRAVRELIRVARG---------LPSK----------STCVSDTMTS- 115  
SjIns    INDYPIRMCGNEFLRHLKRVCAIRGIYTPLVRFKR--------SLEQYYD------RILQRGKRFDDLCTLYTIYEPDQV 109  
 
                 170       180  
         ....|....|....|....|. 
EmIlp1b  VTECCCRGCTRRFLEQFCAKG 170  
EmIlp2a  -VKCTCDTNPIVHFLNAVV-- 133  
HmILP1   ITECCCRGCTRRFLEQYCAKD 165  
HmILP2   ISQCCCLGCTRAYLENFCAEP 160  
EgILP1   VTECCCRGCTRRFLEQFCAKG 170  
EgILP2   -VKCTCDTNPIVHFLNAVV-- 133  
TsILP1   VTECCCRGCTRRFLEQFCAKG 170  
TsILP2   -VKCICATNPRVHCPNAAV-- 133  
SjIns    VTKCCCIGCTRSYLEQFCNPS 130  
 
Fig. 4.22: Alignment of EmIlP1 and EmIlP2 with members of the Ins/ILP family of other helminths.
Identical residues are highlighted in black, similar in grey.
To confirm ilp expression analysis [125] semi-quantitative RT PCR was repeated to include
primary cell samples from the same origin as the metacestode vesicles and protoscoleces.
In contrast to previous results expression was now observed in all stages, but still with the
highest expression in protoscoleces (Fig. 4.23 ).
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Fig. 4.23: Expression analysis of emilp1 and emilp2 by semiquantitative RT-PCR. Emilp1 was am-
plified with the primers ins1dw3 and ins1 upnested, and the primer combination ins2dw2
with ins2 upnested was used to amplify emilp2. Emelp was used as cDNA control and
amplified with the primers Em10 15 and Em10 16. Triangles indicate serial 10 times
serial dilution of the cDNA. Samples were separated on a 1 % agarose gels and subse-
quently stained with ethidium bromide. (Ps-) non-activated protoscoleces, (Ps+) activated
protoscoleces, (Pc) primary cells, (Mc) metacestode vesicles
Y2H analysis was carried out to study binding of EmILP1 and EmILP2 to the human and
Echinococcus insulin receptors. Constructs amplified from ilp1b and ilp2a were used for
the experiments. The fragments were amplified with the primers emilp1EcoRI and im-
ilp1BamHI for Ilp1A and emilp2EcoRI and imilp2BamHI for Ilp2A and cloned into the
pBKT7 plasmid. Constructs for HIR and EmIR1 containing the ligand binding domain
were cloned by Christian Konrad [53] and the EmIR2-LBD was already used in section
4.1.7. All constructs were tested for expression with western blot analysis. Co-transfection
of the plasmids pGADT7 and pBKT7 with the corresponding constructs was used as nega-
tive controls.
In the Y2H experiments only EmIR2 interacted with the ILPs, whereas HIR and EmIR1
did not show any interaction with EmILP1 and EmILP2.
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Tab. 4.3: Interaction studies of HIR, EmIR1 and EmIR2 with EmILP1 and EmILP2. The ligand
binding domains (LBD) of HIR, EmIR1 and EmIR2 were expressed with the activation
domain of Gal4 (pGADT7). Insulin, EmIlp1 and Emilp2 were expressed as pro-peptides
with the Gal4 binding domain (pBKT7). Co-transfection with pGADT/ or pBKT7 was
used as negative control. (-) no growth, (+) weak growth, (++) moderate growth, (+++)
strong growth
pBKT7 pro-Insulin ILP1 ILP2
pGADT7 - - - -
HIR-LBD - +++ - -
EmIR1-LBD - +++ - -
EmIR2-LBD - +++ ++ ++
The finding that EmILP1 and EmILP2 bind EmIR2 and not EmIR1 and HIR lead to the
assumption that the peptides could have proliferative effects in primary stem cell cultures.
Therefore, the EmILPs were expressed by transient transfection of mammalian cells, an
approach that was previously used for expression of active IGF-I, IGF-II and insulin pep-
tides [141–143]. To this end, emilp1 and emilp2 were amplified with the primer pairs
ilp1HindIII dw and ilp1NotI Stop for emilp1 and ilp2HindIII dw with ilp2NotI Stop for
emilp2. The fragments were cloned into the pSecHygro/Tag2 plasmid for heterologous ex-
pression in eukaryotic cell lines. As the 3´ end primers contained a stop codon, the peptides
were expressed without the C-terminal Tag of the plasmids. Therefore, no analysis on ex-
pression of theses two peptides were available. Hek293T cells were transfected with the
constructs with the PEI method. The experiments showed that primary cells stimulated
with EmIlp2 containing supernatant incorporated more BrdU than samples stimulated
with pSec or EmILP1 (Fig. 4.24). However it is not clear, if EmILP1 has no effect or is not
expressed in a similar manner as EmILP2.
Fig. 4.24: BrdU incorporation of primary cells stimulated with
Hek293T cell supernatant. Hek cells were transfected with
plasmids containing EmILP1 or EmILP2. The pSecHygro/
Tag2 plasmid was used as a control. 24 h after transfec-
tion the supernatant was collected and freshly isolated pri-
mary cells were stimulated with the supernatant for 20 h
and subsequently 4 h with BrdU. BrdU incorporation was
measured with the colorimetric BrdU ELISA kit (Roche).
(*) p below 0.05
77
4 Results
4.2 The effect of the anti-cancer drug Imatinib and Imatinib responsive kinases in E.
multilocularis
4.2.1 Characterisation of Abl kinases in E.multilocularis
BlastX search on genome data of E. multilocularis revealed the presence of three kinases
with high homologies to Schistosoma Abl1, Abl2 and TK6. Based on the genome data
complete cDNA sequences were amplified and sequenced using the yeast two hybrid library
[40] as template.
Characterisation of EmAbl1
The cDNA of emabl1 was 3558 bp in length coding for a protein with 1186 aa and a de-
duced weight of 127.9 kDa. Domain analysis indicated the presence of a SH3 (63- 136),
SH (169-252) and tyrosine kinase (TK, 306-559) domains with the classical arrangement
for Abl kinases. A low conserved F-actin binding domain (FABD, 1012- 1151) could be
present, although the C-terminus is not strongly conserved and no other Abl typical do-
mains were identified. Two small inserts were found in the SH3 domain (106- 121; 137-
164) and one (268- 286) between the SH3 and SH2 domain. In the kinase domain im-
portant motifs for kinase activity were found including the activation loop Tyr412, which
corresponds to Tyr459 in EmAbl1 [106]. Several other tyrosine residues are reported to
be phosphorylated in Abl kinases including residues at the positions 70, 214, 225, 253 and
257 (HsAbl1) [106]. The residues correspond to Tyr69, Tyr259, Tyr316, Tyr320, Ser625 and
Thr792. The phosphorylation sites 225 and618 are not preserved. The human Abl1b form
was shown to be myristoylated [144]. InEmAbl1 the sequence MGGSIG was found, which
corresponds closely to the myristoylation motif MGNCFT (MGXXX(S/T)), missing only the
Ser/Thr residue, which is not obligate for myristoylation [145]. Prolin rich sequences with
the motif PXXP [106] were found at the positions 112, 645, 818, 946, 956-967, 1167. Fur-
thermore two arginine rich stretches R798RR and R898RMR were found that could serve
as NLS [106]. Alignment with human Abl1 and SmAbl1 revealed 33/ 44 % (identities/ sim-
ilarities) homology between EmAbl1 and SmAbl1 and 33/ 46 % with HsAbl1. The highest
conservation was calculated for the TK domain with 82/ 91 % for SmAbl1 and 63 / 78%
for HsAbl1. The sequence of EmAbl1 with the identified characteristics is depicted in Fig.
4.25.
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1    MGGSIGKPASSKEGSEKVDLSLSFNQQPDEISTGGECEKSAPVKKQILSVTQNFETSGLVEQCIMIVLYDFSATLDSQLT  
       m                                                                   * 
81   VKRGEIVRLLSYSPAGDWSEVEAPSHLPNRTPRVPWAGAGGWVRGWVPTSYLTEHVRPPRVGGIGSGTNGWRRVGDEEEA  
 
161  GAAAATMAYPWYHGAVSRQAAEQLLRSGITGSYLVRESESAPGQLSVTVRNLGRVYHYRISRDSCGWYFITETHRFPTVV  
 
241  QLIHHHSQAADGLICPLLYPAARREQPSVMRGAATNSGAVEGCADSKGGGGYVGFDDWEIDRSEIMMRNKLGWGQYGDVY  
                       *                                                        *   * 
321  EALWKRYNSIVAVKTLKQDVDLNLNDFLAEASIMKNLQHKNLVRFLGVCTREPPYYIVAEYMPHGNLLNYLRQRSPGELT  
 
401  PPILLYMAVQIASGMAYLEANNFIHRDLAARNCLVGDQYTIKVADFGLARYMQLHEDTYTARNGAKFPIKWTAPEGLAYF  
                                                               * 
481  RFSSKSDVWAFGVVLWELATYGLSPYPGVELHGVYQLLEKGYRMQRPHGCPESVYSIMLRCWSWEAADRPTFLSIKAELE  
 
561  EMWRTIDMTEAVAQELATPPAAQTTDHMQFITATSTTATTTITTAVGVGPGINGGGEAMLSSVPVSMIVRMPSYQQDDDE  
                                                                      * 
641  AAEDPSSPSQSTTSCTSSSSAAVSSSSAAETDGQDGDDEGEEDLCLKSLVDKGALSSTANWITTRTSDSLYQGDYIVSGG  
 
721  GGGGGGVVRATPASDLPFATHKSTTCDSQVSAPASLPPLHHLQQFQHHRNRANNHSHHYHRHYQHQLQHSETGRSMPRRR  
                                                                            * 
801  SGPNHLAGQFEEGSLRCPMRPKEKNITPAESGVGESIVSADSPGGNSNAMQQEEGAVVMAPQRSNHKAAAVVAVAVEANN  
 
881  CCVTPTRDMISEVAPDERRMRLDVESVTQFTTLPAQDRITRYLESLGELGDASEERTPKAKGGAHPPHPPLLSHFPPPPP  
 
961  VPPPPQPAQHLRNSRMLPTEHRRNAVGRSASCYQTVSSVQLLLPPSTTTTNGSVETQESLPTTSTPSPAVGETITPTDDV  
 
1041 YQAPTLAQDSSIGGNGGVKAAPTAEVSSEVEQAELTACLNTLSLEATELSTACPQLAAELSALSLQLSACRGKVEARLRA  
 
1121 SANGVGGTAEENLCLAGVAQALRHIQQALAEMRARVEEAQTPTPSLPAPSATAPAATNANATTVST  
 
SH2$
TK$
SH3$
Fig. 4.25: Deduced amino acid sequence of EmAbl1. Domains are underlined with the inserts de-
picted as dotted lines. Activation loop motifs are highlighted by bold letters. Asterics
mark phosphorylation sites and boxes indicate proline rich motifs. Putative NLS are
highlighted grey and the myristoylation motif is marked by an (m).
Characterisation of EmAbl2
The ORF of emabl2 consisted of 3297 bp with a deduced amino acid sequence of 1099 aa
and 119,9 kDa. Fig. 4.26 displays the amino acid sequence with the structural character-
istics of EmAbl2. A putative myristoylation site was found at the N-terminus. A Smart
domain search revealed the presence of a SH3 domain (50- 111), a SH2 domain (140- 223)
and the tyrosine kinase domain (257- 509). A low conserved FABD was indicated in the C-
terminal part (932- 1069). A small inserts was present in the SH3 domain (112- 135) that
corresponds to the second insert in EmAbl1. The phosphorylation sites 214, 253, 257, 412
and 569 of HsAbl1 were found at the positions, 230, 268, 272, 409 and 566. Furthermore
eight prolin rich stretches (534- 543, 634, 664, 706, 748, 821, 861, 1072) and 2 putative
NLS motifs (695, 873) were identified. At the N-terminus the sequence MGSQHA closely
resembled the myristoylation motif MGXXXS/T. The highest homology of EmAbl1 was cal-
culated for SmAbl2 with 37/ 51 % (identities/ similarities) for the full length sequence and
76/ 85 % for the TK domain.
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1    MGSQHAKPKKAASESVDRNFTFRINKGKKSKCGDDGTSVSSLDVMSVPDGDLTALYDYDPPVNAHGSAIVVRKGDSLWLY  
        m 
81   GRSSTGDWLDVLCRRTGERGWVPVSCLFDPTSSKPLIASGAATASSAPSAHVSCPSLIGERWYHGAIHRSYAEYLLNSGI  
 
161  TGSFLVRESESSFGKLTLSLRSDGRIFHYRISTDENNQFYVNEVSRFATVSELVQHHEKVADGLACPLLYGVSKRDQNNH  
                                                                          * 
241  GGFDSDYDAWEIDRTDVIMKHKLGSGQYGVVYEAIFKPYDVTVAVKTLKEDITLRDEFLQEARLMKSLRHPNLVRLLGVC  
                                *   * 
321  TQEPPYYIITEFMCNGNLLDYLRIQPRDVLSPPVLLQMAIHVCCAMTYLEEHNFIHRDLAARNCLVGEAMTVKVADFGLA  
 
401  RYMERDVTYRAREGAKFPIKWTAPEGLVYNCFSIKSDVWAFGVLLWEIATYGAAPYPGVELQDVYVLLQRGTRMEAPQGC  
             * 
481  PDAVYQLMLDCWSWNSEDRPSFKEVYTRLETIRTSSDISEAVEHELQRHRIRMPPPPLPPPSPTTVAAFTPRRSSSCDRI  
 
561  DESNLSPTAEMGRRGHAESFTVQDAVSRLVDSGGGSGSDLHQQQQQFSAYPCCQQGCMVPGNRFSEVFPSSLLPPPPLHT  
          * 
641  NADFAVVGAEIGGAGSLGRRKAAPPAPPLRTTTLRADEPCEKVPVSLQVSTDDRQTFSQPGEERLPSPPNAVLCGVNWPS  
 
721  SRSQSSPPLNSDVAVSVTASVPRRTPIPVPPQRTESTRSQDSEVAEGVPKSSPKMGLPSTTQSPSNGLATASSGSTNSEL  
 
801  SSRLKRQLDNSRSTDSPTRSPVPPGAATVTAEMIQASKSKLKATTTTTPATITAIETQPAPSVPAWRELVVQRRLKNAEP  
 
881  PAGKRMSWTPMSNSCSSSSALKQQQQSSNVEVFPEVVEEEEEGGEEREGALPAIMSQSVTYTSSSTVMPPSSLVSRSSYE  
 
961  HLLRQVTDLCADLNLAKVNLPNEHNSTLVDRIEGLKQACLGYADEMDCSAHAKFRFRDECARLQAAADTLRSICGVGAKA  
 
1041 AVGAELGGRRKTYQAVYTTVEAIHQSLLRLTPAVPSSDAVEESTAPSTRSAFVSTGVIS  
 
SH2$
SH3$
TK$
Fig. 4.26: Deduced amino acid sequence of EmAbl2. Domains are underlined with the inserts de-
picted as dotted lines. Activation loop motifs are highlighted by bold letters. Asterics
mark phosphorylation sites and boxes indicate proline rich motifs. Putative NLS are
highlighted grey and the myristoylation motif is marked by (m).
Characterisation EmTK6, a Src-Abl hybrid kinase of
E.multilocularis
Besides the previously identified Abl kinase EmAbl1 and EmAbl2, a Src-Abl hybrid kinase
was identified in E. multilocularis (Fig. 4.27). BlastX analysis was carried out on avail-
able genome data using the sequence of SmTK6 [120]. The emtk6 cDNA comprised 1710
bp coding for a protein with 570 aa and a deduced weight of 64 kDa. A SH3 (115-172),
SH2 (179-267) and tyrosine kinase domain 296-551) were identified, which is the classical
structure for a src and abl kinases. At the N-terminus a myristoylation motif MGNCFT
(MGXXX(S/T)) was identified. In the kinase domain the important motifs for kinase activ-
ity were found. However, at position 446, which corresponds to the Tyr412 in the HsAbl1
an exchange to valine occurred. In EmTK6 tyrosines at position 121 and 311, correspond-
ing to 70 and 257 were conserved, the later being specific for Abl kinases. Two tyrosine
residues Tyr527 and Tyr416 in src kinase are reported to have regulatory function [146].
Tyr527 is found in EmTK6 at position 562 whereas tyrosine 416 is not conserved. Proline
rich motifs were found at the positions 196, 515 and 518. The highest homology of EmTK6
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was found for SmTK6 and was 53/ 68 % (identities/ similarities) for the full length sequence
and 67/ 81 % for the TK domain.
1   MGNCFTCHDHKENLQCHGDNGMTPMGANSQGGGQGLGQAPFGRHYGPSGDAASVGANQSAIVPASRGAHQPSQQYSVNLY  
      m 
 
81  GMQNGPQQSASYAYSLAQPPATLDQQLAEQSPRVVRVHALYTYVAQNADDLSFQKGDVMLVESGLSEAWWLARHLRTGQQ  
                                            * 
 
161 GYIPSNYVTVENGLSTQMEAWYDITRKDAERMLLMPGLPQGTYILRPCSDSRSYALSIRFEIERNMYAIKHYKIRTRDNG  
 
 
241 AGFYITNRTNFASVADLISHYQSTSDGLCCRLSQPCPRKYTPPVQFRDIEANRRSLEFICELGNGSFGMVYRARWNKTFD  
                                                                          * 
 
321 VAVKKRLATTDRALFIEEAKVMHKLHHRRIVRLLGVCTEPADEPVFIITELLEKGALRNFLSSEEGRQLFLSDLIDMIAQ  
 
 
401 IAEGMAYLEEMNFVHRDLRAANILVDRDNSVKVADFGLAKMLDSDVQNDGVIKFPIKWTAPEAALPDHHFSIKSDVWSFG  
   
 
481 VLMYEIVTYGGTPYPRFTNRETVQQVERGYRMPNPNTPTQPCPDDLYDIMMQCWSARPEDRPTFHNLYDIFENWAVQTEG  
 
 
 
561 QYISDGAQNT  
     * 
SH3$
SH2$
TK$
Fig. 4.27: Deduced amino acid sequence of EmAbl2. Domains are underlined with the inserts de-
picted as dotted lines. Activation loop motifs are highlighted by bold letters. Asterics mark
phosphorylation sites and boxes indicate proline rich motifs.
4.2.2 Expression analysis of emabl1, emabl2 and emtk6
A semi-quantitative RT-PCR approach was used to investigate expression of emabl1, emabl2
and emtk6 [147]. All three transcripts are present in non-activated and activated pro-
toscoleces, primary cell cultures and metacestode vesicles at nearly equal amounts (Fig.
4.28), indicating an important role of the protein throughout parasite development.
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abl1
abl2
tk6
elp
Ps+Ps- Mc Pc
Fig. 4.28: Expression analysis of emabl1, emabl2 and emtk6 by semiquantitative RT-PCR. Emabl1
was amplified with the primers abl1dw1 and abl1up1, emabl2 with abl2dw and abl2up-
II and the primer combination tk6 dw and tk6up was used to amplify emtk6. Emelp was
used as cDNA control and amplified with the primers Em10 15 and Em10 16. Triangles
indicate serial 10 times serial dilution of the cDNA. The PCR products were separated on
a 1 % agarose gel and stained with ethidium bromide. (Ps-) non-activated protoscoleces,
(Ps+) activated protoscoleces, (Pc) primary cells, (Mc) metacestode vesicles.
4.2.3 The effect of Imatinib on E. multilocularis larval stages
Imatinib (Glevec) is used in cancer therapy against chronic myelogenous leukemia (CML),
which is caused by constitutively active BCR-Abl fusion protein [112]. The compound tar-
gets the ATP binding pocket, where 21 amino acids were identified that mediate bind-
ing [148]. Alignment of the kinase domains of Echinococcus Abl1, Abl2 and TK6 sequences
with those of Schistosoma and the human Abl kinase revealed conservation of binding-
mediating residues (Fig. 4.29). Of the 21 amino acids important for Imatinib binding 18
are conserved in EmAbl1, 20 in EmAbl2 and 18 in EmTK6 (SmAbl1: 18/21; SmAbl2: 19/21;
SmTK6: 15/21). The high conservation in the Imatinib binding site suggested a likely bind-
ing of Imatinib to Echinococcus homologues.
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                 10        20        30        40        50        60        70        80                
        ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmAbl1  IMMRNKLGWGQYGDVYEALWKRYNSIVAVKTLKQDVDLNLNDFLAEASIMKNLQHKNLVRFLGVCTR--EPPYYIVAEYM 382 
EmAbl2  VIMKHKLGSGQYGVVYEAIFKPYDVTVAVKTLKEDI-TLRDEFLQEARLMKSLRHPNLVRLLGVCTQ--EPPYYIITEFM 333   
EmTK6   LEFICELGNGSFGMVYRARWNK-TFDVAVKKRLATT--DRALFIEEAKVMHKLHHRRIVRLLGVCTEPADEPVFIITELL 372  
SmAbl1  IIMRQKLGCGQYGDVYEAVWKRFNSVVAVKTLKQDVNLNVNDFLKEAAIMKKLRNRNLVQLLGVCTR--ELPLYLITEYM 505  
SmAbl2  IVMKHKLGSGQYGVVYEAVWKPYNVLVAVKTLKENV-TVRDEFLEEARLMKSLRHPNLVTLLGACTR--EPPYYIVTEFM 359  
SmTK6   ITRIRKLGQGTFGEVYLAKWNG-SVEVAVKMRLDPT--DRSRFIEEARLMHAFHHPRIVQLLGVCTEPEDQPVYIITELM 373  
hsAbl   ITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDT-MEVEEFLKEAAVMKEIKHPNLVQLLGVCTR--EPPFYIITEFM 318  
              *    *  *            * *               *  **             *          * * ** 
                 90       100       110       120       130       140       150       160         
        ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmAbl1  PHGNLLNYLRQRSPGELTPPILLYMAVQIASGMAYLEANNFIHRDLAARNCLVGDQYTIKVADFGLARYMQLHEDTYTAR 462  
EmAbl2  CNGNLLDYLRIQPRDVLSPPVLLQMAIHVCCAMTYLEEHNFIHRDLAARNCLVGEAMTVKVADFGLARYME-RDVTYRAR 412  
EmTK6   EKGALRNFLSSEEGRQLFLSDLIDMIAQIAEGMAYLEEMNFVHRDLRAANILVDRDNSVKVADFGLAKMLD---SDVQND 449  
SmAbl1  PNGNLLNYLRTRSPGELTPLTLLYMAVQIASGMAYLEANNFIHRDLAARNCLVGDQHLIKVADFGLARYMQ-RQDTYTAR 584  
SmAbl2  CNGNLLDYLRTHPRTELTPSVLLHMATQVARGMAYLEQHNFIHRDLAARNCLVGTQHTIKVADFGLARCIE-RDLTYRAH 438  
SmTK6   RKEALYDFLRTEEGHKLTLDDLIDIMAQIASGMSYLEXMNSVHRDLRAANILVDQDYSVKVSDFGLAKIIS---DDSHAD 450  
hsAbl   TYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMT--GDTYTAH 396  
          *                                      ***       *         *** 
                170       180       190       200       210       220       230       240        
        ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmAbl1  NGAKFPIKWTAPEGLA-YFRFSSKSDVWAFGVVLWELATYGLSPYPGVELHGVYQLLEKGYRMQRP----HGCPESVYSI 537 
EmAbl2  EGAKFPIKWTAPEGLV-YNCFSIKSDVWAFGVLLWEIATYGAAPYPGVELQDVYVLLQRGTRMEAP----QGCPDAVYQL 487  
EmTK6   GVIKFPIKWTAPEAALPDHHFSIKSDVWSFGVLMYEIVTYGGTPYPRFTNRETVQQVERGYRMPNPNTPTQPCPDDLYDI 529  
SmAbl1  NGAKFPIKWTAPEGLS-YYLFSSKSDVWAFGVVLWELATYGLSPYPGVELHDVYHLLEKGYRMERP----HGCPEAVYSI 659  
SmAbl2  EGAKFPIKWTAPEGLV-YNLFSTKSDVWAFGILLWEIATYGKTPYPGVELQDVYVLLERGTRMLCP----EGCPEPVYEL 513  
SmTK6   PNTKFPIKWTAPEAAL-QHIFSIKSDAWSFGILMYEIVTYGGTPYPGMTTRQTVAEVEKGYRLPCPHTPEHPCPDDLYNL 529 
hsAbl   AGAKFPIKWTAPESLA-YNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERP----EGCPEKVYEL 451  
 
                250       260  
        ....|....|....|....|.. 
EmAbl1  MLRCWSWEAADRPTFLSIKAEL 559  
EmAbl2  MLDCWSWNSEDRPSFKEVYTRL 509 
EmTK6   MMQCWSARPEDRPTFHNLYDIF 551  
SmAbl1  MLRCRSWDPNLRPSFSEIHAEL 681  
SmAbl2  MLQCWQWLPEQRPPFSDILNQL 535 
SmTK6   MRKCWDARPENRPTFRSLYDVF 551  
hsAbl   MRACWQWNPSDRPSFAEIHQAF 493  
 
Fig. 4.29: Alignment of Abl and TK6 kinase domains [147]. Em: E. multilocularis; Sm: S. mansoni,
Hs: H. sapiens. Identical residues are highlighted in black, similar in grey. Asterics
indicate residues important for Imatinib binding.
The high conservation of the Imatinib binding site and the presence of transcripts in all
larval stages suggested that Imatinib could block parasite development in vitro. There-
fore, Imatinib was tested on Metacestode vesicles, primary cell cultures and protoscole-
ces [147].
Metacestode vesicles were treated with 10, 25 and 50 µM Imatinib for up to 7 days (Fig.
4.30). At day 5 a significant decrease in survival was observed in samples treated with 25
and 50 µM Imatinib. At that time point no difference was observed in samples treated with
10 µM inhibitor. At day 7 nearly all vesicles in the 25 and 50 µM groups were dead and
survival of vesicles in 10 µM treated samples was reduced to 50 %. In cultures treated with
100 µM all vesicles were dead at day 2 (data not shown).
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Fig. 4.30: Survival of metacestode vesicles
treated with Imatinib [147].
Metacestode vesicles were cul-
tivated for 7 days in 0.2 %
FCS/DMEM supplemented with
reducing agents and the indicated
concentration of Imatinib. p below
0.0001 (Chi2)
Because 10 µM lead only to a slight decrease of survival to about 50 % in 0.2 % FCS/DMEM,
viability and regenerative ability of primary cells from these cultures was investigated.
Metacestode vesicles were pre-treated for 9 days in 2 % FCS/DMEM to ensure a better vi-
ability of the primary cells. Subsequently, primary cell were isolated and cultivated under
axenic conditions. Although nearly all vesicles treated with 10 µM Imatinib were intact
in this experiments, no regeneration occurred in the corresponding primary cell culture at
day 7 (Fig. 4.31). As was expected no regeneration was observed in the 25 µM pre-treated
samples.
Fig. 4.31: Regeneration of primary cell cultures from Imatinib pre-treated metacestode vesicles.
Vesicles were cultivated for 9 day with or without Imatinib in 2 % FCS/DMEN. Pri-
mary cells were isolated from theses vesicles and cultivated in conditioned medium. After
7 days, regeneration was documented.
Protoscoleces were treated with Imatinib for 7 days in 2 % FCS/DMEM. Subsequently,
protoscoleces were stained with methylen blue and dead parasites were counted. 50 µM
Imatinib had a drastic effect, killing all protoscoleces in the samples (Fig. 4.32). Treatment
with 25 µM Imatinib showed a 50 % reduced survival, while 10 µM had no significant ef-
fect. The low effect for 10 µM is comparable to metacestode vesicles in 2 % FCS/DMEM
(Fig. 4.31) and is therefore probably caused by the FCS in the culture.
84
4 Results
Fig. 4.32: Survival of protoscoleces treated with Imatinib
[147]. Protoscoleces were isolated from infected
jird material and cultivated for 7 days in 2 %
FCS/DMEM supplemented with reducing agents
and the indicated concentration of Imatinib. Af-
ter the indicated time protoscoleces were stained
with 0.03 % methylen blue and dead protoscole-
ces were counted. (*) p values below 0.05 (**) p
between 0.001 and 0.01, (***) for p below 0.001
In a next set of experiments Imatinib was tested on primary cells to investigate the effect
of Imatinib on stem cell rich cultures. Imatinib significantly decreased viability of primary
cell cultures treated with 25 µM and 50 µM to 50 and 25 %, respectively (Fig. 4.33A). 10 µM
only had a slight effect on viability. However, when primary cell cultures were treated
with Imatinib for a period of 3 weeks, vesicle formation was drastically decreased (Fig.
4.33B) [147]. Samples treated with 10 µM or 25 µM Imatinib still showed aggregation,
although it was severely impaired in the 25 µM samples (Fig. 4.33C). No regeneration
and therefore also no vesicle formation was observed in cultures incubated with 50 µM
Imatinib.
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Fig. 4.33: Treatment of primary cells with Imatinib. (A) Freshly isolated primary cells were incu-
bated with or without Imatinib for 2 days in 10 % FCS/DMEM without phenol red. Via-
bility was measured using the Resazurin assay. p below 0.0001 for all samples compared
to the control. (B) Primary cells were cultivated in conditioned medium supplemented
with Imatinib in the indicated concentrations. After 3 weeks the formed vesicles were
counted. (*) p values below 0.05 (**) p between 0.001 and 0.01, (***) for p below 0.001. (C)
Aggregation of primary cells treated with Imatinib for 3 weeks in conditioned medium.
Next, morphological changes after short term treatment with Imatinib were investigated.
Samples from metacestode vesicles [147], primary cells and protoscoleces were treated for
24 h with Imatinib and subsequently embedded for haematoxylin/eosin staining (HE). In
metacestode vesicles, non-treated vesicles showed a strong staining in the tegument (Teg)
and an intact and healthy germinal layer (GL) (Fig. 4.34Mc). Treatment with 10 µM
Imatinib already induced morphological changes in the tegument, reflected by a loss of
staining. In 25 and 50 µM treated samples the germinal layer was detached from the
laminated layer (LL), organisation of the germinal layer is lost and the cells appear to
die. Treatment of 50 µM Imatinib lead to complete killing of parasitic cells. Non-treated
primary cells looked healthy, the cavities (CA) and the cells surrounding them were well
structured (Fig. 4.34Pc). Treatment with 10 µM Imatinib already lead to a loss of structure
surrounding the cavities. In 25 and 50 µM treated samples the cavities were disrupted and
the cells appeared to be dead. In untreated protoscoleces the apical basal structure was
clearly visible . Muscle fibers (Mf) were running longitudinal through the protoscolex body
(Fig. 4.34Ps). These fibers already vanished in samples treated with 10 µM Imatinib. 50
and 100 µM Imatinib lead to dying of the cells and complete loss of structural integrity.
It is interesting to note that in samples treated with 10 µM or DMSO still invaginated
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protoscoleces were found, with a higher number in the control, while in 50 and 100 µM all
protoscoleces were evaginated (data not shown).
Fig. 4.34: (Mc) Axenic metacestode vesicles were cultivated for 24 h in 2 % FCS/DMEM supple-
mented with the indicated concentrations of Imatinib, after which they were embedded in
Technovit 8100 and 4 µm sections were stained with haematoxylin/ eosin. (Pc) Primary
cell cultures were grown for 5 days in conditioned medium and subsequently transferred
to 2 % FCS/DMEM supplemented with Imatinib for 24 h. Aggregates were embedded
in Technovit 8100 and 4 µm sections were stained with HE. (Ps) Protoscoleces, isolated
from infected jirds were cultivated in conditioned medium for 3 days. The medium was
changed to 2 % FCS/DMEM and Imatinib was added for 24 h. The samples were em-
bedded in Technovit 8110, 4 µm were prepared and stained with HE.Mc: metacestode
vesicles; GL: germinal layer; LL: laminated layer; Teg: tegument; Pc: primary cells; CA:
cavity; Ps; protoscolex; Mf: muscle fibers; the larval stage is indicated above the pictures
and on the left site of the pictures the concentration of Imatinib is indicated.
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4.3 K11777 a new inhibitor in anti-AE chemotherapy?
Cysteine proteases of the papain superfamily are involved in numerous cellular processes
and play an important role in the pathogenesis of parasitic infections [149]. K11777 (N-
methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl), a new inhibitor of the vinyl sulfone
group emerged as an effective inhibitor of papain proteases and already showed high effi-
cacy in reducing egg burden and organ pathology in mice infected with Schistosoma man-
soni [129]. To identify possible targets for K11777 a genome wide Pfam search with the
papain family cysteine protease domain (PF00112) was carried out on the E. multiloc-
ularis genome. Ten genes coding for Echinococcus cathepsin-like proteases were identi-
fied (Tab. 4.4), among them were two cathepsin B-like and 7 cathepsin L-like proteins.
EmW 000654500 and EmW 000654600 sequences were identical and characterised by Sako
et al. [150] as EmCLP1. Interestingly, the two genes were found directly next to each other
in the genome. The five genes on scaffold 7728 were highly homologous, sharing over 92
% identical amino acids and most probably are the result of gene multiplications. K11777
forms irreversible, covalent complexes with the cysteine of the catalytic triad character-
istic for the papain superfamily enzymes [151]. Further bindings involve Gln19, Gly66,
Asp161, His162, Trp184 (TcCruzain, Papain family cysteine protease domain). Alignment
of the papain family cysteine protease domains of the Echinococcus cathepsins with Sm-
CathepsinB1 ad TcCruzain revealed conservation of the papain specific catalytic triad and
the presence of the Gln19, Gly66, Trp184 corresponding residues (Fig. 4.35). Asp161 is only
conserved in EmW 000654100, EmW 000654500 and EmW 000654600 and is exchanged
to a Gly in the cathepsin B-like proteins and to Asn in the other cathepsin L-like homo-
logues.
Tab. 4.4: Identification of cysteine proteases in E. multilocularis. Pfam search on sequence data
available under http://www.genedb.org. EmCLP1 (Acc. No: BAF02516) and EmCLP2
(Acc. No: BAF02517) were characterised by Sako et al. [150], EmCBP1 (Acc. No:
BAJ83490) and EmCBP2 (Acc. No: BAJ83491) were identified by Sako et al. [152].
Systematic Name Location Product Name
EmW 000654100 scaffold 007728 : 8608026-8610326 cathepsin L-like
EmW 000654500 scaffold 007728 : 8635659-8637959 cathepsin L-like EmCLP1
EmW 000654600 scaffold 007728 : 8641231-8643531 cathepsin L-like EmCLP1
EmW 000654200 scaffold 007728 : 8617974-8620387 cathepsin L-like
EmW 000654800 scaffold 007728 : 8656821-8659233 cathepsin L-like
EmW 000790300 scaffold 007768 : 5441376-5443678 cathepsin B-like EmCBP2
EmW 000790200 scaffold 007768 : 5437741-5440037 cathepsin B-like EmCBP1
EmW 000967900 scaffold 007780 : 3105356-3111019 cathepsin L-like
EmW 000989200 scaffold 007780 : 5012240-5015594 cathepsin L-like EmCLP2
EmW 000477200 scaffold 007614 : 4912844-4914073 cathepsin L-like
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                         10        20        30        40        50        60        70        80                
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmW_000654100   VPDSIDWRKKGL----VTPIKDQGDCGSCWAFSATGALEGQLKRKTGKLIS------LSEQQLVDCSTYTGNEGCNGGEM 191   
EmW_000654500   VPDSIDWRKKGL----VTPIKDQGDCGSCWAFSATGALEGQLKRKTGKLIS------LSEQQLVDCSTYTGNEGCNGGDM 191   
EmW_000654600   VPDSIDWRKKGL----VTPIKDQGDCGSCWAFSATGALEGQLKRKTGKLIS------LSEQQLVDCSTYTGNEGCNGGDM 191   
EmW_000654200   VPDSIDWRKKGL----VTPIKDQGDCGSCWAFSATGALEGQLKRKTGKLIS------LSEQQLVDCSTYTGNEGCNGGDM 191   
EmW_000654800   VPDSIDWRKKGL----VTPIKDQGDCGSCWAFSATGALEGQLKRKTGKLIS------LSEQQLVDCSTYTGNEGCNGGDM 191   
EmW_000790300   LPSEFDARKAWPDCPTIGEIRDQGTCGSCWAFGATEAMSDRICIHSEGKE----VVRISADDLLSCCGLFCGFGCNGGLP 159   
EmW_000790200   LPASFDPRKKWPNCKTLFEIRDQGSCGSCWAFGAAEAMSDRLCIQQQTVSGRAVMVRLSADDLLSCC-RDCGMGCNGGFP 174   
EmW_000967900   YLGNFDWRERFP----DRKVRDQMSCGSCWAFASVSAVEWHWAIHHGRSLP------LSVQQLVDCVHS--NFGCNGGII 214 
EmW_000989200   LPDMVDWRDKNL----VTEVKNQGNCGSCWAFSSTGALEGALAKKTGKLIS------LSEQQLVDCTLENGNDGCNGGYM 192 
EmW_000477200   LPKHVDWRLKGR----VTGVKDQGHCGSCWAFSAIGAIEGQYQRASGNLVS------LSEQQLVDCSSSFGNMGCNGGLM 196 
SmCathepsinB1   IPSSFDSRKKWPRCKSIATIRDQSRCGSCWAFGAVEAMSDRSCIQSGGKQ----NVELSAVDLLSCC-ESCGLGCEGGIL 163 
TcCruzain       APAAVDWRARGA----VTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTN------LSEQMLVSCDKT--DSGCSGGLM 190                  
                         *                                                     * 
                         90       100       110       120       130       140       150       160         
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmW_000654100   NDAFRYCMQME----------------------PENESDYPYTA----MDGKCK-------FNSSKVVTKVSKFVKVPKK 238  
EmW_000654500   NDAFRYWMRNG----------------------AESESDYPYTA----MDGKCK-------FNSSKVVTKVSKFVKVPKK 238  
EmW_000654600   NDAFRYWMRNG----------------------AESESDYPYTA----MDGKCK-------FNSSKVVTKVSKFVKVPKK 238  
EmW_000654200   NDAFRYWMRNG----------------------AESESDYPYTA----MDGKCK-------FDRSKVVIKVSKFVKVPEK 238  
EmW_000654800   NDAFRYWMRNG----------------------AESESDYPYTA----MDGKCK-------FDRSKVVTKVSKFVKVPEK 238  
EmW_000790300   ENAWRYWAIDGIVSGGLYGSHVGCRPYEIPPCEHHTSGNRPDCKGNS-KTPKCQRQCVESFDGKYQADKHFASNVYNVRA 238  
EmW_000790200   SQAWNFWKHEGLVSGGLYGTKGVCRAYEIPPCEHHVNGTRPPCEGDA-PTPKCKNVCQEEYKVPYKKDKHYAVKVYSVHS 253  
EmW_000967900   ENALAYIQSHG----------------------IMPNRDYPYRS----RVTQCT-------ENPDKVALKIKGYETLYGV 261 
EmW_000989200   SNAFKYLEGHS----------------------IEPESAYPYRA----TDGPCR-------YNESLGVGSVTDIGDIPEG 239 
EmW_000477200   DNAFNYVKEAGG---------------------VDREVDYPYVSGVTEKPDNCS-------FKANISVAKVTGLVDVMSG 248 
SmCathepsinB1   GPAWDYWVKEGIVTGSSKENHTGCEPYPFPKCEHHTKGKYPPCGSKIYKTPRCKQTCQKKYKTPYTQDKHRGKSSYNVKN 243 
TcCruzain       NNAFEWIVQENNGA-------------------VYTEDSYPYASG-EGISPPCT-------TSGHTVGATITGHVELPQ- 242 
                *  
                        170       180       190       200       210       220       230       240        
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
EmW_000654100   REDQLKLSVAQVGPVSVAIDATSSGFMLYKKGIYQDNTCSQ--QYLDHAVLVVGYDADKTRQKYWIVKNSWGEDWGQRGY 316 
EmW_000654500   REDQLKLSVAQVGPVSVAIDATSSGFMLYKKGIYQDNTCSQ--QYLDHAVLVVGYDADKTRQKYWIVKNSWGEDWGQRGY 316  
EmW_000654600   REDQLKLSVAQVGPVSVAIDATSSGFMLYKKGIYQDNTCSQ--QYLDHAVLVVGYDADKTRQKYWIVKNSWGEDWGQRGY 316  
EmW_000654200   SEDQLKLSVAKVGPVSVAIDASSSGFMFYEKGIFQDNNCSE--NDLNHGVLVVGYDADKTRRKYWIVKNSWGEQWGQRGY 316  
EmW_000654800   SGDQLKLSVAKVGPVSVAIDASSSGFMFYEKGIFQDNNCSE--NDLNHGVLVVGYDADKTRRKYWIVKNSWGEQWGQRGY 316  
EmW_000790300   SEEDIMNEILVYGPVEADFIVYAD-FLTYKSGVYQHVKGGF---LGGHAVKILGWG-EENGVPYWLCANSWNTDWGDGGF 313 
EmW_000790200   NEDAIKHELITHGPVEADFEVYAD-FPTYKSGVYQHVSGAL---LGGHAIKLMGWG-EEDGVPYWLCANSWNTDWGEGGF 328  
EmW_000967900   SEAVLACVVQRLGPVVIGFDASGSGLQHYKSGIYDGTDCNG--EMLNHGLVLLGFGTDARGNRYWICQNSFSQRWGDNGF 339 
EmW_000989200   NETALMEAVATVGPISIAIDASTLGFMFYHHGIYKSHWCSS--KFLNHGVLAIGYG-KLDGKPYWLVKNSWGSRWGMKGY 316 
EmW_000477200   NDEELMEALAFNGPISVAINAGLTSFMMYHEGIYDDPKCEGGVEDLNHGVLLVGYG-EQNGIPYWLIKNSWGTDWGEHGY 327 
SmCathepsinB1   DEKAIQKEIMKYGPVEAGFTVYED-FLNYKSGIYKHITGET---LGGHAIRIIGWG-VENKTPYWLIANSWNEDWGENGY 318 
TcCruzain       DEAQIAAWLAVNGPVAVAVDASS--WMTYTGGVMTS--CVS--EQLDHGVLLVGYN-DSAAVPYWIIKNSWTTQWGEEGY 315 
                                                              *                     *   
                        250       260                          * 
                ....|....|....|....|. 
EmW_000654100   IWMARDKGNMCGIATMASYPL 337  
EmW_000654500   IWMARDKGNMCGIATMASYPL 337  
EmW_000654600   IWMARDKGNMCGIATMASYPL 337  
EmW_000654200   IWMARDKGNMCGIATMASYPL 337  
EmW_000654800   IWMARDKGNMCGIATMASYPL 337  
EmW_000790300   FKILR-GYNHCKIEADINAGI 333  
EmW_000790200   FKILR-GKNHCGIESDIVAGI 348  
EmW_000967900   FRFKF-GSNLCGVAATPIIPV 359 
EmW_000989200   IMMAKDYHNMCGVASLADFPY 337 
EmW_000477200   VRIKR-AGNMCGVATAASYPL 347 
SmCathepsinB1   FRIVR-GRDECSIESEVTAGR 338 
TcCruzain       IRIAK-GSNQCLVKEEASSAV 335 
Fig. 4.35: Alignment of the papain family cysteine protease domains of Echinococcus cysteine pro-
teases with SmCathepsinB1 (Genebank accession number: AJ506157), TcCruzain(Acc.
No: M84342). Identical residues are highlighted in black, similar in grey. Squares in-
dicate residues of the catalytic triad, asterics mark residues that are involved in polar
interactions with K11777.
In a first experiment the inhibitor K11777 was tested on metacestode vesicles (Fig. 4.36A).
After 7 days treatment with 25 µM and 50 µM K11777 had severe effects on survival of
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metacestode vesicles. Nearly all vesicles were dead after that time. At day 4 a difference in
the concentration dependent effect was visible with a 25 % higher effect of 50 µM than with
25 µM K11777. 10 µM had no effect on survival of metacestode vesicles. Therefore, a pre-
treatment experiment was carried out, which clearly showed that regeneration of primary
cells pre-treated with 10 µM K11777 was severely impaired in comparison to the control
(Fig. 4.36B). Regeneration in the control was very low due to a low amount of starting ma-
terial. Further experiments on the influence of K11777 on viability of primary cells showed
that the inhibitor has a devastating effect on this culture system (Fig. 4.36C). Concentra-
tions as low as 10 µM reduced viability to 50 % of the control. Viability in samples treated
with 25 µM and 50 µM was decreased to 25 and 10 %, respectively. Taken together these
results show, that the inhibitor K11777 has a severe effect on both, metacestode vesicles
and primary cell cultures.
Fig. 4.36: Effects of K11777 on metacestode vesicles and primary cells. (A) Metacestode vesicles were
cultivated for 7 days in the presence or absence of K11777. Disrupted vesicles were counted
on day 2, 4 and 7. The control was supplemented with DMSO. p below 0.001 for 25 µM
and 50 µM samples. (B) Metacestode vesicles were treated with DMSO or 10 µM K11777
for 7 days in conditioned medium, followed by primary cell isolation and cultivation in
conditioned medium. The regeneration of primary cells was documented on day 7. (C)
Freshly isolated primary cells were cultivated in 10 % FCS/DMEM without phenol red
supplemented with K11777 in the indicated concentrations. After 2 days the Resazurin
viability assay was performed. (***) p below 0.001.
90
4 Results
4.4 Targeting Jun kinase (JNK) with the inhibitor AS601245
Jun kinase in E. multilocularis was previously described by Riedl [153]. However only
a weak effect was observed with the JNK inhibitor II (SP600125, Biomol). The inhibitor
AS601245 (JNK inhibitor V, Calbiochem) was therefore tested for an effect on E. multiloc-
ularis larval material. Survival of metacestode vesicles treated with 50 µM AS601245 (AS)
was severely decreased (Fig. 4.37), lower concentrations however showed no effect (data
not shown). To investigate if AS affects viability of parasite material at lower concentra-
tions pre-treatment experiments were carried out. Metacestode vesicles were treated with
AS for 7 days. Subsequently, primary cells were isolated and regeneration of aggregates
from theses cells was observed. Primary cell cultures of vesicles treated with 20 µM AS for
7 days showed no regeneration, while in samples pre-treated with 2 µM viability was only
slightly impaired (Fig. 4.38). These results showed, that also no killing effect on vesicles
was observed viability of the parasite was affected.
Fig. 4.37: Survival of metacestode vesi-
cles treated with AS601245.
Metacestode vesicles were in-
cubated for 7 days in 10 %
FCS/DMEM supplemented
with AS. Disrupted vesicles
were counted at day 2, 4 and
7. p below 0.001
Fig. 4.38: Regeneration of primary cell aggregates from pre-treated metacestode vesicles. Axenic
metacestode vesicles were incubated in conditioned medium supplemented with the indi-
cated concentration of AS for 7 days. The control was supplemented with DMSO. Subse-
quently, primary cells were isolated and cultivated in conditioned medium. Aggregation
was documented on day 4.
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Pre-treatment experiments indicated that AS601245 could have an influence on viability
of E. multilocularis stem cells. Therefore AS was subsequently tested on primary stem cell
cultures in the Resazurin assay. The experiments revealed that a concentration of 20 µM
reduced viability of primary cell cultures to 50 % and 50 µM had an even stronger effect,
decreasing living parasite material to 25 % (Fig. 4.39A). 2 µM AS had no effect in this
experiment, although this is probably due to a short treatment period of 2 days. Treatment
of protoscoleces with 20 or 50 µM AS for up to 2 weeks revealed a time dependent effect
of AS601245 on survival of protoscoleces (Fig. 4.39B). While treatment with the inhibitor
showed only a slight effect after two days, survival was reduced to 50 % on day 7 and to
25 % on day 14. In these experiments the difference between 20 µM and 50 µM was not
significant.
A B
Fig. 4.39: Treatment of primary cells and protoscoleces with AS601245. (A) Freshly isolated primary
cells were incubated in 10 % FCS/DMEM without phenol red supplemented with the
indicated concentration of AS. After 2 days the Resazurin assay was carried out. (B)
Protoscoleces were isolated from secondary infected jirds and cultivated in conditioned
medium with 20 µM or 50 µM AS for the indicated time. Samples were stained with 0.03
% methylen blue and dead protoscoleces were counted. (**) p between 0.001 and 0.01,
(***) for p below 0.001.
4.5 The effect of Albendazole in the new E. multilocularis in vitro cultivation
systems
The current standard in AE treatment with Albendazole (ABZ) is 400 to 800 mg daily,
given in two doses, which should give the optimal plasma level of 0.65- 3 µM 4 h after
the morning dose [23]. In recent years much progress in in vitro cultivation systems have
been made [43] that could also influence the effect of inhibitors in vitro. Therefore, it
is necessary to study ABZ effect in these in vitro systems for a better evaluation of the
putative new inhibitors against E. multilocularis. ABZ was used on metacestode vesicles
in in vitro experiments (Fig. 4.40A). The chosen concentrations varied from 4 µM, which
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is the therapeutic plasma concentration to 50 µM, a concentration that was used for other
tested inhibitors. With 50 µM effective killing of metacestode vesicles was achieved, while
a concentration of 4 µM lead to a 50 % decreased survival. 10 µM and 20 µM both reduced
survival to 37 %. On primary cells, using the Resazurin health assay no effect was seen,
even a high concentrations of 100 µM (Fig. 4.40B).
All together these data show, that ABZ was very efficient against metacestode vesicles, but
showed no effect against primary cell cultures.
A B
Fig. 4.40: Effect of ABZ on E. multilocularis. (A) Axenic metacestode vesicles were cultivated in 2 %
FCS/DMEM supplemented with DMSO or ABZ. Dead vesicles were counted at day 7.(*)
p below 0.05, (***) p below 0.001. (B) Primary cells were incubated in 10 % FCS/DMEM
without phenol red in the presence of ABZ or DMSO. Subsequently the Resazurin Health
assay was carried out.
4.6 The utilization of inhibitor combination treatment against E.multilocularis
larvae
Treatment options against AE are currently very limited and rely mostly on benzimida-
zoles [20], which are mostly parasitostatic and depend on a life-long treatment of the pa-
tients [24]. For a new approach of anti-AE treatment ATP-competitive inhibitors of con-
served signalling systems are considered. However, most inhibitors promote resistance
development. Combination therapies are already successfully employed in Plasmodium
falciparum [154] as well as in cancer treatment [155]. For a first step into testing the ef-
fect of combination-based therapy of AE several inhibitor combinations were tested on E.
multilocularis in vitro cultures.
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4.6.1 Comparison of inhibitors in single drug in vitro assays
To evaluate the efficacy of the employed compounds against E. multilocularis the effect of
the inhibitors in metacestode vesicles and primary cells was compared. In metacestode
vesicles survival on day 7 for the different compounds and concentrations was summarized
in Tab. 4.5. In the experiments HNMPA(AM)3 and LY294002 showed the lowest perfor-
mance. Effects below 100 µM and 50 µM, respectively, were not detected. Imatinib and
K11777 showed the highest effectivity in killing metacestode vesicles in vitro, while the
effects of AS601245 were observed at higher concentrations. In metacestode vesicles Ima-
tinib reduced survival of metacestode vesicles at 10 µM stronger than K11777. Interest-
ingly Albendazole (ABZ) which is currently used in anti-AE therapy only shows weak effect
in this cultivation system. 4 µM ABZ corresponded to the desired plasma levels in patients
only reduced survival of metacestode vesicles to 53.3 %.
Tab. 4.5: Summary of inhibitor treatment on metacestode vesicles. Depicted is the effect on survival
of metacestode vesicles [%] at day 7. (n.e) no effect, (n.d) not determined.
4 µM 10 µM 20 or 25 µM 50 µM 100 µM
HNMPA(AM)3 n.d n.e n.e n.e 20
LY294002 n.d n.e n.e 71.3 66
Imatinib n.d 46.7 10 0 0
AS601245 n.d n.e n.e 22.5 n.d
K11777 n.d 90 10 0 n.d
Albendazole 53.3 36.7 36.7 6.7 n.d
In primary cells viability of the cultures was compared with the Resazurin health assay,
which reflects the status of the cells after two days of treatment (Tab.4.6). In primary cells
HNMPA(AM)3 was more effective than in metacestode vesicles, showing an effect already
at 25 µM. LY294002 was less effective compared to metacestode vesicles. ABZ showed
no reduction in viability of primary cells. Highest effects were seen with Imatinib and
K11777.
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Tab. 4.6: Summary of inhibitor treatment on Primary cell cultures. Primary cells were incubated
with the indicated amount of inhibitor for 2 days. Subsequently the Resazurin health
assay was carried out and the viability [%] compared to the control was measured. (n.e)
no effect, (n.d) not determined.
10 µM 20 or 25 µM 50 µM 100 µM
HNMPA(AM)3 n.e 67.9 50.7 n.d
LY294002 n.e n.e 97.2 77
Imatinib 82.7 49.4 23.2 n.d
AS601245 n.e 44.9 22.6 n.d
K11777 50.4 25.6 10.6 n.d
Albendazole n.e n.e 94.6 111.5
Taken together these results showed that Imatinib and K11777 both had a strong effect on
metacestode vesicles and primary cells. ABZ was most effective on metacestode vesicles,
but had no activity against primary cells. HNMPA(AM)3, LY294002 and AS601245 only
showed medium performance against metacestode vesicles and primary cells.
4.6.2 Combination-treatment of parasite material
The insulin signalling cascade was shown to promote parasite development and inhibitors
against the insulin receptor and the PI3K were decreasing parasite survival. A combina-
tion of two inhibitors, HNMPA(AM)3 and LY294002 was tested to study, whether this leads
to a more effective shutdown of the signalling cascade (Fig. 4.41A). Aditionally, Imatinib
was tested in combination with HNMPA(AM)3, to block two different signalling cascades.
LY294002 had no significant effect in the Resazurin assay, while HNMPA(AM)3 reduced
viability to 59 %. Combination of HNMPA(AM)3 and LY294002 had a synergistic effect
on the cultures and reduced viability by another 17 % to 42 % in total. Combination of
HNMPA(AM)3 with Imatinib was even more effective, reducing viability to 19 % compared
to the control. Taken together, these results show that targeting of two different signalling
cascades is a more promising approach than combination of two inhibitors in the same
pathway.
In a second experiment Imatinib was tested together with AS601245 as both inhibitors
displayed activity against primary cells and metacestode vesicles (see Tab. 4.6). Ima-
tinib and AS601245 reduced viability of primary cell to 49.4 and 44.9 %, respectively. A
combination of the two compounds resulted in a survival of 8.4 % after only 2 days (Fig.
4.41B).
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A B
Fig. 4.41: Effect of inhibitor combinations in the Resazurin health assay. Primary cells were in-
cubated in 10 % FCS/DMEM supplemented with the indicated inhibitors for 2 days.
Subsequently the Resazurin assay was carried out. (A) HNMPA(AM)3 was used in the
concentration of 25 µM, LY294002 with 50 µM and Imatinib with 25 µM. DMSO was
added to the control. (B) 25 µM Imatinib and 20 µM AS601245 were added. The control
was supplemented with DMSO. (**) p between 0.001 and 0.01, (***) for p below 0.001.
Imatinib was one of the most effective inhibitors used in the study. Therefore, Imatinib
was investigated in the combination with ABZ for its potential use as a supplement in ABZ
based therapy. In a first approach metacestode vesicles were treated with ABZ, Imatinib
and a combination of both for 7 days. In this experiment Imatinib had a stronger effect
than ABZ in killing metacestode vesicles. Combination of Imatinib and ABZ intensified
the effect of Imatinib, however no significane could be achieved (Fig 4.42A). A lower con-
centration of Imatinib (10 µM) had no effect on parasite survival and also no additive effect
to ABZ (data not shown).
In primary cells Imatinib reduced viability to 50 %. Combination of Imatinib and ABZ lead
to a total viability of 27 %, although ABZ alone had no effect on primary cells (Fig. 4.42B)
Treatment of primary cells in long term cultures 20 µM ABZ affected regeneration nega-
tively. Cavities were visibly smaller than in the control. 10 µM Imatinib reduced cavity
size, furthermore, the aggregates had an unhealthy, deteriorating appearance. The combi-
nation of both inhibitors blocked aggregation and regeneration efficiently (Fig. 4.42C).
Having shown that K11777 is one of the most effective inhibitors tested on primary cells
and metacestode vesicles, K11777 was additionally investigated in combination with ABZ
(Fig. 4.43). 10 µM K11777 reduced survival of primary cells in the Resazurin assay to 55
%. Combination of K11777 with 50 µM ABZ lead to an overall survival of 36 %, which indi-
cated that ABZ and K11777 worked synergistically in these experiments.
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Taken togehter the data show that the most effective inhibitor combination was Imatinib
with AS601245. Furthermore, Imatinib and K11777 both displayed promoted effects to-
gether with ABZ.
Fig. 4.42: Effect of ABZ and Imatinib combination treatment on E. multilocularis. (A) Metacestode
vesicles were cultivated in 2 % FCS/DMEM supplemented with ABZ and Imatinib for up
to 7 days. The control was supplemented with DMSO. Dead vesicles were counted after 3,
5 and 7 days. (B) Primary cells were incubated in 10 % FCS/DMEM supplemented with
the indicated amounts of the inhibitors for 2 days. Subsequently the Resazurin assay
was carried out. DMSO was added to the control. (C) Freshly isolated primary cells
were cultivated in conditioned medium in the presence of ABZ and Imatinib or DMSO.
Development of aggregates was documented at day 14. (**) p between 0.001 and 0.01,
(***) for p below 0.001.
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Fig. 4.43: Combination treatment of primary
cells with ABZ and K11777. Pri-
mary cells were incubated in 10 %
FCS/DMEM supplemented with the
indicated amounts of the inhibitors for
2 days. Subsequently the Resazurin as-
say was carried out. DMSO was added
to the control. (*) p below 0.05, (***) for
p below 0.001.
4.7 The effect of the Clostridium botulinum C2 toxin on E.
multilocularis
The C2 toxin is a binary bacterial toxin of the AB-type toxins, composed of two non-linked
proteins that act as a binding/translocation component and an enzyme component. C2
toxin exhibits actin-ADP-ribosylation activity [156]. Furthermore, those toxins are cur-
rently investigated as possible delivery systems for eukaryotic cells [157].
C2 toxin was tested on metacestode vesicles and primary cells. Treatment of metacestode
vesicles had no visible effect on the cultures (data not shown), neither inducing killing, nor
increasing or decreasing growth. However in primary cell cultures high numbers of vesicles
formed in samples treated with a combination of C2II and C2I components of the toxin,
which were not present in the controls (Fig. 4.44B). Aggregation in these cultures was not
affected (Fig. 4.44A). Staining of vesicles with HE revealed that the vesicles contained no
cells (Fig. 4.44C) and are therefore no metacestode vesicles. The origin of the vesicular
structures are unknown, as they also appeared in experiments with low aggregation and
also in cultures of protoscoleces (data not shown). In protoscolex cultures no effect on
killing was observed.
Fahrer et al. [158] developed a carrier system system to transport C2I-fusion proteins
into cells. This system was used to study cellular uptake of the C2I subunit in form of
a C2I-streptavidin fusion protein. Biotin was incubated with the fusion protein to al-
low binding to the streptavidin part. The C2II-C2I-Biotin complex was incubated with
primary cell aggregates and uptake of Biotin into the cells was documented with fluo-
rescence microscopy. For the Echinococcus experiments periods of 2 to 10 h were tested.
Furthermore different concentrations of C2II and C2I components were used. In none of
samples an uptake of Biotin into E. multilocularis cells was observed (data not shown).
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Taken together the results suggest that C2 toxin binds to Echinococcus cells, but is not
internalised. Stimulation of vesicle formation therefore must be due to a stimulation of
parasite material from binding of the toxin. As the toxin was not taken up, it had no
lethal effects by interacting with the parasite actin cytoskeleton. The mechanism by which
vesicle formation is stimulated is still unknown, as well as the origin of the vesicles them-
selves.
Fig. 4.44: Effect of C2 toxin on parasite material. (A) Primary cells were cultivated in conditioned
medium supplemented with 200 ng/ml C2IIa and 100 ng/ml C2I or 100 ng/ml C2I-C3.
Vesicles formed after 4 to 9 days. Ag: aggregate, Ves: vesicle. (B) Formation of vesicles in
primary cell cultures. (**) p between 0.001 and 0.01, (***) for p below 0.001. (C) Samples
were embedded in Technovit 8100 and 4 µm sections were stained with HE. Depicted is a
vesicle and part of a primary cell aggregate.
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As a multicellular metazoan organism the fox tapeworm Echinococcus multilocularis re-
lies on signalling mechanisms for its developmental processes that have arisen early in
metazoan evolution [16, 48]. These signalling systems are based on soluble factors that
bind to surface or intracellular receptors and activate intracellular signalling cascades to
evoke the appropriate cellular response. As these signalling cascades also mediate cell-cell
communication, they could serve as potential host-parasite communication channels. By
sensing host factors the parasite could regulate its development depending on the current
status of the host. Evidence of this hormonal-crosstalk between host and parasite has been
already obtained and further investigation are currently performed [53,99,159].
Although the molecules that are involved in cellular signalling are highly conserved, many
significant changes were induced since the separation of Protostomia and Deuterostomia.
These changes on structural and functional level therefore can be employed to find new
targets for chemotherapy. The goal is to find inhibitors that target only parasite enzymes
without cross-reacting with human homologues. The study of Echinococcus signalling sys-
tems helps to understand the factors that promote development to identify new targets for
anti-AE therapy.
5.1 Insulin signalling in E. multilocularis
Insulin signalling is of special interest in E.multilocularis as the disease is first established
in the liver near the portal vein, where the highest body concentrations of insulin is reached
[64, 65]. Furthermore, IGF-I is highly expressed in the liver [66] and its involvement in
cancer development in humans emphasises proliferative functions of this factor [62, 63].
Although in mammals mitogenic IGF-I and metabolic insulin signalling are usually sepa-
rated, cross-talk between the two signalling systems as well as hybrid receptor complexes
were reported [63,160]. Additionally, interaction between human insulin and invertebrate
insulin receptors was shown to be possible [52]. The presence of two host-derived members
of the insulin family in the vicinity of the parasite implied that insulin could be involved in
host-parasite cross-communication and organ tropism of E.multilocularis by sensing host
derived factors with endogenous surface receptors.
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Previous works on E. multilocularis larval material indicated that host insulin might be in-
volved in proliferative processes, as it stimulated metacestode growth, survival and BrdU
incorporation when exogenously added to in vitro cultivated vesicles [124,130]. Two insulin
receptor homologues, EmIR1 [161] and EmIR2 [125] were identified in E. multilocularis.
EmIR1 was shown to be expressed in metacestode vesicles and protoscoleces and immuno-
histological experiments revealed a high abundance of EmIR1 in glycogen storage cells of
metacestode vesicles. Furthermore, Yeast two Hybrid (Y2H) experiments indicated that
the ligand binding domain of EmIR1 is able to interact with pro-insulin [124]. The same
work also demonstrated that in the course of host insulin stimulation the MAP kinase
cascade is activated [124].
In this work we extended our knowledge on insulin signalling mechanisms in E. multi-
locularis. Several lines of evidence clearly suggest, that insulin promotes parasite de-
velopment in vitro. First, insulin stimulated proliferation of primary cell cultures and
metacestode vesicles, as it was shown by BrdU incorporation experiments. Second, insulin
increased the development of new metacestode vesicles from primary cells and protoscole-
ces. Furthermore, aggregate and cavity size of the primary cell cultures was significantly
increased. The effects of insulin on E. multilocularis larvae could be blocked by the insulin
receptor inhibitor HNMPA(AM)3. And third, insulin stimulated phosphorylation of EmIR2
and the PI3K/ Akt pathway proteins in response to host derived insulin. The IR inhibitor
HNMPA(AM)3 and the PI3K inhibitor LY294002 both blocked insulin induced phosphory-
lation, thereby giving proof of the link between insulin, the insulin receptors and the PI3K/
Akt pathway. Additionally, it was already reported that EmIR1 and the MAPK cascade are
activated in response to insulin [124].
In previous experiments it was shown that insulin increases the volume of metacestode
vesicles [124, 130]. However, due to a high variation between the experiments no sig-
nificant result could be gained. Nevertheless, this work and previous experiments [124]
clearly proved that exogenous insulin stimulated proliferation of primary cell cultures and
metacestode vesicles. Additionally, in primary cells the aggregate and cavity size increased
in response to insulin, which indicated a better development of the cultures compared to
the control. Therefore, it can be concluded, that host insulin has mitogenic effects on E.
multilocularis larvae. Interestingly, in the culture system for metacestode vesicles used in
this work, a negative effect was observed for 100 nM insulin. A similar effect was already
reported in experiments with T. crassiceps [103], where it was suggested that a satura-
tion concentration of ligand could activate negative feedback mechanisms. However, the
saturation concentration in E. multilocularis experiments clearly depended on the exper-
imental setup, since it was observed in BrdU incorporation assays, but not in long-term
cultivation experiments. Furthermore, the overall insulin concentration used by Escobedo
101
5 Discussion
et al. [103] was much higher and is not directly comparable to the concentrations used in
this work.
In primary cell cultures and protoscoleces parasite metacestode vesicle formation was in-
creased when host insulin was added to the cultivation medium. These data indicate, that
insulin might drive the development of larval material towards the metacestode stage. In
the case of primary cell cultures, which mimic stem cell driven oncosphere-metacestode
transition [45] these data might represent the primary vesicle formation from the onco-
sphere during the establishment of the disease. Furthermore, it was demonstrated that
protoscoleces can contribute to the existing pool of vesicles [131, 132]. Protoscoleces could
come into contact with the surrounding host tissue, when a vesicle is broken or dying. In
that case, the de-differentiation of protoscoleces could be regulated by host insulin.
Next to mitogenic and developmental effects, host insulin also stimulated glucose up-
take of metacestode vesicles, thereby acting as a metabolic regulator. Similar results
have also been obtained for S. mansoni, S. japonicum and M. vogae [100–102], although
with much higher (unphysiological) insulin concentrations. Taken together these results
demonstrated that insulin regulates proliferation of E. multilocularis larval stages, but
also promotes the development towards the metacestode stage and regulates the glucose
metabolism.
Two members of the insulin receptor family were already identified that could mediate the
insulin response. Extensive mining of available genome data supported the assumption
that EmIR1 and EmIR2 are the only insulin receptors present in E. multilocularis. RT-
PCR analysis showed only slight differences in the abundance of emir1 and emir2 cDNAs
and they seemed to be expressed in all tested larval stages. The Emir2 isoform seems to be
expressed in a stage specific manner, as it was more abundant in non-activated protoscole-
ces and primary cell culture. Emir2a and b were found in all tested larval stages, whereas
emir2d was only weakly expressed. These data indicated that the emir2 isoforms could
serve distinct signalling functions.
For EmIR2 a specific antibody was produced against the β subunit, complementary to the
EmIR1 immunserum [124]. The antibody recognised a band at 87 kDa that corresponds to
the calculated size of the EmIR2β chain. A smaller band was detected at 60 kDa, that could
either represent solubilised immunoglobulin or a degradation product of EmIR2. Analysis
of the receptor processing indicated an assembly of the receptor complex similar to other
known members of the IR family [67,69].
EmIR1 [124] and EmIR2 immunsera where used to analyse the expression of the two re-
ceptors on protein level. Interestingly, EmIR1 is not present or only weakly expressed
in primary cell cultures, while EmIR2 is absent in metacestode vesicles. This finding is in
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contrast to the RT-PCR data and could be explained by post-transcriptional regulation that
results in a repression of the translation. Furthermore, differential expression of EmIR1
and EmIR2 in vesicles and primary cells indicated a functional difference of the receptors.
EmIR1 is highly abundant in glycogen storage cells [124] and could therefore mediate the
glucose uptake observed in this study. In S. mansoni it was demonstrated that SmIR1 is
involved in glucose uptake, but not SmIR2 [102]. Interestingly, SmIR1 is the homologous
receptor to EmIR2 and SmIR2 to EmIR1. Therefore, the glucose uptake in E. multilocu-
laris and S. mansoni is not mediated by the same receptor homologue. Assuming a similar
functional divergence of the two insulin receptors in E. multilocularis it must have devel-
oped after the separation of cestodes and trematodes.
Primary cells are characterised by a high proliferative activity and especially early cultures
consist mainly of stem cells (communication Uriel Koziol). Therefore a low EmIR1 expres-
sion could be expected when this receptor is specific for mediating the glycogen synthesis in
E. multilocularis. That EmIR2 is the only insulin receptor expressed in this culture system,
suggests that it might be responsible for the observed proliferative effects. However further
analysis has to be carried out to confirm this assumption.
Immunohistochemical analysis on the EmIR2 distribution in the larval stages was per-
formed using the EmIR2 immunserum. In primary cell aggregates stained cells were dis-
tributed evenly throughout the aggregate, but no specific cell types could be distinguished
with this method. A stronger staining was observed on the cavity border, which could in-
dicate that EmIR2 is able to sense signals from cavity fluid. In protoscoleces EmIR2 is
found mainly in the scolex and the periphery. It is interesting to note that although no
EmIR2 was detected in metacestode protein samples, staining of infected liver material
showed a staining of metacestode vesicles. Therefore, it is likely that EmIR2 is expressed
in this larval stage, although to a very low extend and thus was not detected in western
blot.
In this work, it was shown that EmIR2 is a functional receptor. Stimulation with host
insulin induced serine-phosphorylation in in vitro cultivated larvae material. However,
no tyrosine phosphorylation was detected for EmIR2. A possible explanation could be the
mutated YXXXYY autophosphorylation motif [162,163] of EmIR2, where only the residues
Y1460Y1461 are present. Wilden et al. [164] reported that mutation of the first tyrosine of
this motif results in a 50 % decreased basal phosphorylation, without affecting the time and
dose- dependent response to insulin. Due to a low sensitivity of the western blot method
and low basal phosphorylation the insulin induced tyrosine phosphorylation might have
been below the detection level. Therefore, serine phosphorylation was used as an indirect
indicator for receptor activation since phosphorylation of various serine residues in the hu-
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man insulin receptor occurred subsequently to tyrosine phosphorylation [133].
Furthermore, Y2H analysis revealed that EmIR2 recognises a broader ligand spectrum
than EmIR1. In the experiments EmIR2 interacted with insulin, IGF-I and E. multilocu-
laris insulin-like peptides 1 and 2, while HIR and EmIR interacted only with insulin.
Expression analysis confirmed that emilp1 and emilp2 transcripts were present in all lar-
val stages, with the highest expression in activated and non-activated protoscoleces and
the lowest expression in primary cells.
Taken together, these data underline the functional divergence of EmIR1 and EmIR2.
EmIR2 might mediate signals from host insulin and IGF-I as well as Echinococcus ILPs.
In the liver, all these peptides should be available. However, in protoscoleces after inges-
tion by the final host, only endogenous ILPs should be present. Therefore, the ILPs seem
to be the main ligand for EmIR2 in protoscoleces. Stimulation of developmental processes
by host insulin might suggest that the EmILPs have a similar function in promoting the
development of the adult worm. However, studies on the expression of the EmILPs in the
adult stage and the effect of EmILp1 and 2 in vitro are needed to confirm this assumption.
EmIR1 was specific for pro-insulin and did not bind IGF-I or EmILP1 and EmILP2. Taking
into consideration previously discussed data on EmIR1, it is likely that EmIR2 senses host
insulin to regulate glucose metabolism and proliferation in metacestode stage.
Previously, the MAPK cascade was identified as mediator of insulin signals in E. multiloc-
ularis [124]. In the mammalian signalling system the PI3K/ Akt pathway is involved in
insulin signalling as well [83,88,89]. Multiple components of this pathway were identified
on genomic level, analysing data from the genome sequencing project. The high conser-
vation of the molecules indicate the presence of a functional signalling cascade similar to
the mammalian system. However, important differences were already detected: First, no
NPXY motif was detected in EmIR2 that is important for interaction with downstream
molecules. Second, no PI3K regulatory subunit was so far identified, which could notify
that the PI3K activity is regulated in an alternative fashion. Third, only one Akt ho-
mologue is present in E. multilocularis, which has unusual N and C-terminal extension.
Therefore, EmAkt is most likely involved in integrating signals from various signalling
systems. These data suggest that the signalling system in E. multilocularis could be sim-
pler and more basic than the mammalian counterpart.
The activation of the PI3K/Akt pathway was measured by phosphorylation of Akt sub-
strates and Em4E-BP. Phosphorylation strongly increased after 5 min and had already
disappeared after 30 min, which indicated a fast signal transmission and tight regula-
tion of the pathway. Furthermore, inhibitors against the insulin receptors and the PI3K,
HNMPA(AM)3 and LY294002, respectively, were able to block the phosphorylation of Em4E-
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BP. These results emphasise the link between insulin binding, the activation of the receptor
and transmission of the insulin signals via the PI3K/Akt pathway.
In in vitro experiments HNMPA(AM)3 and LY294002 killed E. multilocularis larval ma-
terial. Additionally, HNMPA(AM)3 reduced the vesicle formation in primary cell cultures
and induced dramatic changes in the morphology of primary cell aggregates, with no living
cells remaining at higher concentrations.
LY294002 was used in concentrations of 10 to 50 µM on eucaryotic cell lines [165–167].
Therefore, the effects of LY294002 in E. multilocularis in vitro cultures were observed in
the upper concentration range. The low effects of this inhibitor could be contributed to a
poor solubility and low bioavailability [167, 168]. Furthermore, in EmPI3K only three of
the four residues that are important for the binding of the inhibitor are conserved, which
could reduce the binding affinity for the Echinococcus protein [136]. Considering that in-
hibition of PI3K with rapamycin had no drastic effects on Echinococcus protoscoleces [169]
and metacestode vesicles (data not shown), the PI3K/ Akt pathway might not be crucial
for survival of Echinococcus larvae. Therefore, it can be concluded that the PI3K pathway
might not be a promising target of anti-AE chemotherapy.
Additionally, LY294002 had only long term effects in primary cells, while HNMPA(AM)3
was very effective in primary cells cultures. HNMPA(AM)3 inhibits the insulin receptor
directly, therefore blocking PI3K and MAPK both, which could result in the overall more
drastic effects on parasite viability. Due to the high proliferative activity of primary cells,
these data could indicate that the proliferative effects of insulin in E. multilocularis are
transmitted via the MAPK cascade.
So far, no information about the binding mechanism for HNMPA(AM)3 to the insulin re-
ceptor ATP- binding site is available. In previous studies HNMPA(AM)3 was used in con-
centrations up to 100 µM [100, 170], which was within range of the experiments in this
study. Taken together, these results show that inhibition of the insulin receptor leads to an
effective killing of E. multilocularis larvae. Development of an inhibitor or antibody with
high specificity for the Echinococcus insulin receptors might be valuable for the treatment
of AE patients.
A further question raised in regard to the role of host insulin is its possible influence on
organ tropism. The oncosphere is taken up by the host along with its food, which ensures
high insulin concentrations in the blood stream. After passing into the blood stream the on-
cosphere might be targeted to the liver by high insulin concentrations, where it settles and
where the mitogenic insulin effects promote the oncosphere-metacestode transition and
later proliferation of larval material. E. multilocularis and E. granulosus infect primarily
the liver [2], where they come into contact with high concentrations of insulin. In contrast
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the T. solium metacestode stage develops in the muscles and the brain, although it takes
the same infection route as Echinococcus species, passing the portal vein [171]. Escobedo
et al. [103] observed that T. crassiceps reacted to insulin stimulation, whereas no insulin
dependance was measured for T. solium. However, in this study T. solium evagination and
T. crassiceps budding was measured. Therefore, these results were not comparable with
the data obtained in the present work, which focused on the developmental effects of in-
sulin. Thus, it can not be excluded that insulin plays a role in the development of Taenia
species during cysticercosis.
To address the question of organ tropism and insulin dependence in vivo experiments are
required. Streptozotocin treatment can mimic diabetes in mice and gives the possibility to
study the effect of insulin on infectivity and organ preference under controlled conditions.
An interesting finding that could relate to organ tropism and metastasis formation is the
observed adaption of parasite isolates to the peritoneal passage. Older isolates showed
no increased proliferation upon stimulation with exogenous insulin, which was shown by
BrdU incorporation experiments. That the PI3K pathway is no longer activated might in-
dicate that insulin is not registered on the cell surface, which would result in an insulin
resistance. However, growth and aggregation is not influenced in these isolates, which
indicates that they rely on other stimuli for proliferation and survival. Since fresh iso-
lates usually represent material that has recently grown in the liver of the host, loss of
responsiveness in old isolates might be caused by an adaption to peritoneal culture, where
availability of insulin should be lower. In the course of a long-time chronic infection this
might lead to metastasis formation in other organs like lung and brain. Furthermore, it
emphasises the need for cryo-conservation techniques and regular isolate turnover as other
signalling systems could be changed as well.
Next to the stimulation by exogenous insulin, insulin-like peptides might also activate the
signalling. As it was observed for EmIR2 was able to bind EmILP1 and EmILP2 in Y2H ex-
periments. Therefore, it was suggested that these peptides could have an influence on the
proliferation of E. multilocularis larvae. In primary cells EmILP2 significantly increased
BrdU incorporation, whereas EmILP1 had no effect. However, it is not clear, if this was
due to a lower expression of EmILP1 or if this peptide serves a distinct function. These
questions have to be answered in future experiments. A next step would be the synthesis
of specific antibodies against the ILPs to enhance purification and detection. Further, it is
unclear whether the ILPs might also affect the surrounding host tissue. Interestingly, on
genome level two ILP homologues were identified in Taenia solium, which could indicate
that insulin signalling also plays a role in this organism. In Schistosoma japonicum one
low conserved insulin homologue was found [124], but no studies have been made so far to
investigate the function of this peptide. Highly conserved insulin-like peptides were also
identified in the cestode Hymenolepis microstoma and identical sequences to emilp1 and
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emilp2 are present in E. granulosus. Among the described organisms E. multilocularis is
the only one, for which it was demonstrated that it can sense host insulin and endogenous
insulin-like factors.
In this study now we gained a deeper understanding of the influence of insulin on E. multi-
locularis development and its use as a possible target for anti-AE chemotherapy. The PI3K
cascade seems not suitable for anti- AE treatment, however the results on insulin receptor
inhibition are more promising and development of suitable inhibitors against the insulin
receptors might lead to effective AE chemotherapy.
5.2 Abl kinases and Imatinib
Abl kinases have arisen early in the evolution of metazoan organisms [106] and play a
pivotal role in regulating essential processes like proliferation, survival, differentiation
and cell adhesion [112, 172]. Due to this key position, deregulation of the Abl signalling
promotes in cancer formation [172] and inhibitors that block Abl activity are available.
Furthermore, the important role of Abl in cellular signalling implied these proteins as
possible targets for anti-helmintic chemotherapy.
In E. multilocularis two homologues of Abl kinases were identified. This finding is in
contrast to other invertebrates, where usually only one Abl is present [106]. However in
the trematode Schistosoma mansoni two homologues were found as well [119]. EmAbl1
and EmAbl2 are 33 and 37 % identical to the Schistosoma proteins. The low homology is
caused by the less conserved C-terminus of the proteins and is with 82 and 76 % much
higher in the tyrosine kinase domain. Furthermore an unusual Scr-Abl hybrid kinase was
found in E. multilocularis, which has high homologies to the S. mansoni TK6 [120]. EmTK6
has Abl and Src specific conserved tyrosine residues, but lacks the elongated C-terminus
found in Abl kinases. Beckmann et al. [120] suggested a role for SmTK6 in the signalling
in the gonads of S. mansoni. In complex with other signalling molecules SmTK6 might
regulate cytoskeletal reorganisation, mitosis, cell growth and polarity. However in vitro
studies on S. mansoni and E. multilocularis have to be undertaken to confirm the proposed
role.
Recently, Beckmann and Grevelding [119] demonstrated that Imatinib has severe effects
on the adult stage of S. mansoni at concentrations between 10 and 100 µM. Imatinib blocks
the function of type III kinases including Abl, c-Kit and the platelet derived growth factor
receptor (PDGFR). Intensive BlastX searches on the available E. multilocularis genome
data have revealed that c-kit and PDGFR are absent in the genome. Therefore, EmAbl1,
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EmAbl2 and EmTK6 are most likely the only binding partners for Imatinib in this organ-
ism. Nagar et al. [148] identified 21 residues in the human Abl1 kinase that are involved
in the binding of Imatinib. Of these 18 are present in EmAbl1, 20 in EmAbl2 and 18 in
EmTK6. The high conservation of the Imatinib binding sites makes it likely that the par-
asite Abl kinases are inhibited by Imatinib, which was already shown for the Schistosoma
proteins [119, 120]. However, in these experiments the inhibition of SmTK6 by Imatinib
was significantly lower than for SmAbl1 and SmAbl2. Therefore, it can be expected that
EmAbl1 and EmAbl2 are more responsive to Imatinib than EmTK6, which has to be inves-
tigated in future experiments.
In in vitro cultures Imatinib had drastic effects on survival and morphology of E. multiloc-
ularis larvae. The effects were clearly time- and dose dependant. Higher concentrations
of Imatinib effectively killed metacestode vesicles and protoscoleces, while low concentra-
tions had weaker and effects and needed longer time periods to appear. Imatinib also
significantly decreased vesicles formation in primary cells and blocked regeneration in
pre-treatment experiments. These data indicate that Abl kinases are important for de-
velopment of E. multilocularis larvae.
Although a concentration 10 µM Imatinib had only weak effects in the survival and viabil-
ity experiments, it induced morphological changes already after a treatment period of 24
h, which indicated decreased viability.
In studies of Imatinib on mammalian cell lines concentrations around 10 µM are regu-
larly used and no significant negative effects on the cells [173]. However in other in vitro
studies concentrations up to 100 µM Imatinib were used [174, 175]. In the treatment of
Abl-related leukemias Imatinib is given in daily doses of 400 to 800 mg, which leads to
a average plasma level of 4 to 6 µM [176, 177]. Taken together, the concentrations used
in he present work were still in the range of previous in vitro studies and the effect of
Imatinib on E. multilocularis was comparable to the results obtained for S. mansoni [119].
Furthermore, although higher concentrations had more drastic effects, significant dam-
age of larval material was already observed at 10 µM Imatinib. Considering the time-
dependence of Imatinib it is likely that prolonged treatment with lower doses might have
a high, beneficial impact on AE-treatment. Additionally, combined treatment with Alben-
dazole and Imatinib could improve the current ABZ based therapy and will be discussed
later. Furthermore, it has to be considered that Imatinib was generated to specifically
target the human Abl. Therefore it might be worthwhile to investigate Imatinib-related
compounds that may exhibit higher affinities for Echinococcus proteins than their human
homologues.
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5.3 The cystein protease inhibitor K11777
A second useful approach in identification of new drug targets in parasitic helminths
is the study of compounds that are efficient against other parasites. Effort has been
made to establish Praziquantel for co-treatment with Albendazole, which showed good
effects against cystic echinoccosis, but was less effective against alveolar echinococcosis
[29,178].
A novel small molecule inhibitor K11777 that blocks cystein proteases and was shown
to be effective against several parasites like Trypanosome cruzii and Schistosoma man-
soni, [129,179].
In E. multilocularis ten genes coding for cysteine proteases were identified by extensive
genome wide BlastX searches. All of these belong to the cathepsin L and B family. Previ-
ously, Sako et al. [150, 152] reported two cathepsin L-like and 2 Cathepsin B like proteins
that are expressed in E. multilocularis and partially secreted. Interestingly, for EmCLP1
two genes are present in the genome. K11777 blocks the activity of both, cathepsin B and
L [180], but in S. mansoni cathepsin B is considered to be the main target of K11777, due
to its predominant activity level [181]. The sequence of the E.multilocularis cathepsins
was very well conserved, including the reported K11777 binding sites [151].
Analysis of the newest transcriptome data available in our lab indicated that three cathep-
sins are predominantly expressed, namely EmCPB1, EmCLP2 and EmW 000477200(L-
like cathepsin). The overall expression of these three candidates were between 11 and 45
%, whereas the expression of the other cathepsins was under 5 % in most stages. The anal-
ysis did not show any indication, which cathepsin of E. multilocularis could be the target
for K11777 and in vitro activity and inhibition assays should be performed.
In the in vitro cultivation systems K11777 was very effective at higher concentrations,
but preliminary pre-treatment experiments proved that also lower concentrations (10 µM)
block E. multilocularis development. K11777 is water soluble and has a high bioavailabil-
ity with low toxicity for host cells [179]. In experiments with T. cruzii [182] and the hook-
worm Ancylostoma duodenale [183] concentrations up to 100 µM were used and it could
be shown that a concentration below 20 µM had no negative effects on host cells [182].
Therefore, the concentrations used for in vitro experiments with E. multilocularis are well
within the range. However, more experiments are needed to study the effects of K11777 in
detail.
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Taken together, these data show that K11777 is a very promising candidate for anti-AE
therapy, as it shows high effects in metacestode and stem cell cultures. In the future, more
detailed analysis in in vitro cultivation systems and in vivo studies on infected rodents
have to be performed. Furthermore, experiments with a combination of ABZ and K11777
have been carried out and are discussed below.
5.4 The JNK inhibitor AS601245
The E. multilocularis Jun kinase was recently characterised by Riedl [153]. In the mam-
malian system, JNK is involved in the regulation of apoptosis, immune response and cell
cycle [184, 185]. Recently, it was shown that JNK is highly active during the blastema
formation in planarians and that inhibition of JNK lead to a defect of blastema formation,
most likely by blocking neoblast mitosis and motility [186]. In the E. multilocularis cul-
tivation system, the JNK inhibitor SP600125 exhibited only weak effects, probably due
to a low binding affinity. Therefore, AS601245, a cell permeable ATP-competitive JNK
inhibitor with a lower selectivity was tested in the in vitro system. Strong effects on para-
site material were observed with 20 and 50 µM. Primary cells in the Resazurin assay were
more sensitive to the JNK inhibitor than metacestode vesicles. In total, JNK is not a likely
candidate for single compound therapy, as its effects range in the medium spectrum of ef-
ficacy compared to other tested substances. However, the results in young primary cells
indicated a good effect on stem cells. It could be worthwhile to consider using AS601245 for
supporting anti-AE therapy based on other compounds. Therefore, AS601245 was tested in
combination with Imatinib where it showed a very strong synergistic reduction of primary
cell viability. Furthermore, AS601245 should be tested in combination with ABZ, as it is
the current standard anti-AE therapy.
5.5 Albendazole
Albendazole (ABZ) is currently used for AE-treatment in two daily 400 mg doses, leading
to a plasma concentration of 0.65 to 3 µM [23]. In previous studies ABZ or other benz-
imidazole derivates were used in concentrations varying from 0.1 to 36 µM. [27,187–189].
For a better evaluation of new compounds ABZ was tested on our currently used cell cul-
ture systems. On metacestode vesicles ABZ had a significant effect, although the con-
centration used for human therapy killed only 50 % of the treated metacestode vesicles.
Higher concentrations were comparable to other inhibitors in that system like Imatinib
and K11777. Interestingly, ABZ had no effect on the viability of primary cells in the Re-
sazurin assay. A possible explanation could lie in the expression of ABZ-resistant beta-
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tubulins, which are the targets of ABZ [27]. Brehm et al. [28] described three β-tubulin
isoforms and further isoforms were identified in the genome data of E. multilocularis
[134]. EmTub-2 shows characteristic exchanges that could result in resistance to ABZ
[134].
According to our newest transcriptome analysis available in our group, EmTub-2 repre-
sents 53 % of the beta-tubulin transcripts in metacestode vesicles and even 79 % in 2 days
old primary cells. The presence of this isoform predominantly in primary cells could be
responsible for the observed ABZ-resistance. However, Real-time PCR experiments have
to be carried out for a comparative analysis of the beta-tubulin expression in E. multilocu-
laris larvae.
In the case that stem cells are resistant to ABZ treatment, surviving stem cells could com-
pensate the loss of differentiated cell during anti-AE therapy. Therefore, the lack of effect
in culture systems consisting mainly of stem cells could explain the problem that ABZ acts
merely parasitostatic.
5.6 Combination therapy as a new approaches for anti-AE
treatment
As observed above ABZ was very effective in killing metacestode vesicles, but showed no
effect in stem cell cultures. This might explain the observed regeneration of parasite tissue
during AE treatment.
Imatinib and K11777 were very active against primary cells in in vitro experiments and
showed high effects against metacestode vesicles. Using these two compounds in combi-
nation with ABZ increased the effect of single treatment. The synergistic effect of these
combinations might improve current chemotherapy, however further studies in parasite
cell culture systems and in vivo experiments in rodents should be performed. Interest-
ingly, the most effective combination used in this study was Imatinib with the JNK in-
hibitor AS601245, although it exhibited only medium effects when used alone. In in vitro
experiments with cancer cell lines AS601245 has been used in combination with other
therapeutics to strengthen their effects. Due to this ability the inhibitor should be tried
together with ABZ in further experiments AS601245, to investigate if it has the same en-
hancing effects. Inhibition of the insulin and PI3K signalling cascade with one or two
inhibitors showed only medium effects. It is not clear, whether this is due to a low binding
affinity of the inhibitors or that blocking of the pathway can be compensated by other
signalling systems. The combination of Imatinib and HNMPA(AM)3 was highly effec-
tive.
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Taken together the data showed that the two most effective inhibitors in the in vitro
experiments were K11777 and Imatinib, which both could improve ABZ based therapy.
AS601245 does not appear to be a promising treatment option on its own, but seems to
enhance the effect of other inhibitors [190]. Furthermore, inhibition of the insulin recep-
tor could be employed as an addition to other inhibitors. Whether it will be possible to
use the tested compounds for therapy directly has to be tested in in vivo experiments.
Side effects are possible as the tested inhibitors are designed against or able to bind the
respective human homologues. Therefore, another option could be the use of related com-
pounds that show decreased affinity for the human protein. The Resazurin assay and
later metacestode vesicle killing assay might be an effective and time saving testing sys-
tem.
5.7 C2 toxin
The C2 toxin belongs to the group of binary toxins and induces actin-ADP ribosylation
when it is taken up by the target cells [156]. C2 toxin was tested on E. multilocularis lar-
vae to study its potential use as a delivery system in this organism [157]. Interestingly, C2
toxin induced massive vesicle formation in primary cell cultures and protoscoleces. How-
ever, it was shown that these vesicles do not contain cells and their origin is still unclear.
Experiments to study uptake of the C2I-Biotin complex failed. Therefore, we assume that
the C2I subunit of the binary toxin is not taken up intoE. multilocularis cells. Conse-
quently, C2 toxin cannot be used as a delivery system. The observed effects on parasite
larvae are probably induced by the activation of signalling cascades.
C2 toxin was reported to bind to asparagin linked complex carbohydrates. The GlcNAc-
TI gene (α-1,3-mannosyl glycoprotein 2-β-N- acetylglucosaminyltransferase), mediates the
assembly of N-linked carbohydrates and its absence abolishes C2 toxin sensitivity [191].
BlastX search in the E. multilocularis genome revealed the presence of the GlcNac-T1 gene
(EmW 000969800; supercontig pathogen EMU scaffold 007780 : 3330552-3333797). How-
ever, it can not be excluded that a protein surface receptor is involved in the uptake of C2
toxin. The lack or mutation of this protein in E. multilocularis might explain that the toxin
is not internalized by the parasite cells.
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A.1 Analysis of ILP homologues
Tab. A.1: Homologues of insulin and ILPs in other helminths. Sj: S. japonicum; Hm: H. micros-
toma; Eg: E. granulosus; Ts: T. solium
Name Systematic Name Location
SjIns Sjp 0020480 supercontig SJC S000110 : 408491-417266
HmILP1 HmN 000294900 supercontig pathogen HYM scaffold 33 : 367620-368253
HmILP2 HmN 000294800 supercontig pathogen HYM scaffold 33 : 350421-350945
EgILP1 pathogen EMU contig 60709 : 60405-603737
EgILP2 pathogen EMU contig 60709 : 589375-585827
TsILP1 contig 11296: 31221-30865
TsILP2 contig 11296 : 50023-49709
A.2 Sequences
Start-, stopcodons and putative poly-A signals are highlighted in grey.
4E-BP
Full length cDNA sequence of em4e-bp
1 GTCACCTAAA CCAGAGTAAG CAACCGCTCT GCCCACTAGA CCGCTGGCGG TCAATTTGGT ACCTCCTAGC
71 CCTCTGCAGT GTTTTGTCTT CTGCATTTCA ACTAGGCTCG TAAATGGCAT CCAATCGCGG TCCTGATGGT
141 ATCCCCTTCC GAAGATTAAA AGTTACTGAT CCTTCTCAGA TTCCTAATGA TTACAGTACA ACTCCAGGTG
211 GGAGCATATT CAGCACCACC CCAGGGGGCA CTCGAATCTT CTACGATCGT GACACAATGC TGATGTGCAA
281 AAATTCACCG ATTGCACGTT CACCACCCAC CGACATGGTA TGTCGACCAG GGATCACCTG TCCGGCCACA
351 TGCGCTGGCG AGTGCCGTCT TCCCGCCGCG ACTGCCCAAA AGCCCGCAAA GAACACTCGT CAGGAACATG
421 CTAGTGTACA AAAAAGTGAC GAAGGGCCTT TCGACATTGA CTTGTGAGGG AAGAGGTGCC ACTCCAGTAT
491 GCAAAACACT TGGTGAAAAA GAAAGAATAC AAAGCAAACA AGTGTAGTAG GTTTTTTCAT ACCTCGCCAC
561 CACCTTTGAT AGCCATCCAT GCGTGCAAAC CCACAAATGA AGAGACAAAC TTTGCGATGC AATCGCTGTT
631 AAAGAAGCGC CCGCTCCATT TAGCTATCCC AAAAGCACCC TTATGAATAT TTATGCCTTT TTGTGAGTTT
701 ACCTTCTCCC AAATGCCTCT ACCAGCTTGC TATGCTTGCT TTTGTGAATA TGTGTATACA TTTGAGAGGA
771 ATTGAGTTTT TATATCACTG AAAAAAAAAA AA
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Putative amino acid sequence of Em4E-BP
1 MASNRGPDGI PFRRLKVTDP SQIPNDYSTT PGGSIFSTTP GGTRIFYDRD TMLMCKNSPI ARSPPTDMVC
71 RPGITCPATC AGECRLPAAT AQKPAKNTRQ EHASVQKSDE GPFDIDL
EmAbl1
Full length cDNA sequence of emabl1
1 CCTAGAATTG AAAGGCGATG AAAGTAGGGG TTTTCTGAGT TGTGGCGAAA ATGGGTGGTA GTATTGGTAA
71 GCCGGCCTCT TCGAAGGAGG GATCTGAAAA GGTGGATTTA TCGCTGAGCT TTAATCAGCA GCCGGATGAA
141 ATTTCTACTG GTGGCGAATG TGAAAAGTCT GCTCCTGTTA AAAAACAGAT TCTTTCTGTC ACCCAGAATT
211 TCGAAACGTC TGGTCTGGTG GAGCAGTGTA TTATGATCGT TCTCTATGAT TTTTCAGCTA CATTGGACTC
281 TCAACTTACT GTTAAACGAG GTGAGATCGT CCGTCTCCTG AGCTACAGCC CAGCTGGTGA CTGGTCTGAG
351 GTCGAAGCGC CTTCCCATCT GCCCAATCGA ACACCGCGCG TGCCCTGGGC GGGAGCCGGT GGGTGGGTGC
421 GCGGTTGGGT ACCCACCAGC TACCTCACAG AGCATGTGCG TCCTCCACGG GTTGGTGGAA TTGGTAGTGG
491 TACCAATGGG TGGCGAAGGG TGGGAGATGA AGAGGAGGCT GGCGCAGCGG CAGCAACGAT GGCTTACCCT
561 TGGTACCACG GTGCCGTCTC GCGTCAGGCC GCTGAACAGC TCCTACGCAG CGGCATCACT GGCTCCTACC
631 TCGTACGCGA ATCTGAATCG GCACCTGGAC AACTCTCTGT CACTGTGCGG AATCTGGGCC GAGTCTATCA
701 CTATCGCATC AGTCGGGATT CCTGTGGATG GTACTTCATC ACAGAGACGC ATCGCTTTCC CACAGTGGTA
771 CAACTGATTC ATCATCACTC ACAAGCCGCA GATGGACTTA TTTGCCCCCT ACTCTATCCG GCCGCCCGGC
841 GCGAACAGCC ATCGGTAATG CGGGGCGCTG CCACCAATAG TGGAGCAGTC GAAGGTTGTG CTGACAGTAA
911 AGGCGGTGGC GGCTACGTTG GCTTCGACGA CTGGGAGATT GACCGCTCTG AGATCATGAT GCGCAACAAA
981 CTCGGTTGGG GTCAGTATGG TGATGTCTAC GAGGCTCTCT GGAAGCGCTA CAATTCTATC GTTGCTGTCA
1051 AGACGCTGAA GCAAGACGTG GACCTGAATC TGAATGACTT TCTTGCTGAG GCCTCAATTA TGAAGAATCT
1121 CCAGCACAAG AACCTTGTTC GATTTCTCGG CGTCTGCACT CGAGAGCCGC CCTACTACAT AGTGGCGGAG
1191 TACATGCCCC ATGGAAACCT GCTGAATTAC CTGCGCCAAC GGAGTCCAGG AGAACTCACC CCACCCATTC
1261 TCCTCTACAT GGCTGTTCAA ATCGCCTCTG GCATGGCCTA TTTGGAAGCC AACAACTTTA TTCACCGCGA
1331 TCTGGCAGCC CGCAACTGTC TAGTGGGCGA TCAGTACACT ATCAAGGTGG CCGACTTCGG CTTGGCGCGC
1401 TATATGCAAC TGCATGAGGA CACCTACACC GCCCGTAATG GGGCCAAATT CCCCATCAAG TGGACTGCCC
1471 CCGAAGGACT TGCCTATTTC CGCTTCTCCT CCAAGTCTGA TGTGTGGGCA TTTGGGGTTG TTCTTTGGGA
1541 ACTGGCCACC TACGGTCTCT CTCCCTATCC TGGTGTGGAA CTGCACGGTG TCTACCAACT TCTGGAAAAG
1611 GGTTACCGCA TGCAACGTCC TCATGGCTGT CCTGAGTCCG TTTACAGCAT TATGCTGCGA TGCTGGTCCT
1681 GGGAGGCAGC AGATCGTCCA ACGTTTTTGT CAATCAAGGC GGAATTGGAG GAAATGTGGC GAACTATCGA
1751 TATGACAGAG GCTGTAGCTC AAGAGCTGGC CACTCCGCCA GCAGCCCAAA CCACGGACCA CATGCAATTC
1821 ATCACTGCCA CCTCTACCAC CGCCACCACC ACCATTACCA CCGCAGTCGG TGTTGGCCCT GGTATCAACG
1891 GCGGGGGAGA AGCGATGCTG TCCTCTGTCC CCGTTTCCAT GATTGTGCGT ATGCCATCAT ACCAACAGGA
1961 TGATGACGAG GCCGCAGAAG ACCCTTCCTC TCCCTCACAA TCCACCACCT CCTGCACCTC TTCCTCTTCT
2031 GCGGCTGTCT CTTCCTCCAG TGCTGCTGAA ACTGATGGTC AGGATGGTGA TGATGAAGGC GAGGAGGACT
2101 TGTGTCTCAA ATCACTTGTT GATAAGGGCG CGTTGAGCTC AACAGCCAAT TGGATCACAA CGCGGACCTC
2171 TGACAGTCTC TACCAGGGCG ACTACATAGT CAGTGGTGGT GGTGGTGGAG GCGGTGGCGT TGTCCGGGCG
2241 ACACCCGCCT CTGATTTACC CTTCGCCACG CACAAATCTA CCACCTGCGA TAGCCAGGTC TCCGCTCCCG
2311 CCTCCCTGCC TCCTCTCCAC CATCTCCAGC AGTTCCAACA CCATCGCAAT AGAGCCAACA ATCACAGCCA
2381 TCACTACCAC CGTCATTATC AGCACCAGCT TCAGCACTCG GAAACTGGAC GAAGCATGCC TAGACGTCGA
2451 AGCGGACCTA ATCATTTGGC CGGCCAGTTC GAGGAAGGTT CCCTGCGGTG TCCGATGCGA CCGAAGGAGA
2521 AGAACATAAC ACCAGCAGAG AGCGGTGTGG GTGAGTCGAT AGTCTCAGCA GACTCGCCGG GCGGGAATAG
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2591 CAACGCAATG CAACAAGAGG AGGGGGCGGT GGTAATGGCT CCACAGCGGA GTAATCACAA GGCGGCTGCA
2661 GTGGTAGCAG TAGCAGTTGA AGCGAACAAT TGTTGTGTGA CACCTACGAG GGATATGATA TCAGAAGTGG
2731 CCCCTGATGA AAGGCGTATG CGGCTCGATG TCGAGTCAGT GACACAATTC ACTACCCTGC CAGCACAGGA
2801 CCGCATCACA CGGTACTTGG AGAGTCTGGG CGAGCTCGGT GACGCGTCGG AAGAGAGGAC CCCAAAGGCC
2871 AAGGGTGGTG CACATCCACC CCACCCCCCT CTTCTGTCCC ATTTCCCTCC CCCTCCGCCA GTACCCCCAC
2941 CACCACAGCC CGCACAGCAT CTTCGCAACT CCCGAATGCT GCCCACTGAA CATCGACGAA ATGCCGTGGG
3011 ACGCTCTGCC TCATGTTACC AGACTGTGTC CAGCGTGCAG CTGCTGCTGC CACCCTCCAC GACCACCACC
3081 AACGGTTCGG TGGAGACGCA AGAGAGCCTT CCAACCACCT CCACTCCTAG CCCCGCGGTG GGTGAGACTA
3151 TCACACCCAC CGACGATGTC TATCAGGCAC CAACTCTAGC GCAGGACAGC AGCATTGGCG GTAATGGGGG
3221 TGTGAAGGCA GCGCCAACCG CGGAAGTGTC GTCTGAAGTA GAGCAAGCGG AGCTGACCGC CTGCCTGAAT
3291 ACCCTCTCGC TGGAGGCCAC TGAACTCTCC ACTGCCTGTC CTCAACTCGC CGCCGAGTTG TCTGCCCTCT
3361 CGCTGCAACT CTCGGCCTGT CGCGGGAAGG TCGAAGCGCG CTTACGTGCC TCCGCCAACG GAGTCGGTGG
3431 CACTGCAGAG GAGAATCTCT GCTTGGCAGG CGTTGCGCAA GCTTTGCGGC ACATTCAACA AGCACTCGCA
3501 GAGATGCGCG CGCGAGTGGA AGAGGCACAA ACTCCCACCC CTTCCCTGCC GGCCCCCTCT GCTACGGCCC
3571 CTGCTGCCAC AAACGCCAAT GCTACTACCG TCTCCACCTA GAATATGTAC ATATGCATGC CTCAACGCGC
3641 ATTTACCGAC GCTGACACCA ACACCAACCT CCGCTAATTC TACTACCGGT TTAGAGTCGA ATTCTTCAAC
3711 CTTCTCGCTC CTTATGCATC TCTCTCCTTT CTTCTCTTCT CAGTTTACTA CGAACGTGCG GGTGATTGCC
3781 TGCCCTGGCA GTAGCTGTAT CATGATGGTG ATGTGGATAA TATGCGTAGC GTGATTTTGA ATTTGCCGTG
3851 CGTTACTTGG TTGGACTTCC TTCCGGGTAG TATGTATGCG AAATAAAACG ATCATGCCAT ATTAAAAAAA
3921 AAAAAAAAAA A
Putative amino acid sequence of EmAbl1
1 MGGSIGKPAS SKEGSEKVDL SLSFNQQPDE ISTGGECEKS APVKKQILSV TQNFETSGLV EQCIMIVLYD
71 FSATLDSQLT VKRGEIVRLL SYSPAGDWSE VEAPSHLPNR TPRVPWAGAG GWVRGWVPTS YLTEHVRPPR
141 VGGIGSGTNG WRRVGDEEEA GAAAATMAYP WYHGAVSRQA AEQLLRSGIT GSYLVRESES APGQLSVTVR
211 NLGRVYHYRI SRDSCGWYFI TETHRFPTVV QLIHHHSQAA DGLICPLLYP AARREQPSVM RGAATNSGAV
281 EGCADSKGGG GYVGFDDWEI DRSEIMMRNK LGWGQYGDVY EALWKRYNSI VAVKTLKQDV DLNLNDFLAE
351 ASIMKNLQHK NLVRFLGVCT REPPYYIVAE YMPHGNLLNY LRQRSPGELT PPILLYMAVQ IASGMAYLEA
421 NNFIHRDLAA RNCLVGDQYT IKVADFGLAR YMQLHEDTYT ARNGAKFPIK WTAPEGLAYF RFSSKSDVWA
491 FGVVLWELAT YGLSPYPGVE LHGVYQLLEK GYRMQRPHGC PESVYSIMLR CWSWEAADRP TFLSIKAELE
561 EMWRTIDMTE AVAQELATPP AAQTTDHMQF ITATSTTATT TITTAVGVGP GINGGGEAML SSVPVSMIVR
631 MPSYQQDDDE AAEDPSSPSQ STTSCTSSSS AAVSSSSAAE TDGQDGDDEG EEDLCLKSLV DKGALSSTAN
701 WITTRTSDSL YQGDYIVSGG GGGGGGVVRA TPASDLPFAT HKSTTCDSQV SAPASLPPLH HLQQFQHHRN
771 RANNHSHHYH RHYQHQLQHS ETGRSMPRRR SGPNHLAGQF EEGSLRCPMR PKEKNITPAE SGVGESIVSA
841 DSPGGNSNAM QQEEGAVVMA PQRSNHKAAA VVAVAVEANN CCVTPTRDMI SEVAPDERRM RLDVESVTQF
911 TTLPAQDRIT RYLESLGELG DASEERTPKA KGGAHPPHPP LLSHFPPPPP VPPPPQPAQH LRNSRMLPTE
981 HRRNAVGRSA SCYQTVSSVQ LLLPPSTTTT NGSVETQESL PTTSTPSPAV GETITPTDDV YQAPTLAQDS
1051 SIGGNGGVKA APTAEVSSEV EQAELTACLN TLSLEATELS TACPQLAAEL SALSLQLSAC RGKVEARLRA
1121 SANGVGGTAE ENLCLAGVAQ ALRHIQQALA EMRARVEEAQ TPTPSLPAPS ATAPAATNAN ATTVST
EmAbl2
Full length cDNA sequence of emabl2
1 TTCGAGGTGT TTTTGTAAAT ATTTTGACTC GTGTGTTGGT GTTTTATTAA CCTAGTAGTT TGGAGGCTTA
132
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71 CTTGAGTGCC ATTAGGTCTT CGTTCTGAGT GTTGACTGAT GTAAATGGGT AGTCAACATG CTAAACCTAA
141 AAAGGCTGCC TCAGAAAGTG TCGACCGAAA TTTCACTTTT CGAATTAATA AGGGCAAAAA GTCGAAATGT
211 GGTGATGATG GAACATCCGT TTCTTCGCTG GACGTGATGT CGGTCCCTGA CGGTGATTTA ACAGCTCTGT
281 ATGATTATGA CCCTCCTGTA AATGCACATG GATCTGCTAT CGTCGTAAGA AAGGGTGATT CACTGTGGTT
351 GTACGGTCGG AGCTCCACGG GCGATTGGTT GGATGTGCTT TGTCGACGCA CAGGCGAACG CGGCTGGGTA
421 CCAGTATCAT GTCTCTTCGA TCCGACTTCG TCGAAACCTC TCATCGCCTC TGGCGCTGCT ACTGCCTCCT
491 CCGCCCCCAG TGCTCACGTC TCCTGTCCCA GTCTGATCGG CGAGCGATGG TACCACGGCG CTATTCACCG
561 GAGCTATGCA GAATATCTTC TCAATAGCGG CATAACTGGC AGTTTCCTTG TGCGCGAATC CGAGAGCAGT
631 TTCGGCAAAC TCACTCTCAG CCTCCGCTCC GACGGACGCA TCTTCCACTA CCGTATCTCC ACGGATGAGA
701 ATAACCAATT CTATGTCAAT GAGGTGAGTC GTTTCGCCAC AGTTTCGGAG CTTGTGCAGC ACCATGAGAA
771 GGTGGCAGAT GGTCTGGCCT GTCCCTTACT CTACGGCGTC TCCAAGCGGG ATCAGAATAA TCACGGCGGC
841 TTTGACTCCG ACTACGACGC CTGGGAGATC GACCGCACCG ATGTCATCAT GAAACACAAA TTGGGCTCGG
911 GCCAGTACGG TGTAGTCTAC GAGGCCATCT TCAAACCCTA TGACGTTACT GTGGCTGTGA AAACGCTTAA
981 GGAGGACATA ACTCTGCGTG ATGAATTCCT TCAGGAGGCC CGGTTGATGA AGAGCCTTCG GCATCCGAAC
1051 CTTGTTCGTC TTTTGGGCGT CTGCACTCAA GAGCCGCCCT ACTACATAAT CACGGAATTC ATGTGCAACG
1121 GCAACTTGCT TGACTACTTG CGAATCCAGC CCCGGGATGT TCTCTCCCCT CCGGTGCTTT TGCAAATGGC
1191 CATTCATGTG TGCTGCGCTA TGACCTACCT GGAGGAGCAC AATTTTATCC ACCGGGACTT GGCGGCGCGC
1261 AACTGCCTAG TTGGCGAGGC AATGACCGTA AAGGTTGCCG ACTTTGGGCT AGCGCGCTAC ATGGAGCGTG
1331 ACGTGACGTA CCGGGCACGG GAAGGCGCCA AGTTTCCTAT CAAATGGACA GCACCCGAGG GCCTTGTCTA
1401 CAACTGCTTC TCCATCAAGT CTGACGTCTG GGCTTTCGGC GTGCTGCTGT GGGAGATCGC GACCTACGGG
1471 GCCGCGCCGT ATCCCGGTGT GGAGTTGCAG GATGTCTATG TTCTCCTCCA AAGGGGCACT CGCATGGAAG
1541 CACCTCAAGG CTGTCCTGAT GCTGTCTACC AACTCATGCT TGATTGTTGG AGTTGGAACT CGGAGGACAG
1611 ACCGAGCTTT AAGGAGGTGT ACACGCGTCT TGAAACCATC CGCACCTCCT CAGACATCAG CGAGGCTGTG
1681 GAACATGAGC TTCAACGCCA TCGCATTAGG ATGCCGCCTC CTCCACTCCC TCCTCCGTCT CCTACAACTG
1751 TCGCTGCCTT CACCCCACGA CGAAGCAGCA GCTGCGATCG TATAGACGAG AGCAATCTAT CCCCAACCGC
1821 CGAGATGGGC AGGCGTGGTC ATGCAGAGTC CTTCACAGTC CAGGATGCGG TCTCACGACT AGTCGATAGT
1891 GGTGGTGGCA GTGGTAGTGA CCTCCACCAA CAACAGCAAC AGTTCTCCGC CTATCCATGT TGTCAGCAGG
1961 GCTGTATGGT CCCAGGCAAC CGATTCTCCG AGGTCTTTCC GTCTTCATTG CTTCCACCTC CTCCTCTGCA
2031 CACCAACGCG GACTTTGCAG TAGTAGGAGC AGAGATTGGT GGTGCAGGTT CTTTAGGCCG CAGAAAGGCT
2101 GCTCCCCCGG CACCGCCGTT GCGCACGACT ACGTTACGAG CTGATGAGCC CTGTGAAAAA GTCCCTGTGT
2171 CACTCCAGGT CTCGACCGAT GATCGCCAGA CCTTCTCACA GCCCGGAGAG GAGCGCTTGC CATCGCCGCC
2241 TAACGCCGTT CTCTGTGGTG TCAATTGGCC CTCATCACGA TCTCAGAGTA GCCCTCCTCT CAACAGCGAT
2311 GTGGCGGTCT CAGTGACAGC TTCAGTTCCT CGCCGCACAC CGATTCCCGT GCCACCACAG CGCACAGAGT
2381 CAACACGAAG TCAGGATTCG GAGGTGGCTG AAGGTGTCCC TAAATCGAGT CCCAAGATGG GCCTGCCCTC
2451 CACCACTCAA TCTCCATCCA ATGGTCTGGC AACGGCAAGT AGTGGCAGTA CCAACAGTGA ACTTTCCTCC
2521 CGCCTGAAGC GCCAACTGGA CAATTCGAGG TCCACTGACA GTCCCACTCG TTCGCCCGTC CCACCCGGTG
2591 CCGCCACTGT CACCGCGGAG ATGATCCAAG CCTCGAAGTC GAAGCTTAAG GCAACCACTA CCACCACTCC
2661 TGCCACCATC ACAGCCATAG AGACCCAACC CGCACCCTCT GTGCCCGCAT GGAGGGAGCT GGTGGTTCAG
2731 CGGCGTCTCA AGAATGCCGA GCCGCCTGCA GGTAAGCGGA TGAGCTGGAC ACCCATGTCC AACTCCTGTT
2801 CTTCCTCTTC CGCCCTCAAA CAACAACAGC AATCATCAAA CGTGGAGGTT TTTCCAGAAG TGGTGGAGGA
2871 GGAGGAAGAG GGTGGAGAAG AACGGGAAGG AGCTCTTCCA GCCATCATGT CGCAGTCGGT GACGTACACA
2941 AGCAGTTCCA CCGTGATGCC CCCATCATCG TTGGTAAGTC GTTCCTCCTA CGAGCATCTG CTGCGGCAGG
3011 TGACGGATCT CTGCGCTGAT CTGAATCTGG CGAAAGTAAA TCTTCCGAAT GAGCACAATA GCACATTGGT
3081 GGATCGAATT GAGGGGCTGA AACAGGCCTG CTTGGGGTAT GCAGATGAAA TGGACTGTTC AGCCCACGCA
3151 AAGTTTCGAT TCAGGGATGA GTGCGCTCGA CTACAGGCTG CGGCAGATAC CCTGCGTAGT ATATGTGGTG
3221 TTGGTGCGAA AGCAGCGGTT GGCGCAGAGC TGGGAGGTCG TCGAAAGACA TATCAGGCCG TCTACACAAC
3291 GGTAGAGGCT ATTCACCAGT CTCTATTGCG TCTGACACCT GCGGTTCCTT CAAGTGACGC TGTGGAAGAA
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3361 TCTACAGCTC CCTCAACCCG CAGTGCCTTT GTCAGCACGG GTGTCATCTC ATAAAGGAGT GGTCTGAATC
3431 CATCTGTATA TACTGTGTAC ATACTTCTTT TTGTCCTCTC AAATCTCTTT CGCGTTCTCC AATATAAGTA
3501 AGGAAGTCAA ACTGCTCTGG TGCAATCTTG TCTCCTCTTT CGTCCCTCTT CTGCTTCTTT TTCCCACGAG
3571 AATGCAAACG CTGCATAGGA ACGTCCCCTT TTTTGCTTCC TAAAAATCCT CAAAAGGTAC TCGCAGCTCT
3641 ACTATTACCT CAAACCAATG TGATTTCGAA TTTCGGGGTG TTTTATTAAA AAAAAAAAAA AAAAAAA
Putative amino acid sequence of EmAbl2
1 MGSQHAKPKK AASESVDRNF TFRINKGKKS KCGDDGTSVS SLDVMSVPDG DLTALYDYDP PVNAHGSAIV
71 VRKGDSLWLY GRSSTGDWLD VLCRRTGERG WVPVSCLFDP TSSKPLIASG AATASSAPSA HVSCPSLIGE
141 RWYHGAIHRS YAEYLLNSGI TGSFLVRESE SSFGKLTLSL RSDGRIFHYR ISTDENNQFY VNEVSRFATV
211 SELVQHHEKV ADGLACPLLY GVSKRDQNNH GGFDSDYDAW EIDRTDVIMK HKLGSGQYGV VYEAIFKPYD
281 VTVAVKTLKE DITLRDEFLQ EARLMKSLRH PNLVRLLGVC TQEPPYYIIT EFMCNGNLLD YLRIQPRDVL
351 SPPVLLQMAI HVCCAMTYLE EHNFIHRDLA ARNCLVGEAM TVKVADFGLA RYMERDVTYR AREGAKFPIK
421 WTAPEGLVYN CFSIKSDVWA FGVLLWEIAT YGAAPYPGVE LQDVYVLLQR GTRMEAPQGC PDAVYQLMLD
491 CWSWNSEDRP SFKEVYTRLE TIRTSSDISE AVEHELQRHR IRMPPPPLPP PSPTTVAAFT PRRSSSCDRI
561 DESNLSPTAE MGRRGHAESF TVQDAVSRLV DSGGGSGSDL HQQQQQFSAY PCCQQGCMVP GNRFSEVFPS
631 SLLPPPPLHT NADFAVVGAE IGGAGSLGRR KAAPPAPPLR TTTLRADEPC EKVPVSLQVS TDDRQTFSQP
701 GEERLPSPPN AVLCGVNWPS SRSQSSPPLN SDVAVSVTAS VPRRTPIPVP PQRTESTRSQ DSEVAEGVPK
771 SSPKMGLPST TQSPSNGLAT ASSGSTNSEL SSRLKRQLDN SRSTDSPTRS PVPPGAATVT AEMIQASKSK
841 LKATTTTTPA TITAIETQPA PSVPAWRELV VQRRLKNAEP PAGKRMSWTP MSNSCSSSSA LKQQQQSSNV
911 EVFPEVVEEE EEGGEEREGA LPAIMSQSVT YTSSSTVMPP SSLVSRSSYE HLLRQVTDLC ADLNLAKVNL
981 PNEHNSTLVD RIEGLKQACL GYADEMDCSA HAKFRFRDEC ARLQAAADTL RSICGVGAKA AVGAELGGRR
1051 KTYQAVYTTV EAIHQSLLRL TPAVPSSDAV EESTAPSTRS AFVSTGVIS
EmAkt
Full length cDNA sequence of emakt
1 GAGTGGTTCG ATTCGCGCGT TGGGGTTTTG GAAGATTGGC TTTTTGATTG CCATTTTTCT CATTACTTGG
71 GTCGAAATGC AGGTGGATGA ATCATTAAAC TGTTCAACAC CTATGGGAAC TCTAACACCC ACATCTGCAC
141 CAATGGCGGT AGACCCTTTA TCTTCCTTTG TACAGTTCCA ATCCGCTTCC ATGTCCCAAA TTCCCTGTAA
211 TACGCCGCAA TTTTCGAATC CCTCTACAGT TTCCTCCCTT GTTCCCGGAG CCGGCACCCC GTGTGCGGGT
281 TTAAGTCAGG AGCACTTTGT TCCCCACGCT CCCGTTTCTA TGCCCCACTT GACGGGTGGA CTGCCCGGCT
351 CCACTGACCT TCTTGGTCAT CAACAGGCTC TTGCCATCAA CCCCACCTCT CTCATGCAAT ATTTCCGAAT
421 TCGCACCCTA CCTCTCACCC GGAAAGTCAT CCGCGAAGGC TGGCTCATGA AGAGGGGTGA ACACATCAAA
491 ACATGGCGCC GACGATACTT CATTCTCAGA GAGGATGGTA CCTTCTATGG ATATAAAAAT ATTCCAAGAG
561 ACAACCTAGA GCAACCTCTA AATAATTTTA CCGTTCGAGA CTGTCAGATA ATATGCCTGA ACAAGCCCAA
631 GCCCTACACA ATCCTAATGC GAGGTCTCCA GTGGACGACG GTGGTGGAGC GATTGTTTTT CGTTGAACAC
701 GAAGTCGAAC GCGATGAGTG GATCAGTGCC ATCCAAATGG TCGCCAACCG ACTTCGCTCT GAAAATGAGG
771 CACCCACAAG CGTTTTCAAA GTCGATTTCG CTGAAGACGT CGTCATTGAT TTTCCTCAGA GGCCACCTAA
841 GCGTTACTCC ACTGATGACT TTGAGCTTTT AAAGGTGCTT GGCAAAGGAA CTTTTGGCAA AGTTGTTCTT
911 TGCAAAGAAA AGGAGTCCGG CTGCTTCTAC GCTATGAAAA TCCTTAAGAA GACCGTTCTA ATTGAGAAAG
981 AGGAGGTCGG TCACACACAG ACAGAACATC GGGTGCTGCA ACTCAATCAC CATCCCTTCA TGACGCAGTT
1051 GAAGTACTCC TTCACCACAC GGGACCATAT CTTCTTCGTT ATGGAGTACT GTAATGGCGG TGAACTCTTC
1121 TACCACCTCT CGCGAGAGCA TGTCTTCTCC GAGTCGCGGA CACAATTCTA CGCCGCCGAA ATCACATCTG
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1191 CTCTTGGATA CCTACATAGT CAGAACATCG TCTATAGAGA CCTGAAATTG GAGAACTTGT TGCTGGATAA
1261 GGATGGTCAT ATCAAGATAA CCGACTTCGG GCTGTGCAAG GAGGACATAG GCTTCGGCTC GACTACAAAG
1331 ACCTTCTGCG GCACGCCTGA GTACTTGGCG CCGGAGCTGC TCCTGGACAA TGATTACGGA CTCTCCGTGG
1401 ATTGGTGGAG TCTAGGCGTC GTCATGTACG AAATGATGTG CGGTCGACTG CCTTTCTACT CCAACGAACA
1471 CGAAATCCTC TTTGAACTCA TCCTCCAGGA GAGCGTAAAG GTGCCGGACA ACCTAAGTCC CGTGGCACGT
1541 GACATTCTAA TCCGCCTCCT CATGAAGGAT CCAGCCGAAC GACTTGGTGG GGGCAAGGCG GACGCCATTG
1611 AAGTCATGGT GCACCCCTTC TTCGAGTCTA TCTCCTGGGA TAAACTGATC CGCAAGGACA TCATACCGCC
1681 GTGGAAGCCG GATGTGAACG GTGACATGGA TACCAAATAC ATTCCCGAGG AGTTCCAGAG GGAGAACGTG
1751 GCAGTTACGC CACCGGAGAA GAGCGTCGCT TCAGCTATCA TGGCAGCCGA CAGAGTCTCA GTCGTCAAAG
1821 TGTTCTCAGC TTCGGAGACA ATGGCTCTAT ACCTGAAGGC GCCCTTCCCA ACTGACTCTC CCACTCTCTC
1891 CTCTGCAAAG GCGCAAAGTT TGACTGTTTA TATCAGGGGG ACTTTTGGAG GCTCCTTCCC GGTGGACGTG
1961 ATCACAGTTC GTCGCATTCA ACCAAATTCC CCTTCTCTCC GTCGTATATT CGGACATGCT TATTTTTCTC
2031 CCCGCGGTCA ACTGTTTGAC TCGTGCCTGC GTGTCTCATT CGTGGAAATC ATGGTCATCT CGCACTGTGT
2101 ATCTCTCTGT CTCTTCATTT CGCTCTCCAT CCCTGCGACG TGGCATTTCT CTTGTACCAT TGCTGACGCG
2171 GTTGTTCGCC CTCTGCTTTC TTCACTACCA CTTTGGGACG TTTAAATCTC AGTCCCGAGT TGTTTTGGCA
2241 ATACTGATAT TGCTAATAAA GAACATATAT ATACTGCTGT AAAAAAAAAA AAAAAAAA
Putative amino acid sequence of EmAkt
1 MQVDESLNCS TPMGTLTPTS APMAVDPLSS FVQFQSASMS QIPCNTPQFS NPSTVSSLVP GAGTPCAGLS
71 QEHFVPHAPV SMPHLTGGLP GSTDLLGHQQ ALAINPTSLM QYFRIRTLPL TRKVIREGWL MKRGEHIKTW
141 RRRYFILRED GTFYGYKNIP RDNLEQPLNN FTVRDCQIIC LNKPKPYTIL MRGLQWTTVV ERLFFVEHEV
211 ERDEWISAIQ MVANRLRSEN EAPTSVFKVD FAEDVVIDFP QRPPKRYSTD DFELLKVLGK GTFGKVVLCK
281 EKESGCFYAM KILKKTVLIE KEEVGHTQTE HRVLQLNHHP FMTQLKYSFT TRDHIFFVME YCNGGELFYH
351 LSREHVFSES RTQFYAAEIT SALGYLHSQN IVYRDLKLEN LLLDKDGHIK ITDFGLCKED IGFGSTTKTF
421 CGTPEYLAPE LLLDNDYGLS VDWWSLGVVM YEMMCGRLPF YSNEHEILFE LILQESVKVP DNLSPVARDI
491 LIRLLMKDPA ERLGGGKADA IEVMVHPFFE SISWDKLIRK DIIPPWKPDV NGDMDTKYIP EEFQRENVAV
561 TPPEKSVASA IMAADRVSVV KVFSASETMA LYLKAPFPTD SPTLSSAKAQ SLTVYIRGTF GGSFPVDVIT
631 VRRIQPNSPS LRRIFGHAYF SPRGQLFDSC LRVSFVEIMV ISHCVSLCLF ISLSIPATWH FSCTIADAVV
701 RPLLSSLPLW DV
EmILP1a
Full length cDNA sequence of emilp1a
1 AATTAGTCAG CAGTGAGTGG TCTGGTGGAG ACCCCGCTCA GACACCGTCG CTTGCAAAGT CCTATGTGCG
71 AAAGGGGTTT CACCTGTTCT CCTTCTTCTT CTTCACTCCT CTTCAGCCCT TTTGAGATGG ATAAACGCAA
141 CAATTTCTCC GATCCACGAC GAATCATGTG CGGCTATCAG TTGATCGTCA ACCTCAAAAT GCAGTGCGGA
211 GATAGAGGGA CGTATTCGCC CTACGAACGG GGTCCGCGTA TCAAGCGAGG TCTTCGATTG GGTCGACCAG
281 CTCCGTTATA CAGTCCGTTG AAGAGTCGAG GAAGAAAGCA TGATGATTTT TGCTCCATTT ACCTTCGCTA
351 CGAGCCTTAC ACCATCGTCA CGGAATGCTG CTGTCGTGGC TGTACTCGTC GGTTTTTGGA GCAGTTCTGT
421 GCAAAAGGCT GAACCGATGT CTCGACCTCC TCTTCCACCC TCTCGCCCTC CTCCATCACC TTCTCCTATC
491 ATCAATCTTT ATTTTTGTAA AAGCCGTATT CAGCAACTAT TTTCCTCCCC CCACTCCTTA ATCCATCAGG
561 CATTTGTATA GATCTCGACT GATCCCTTTG TGTAAAAAGC CTTGTCGATT AATTGGCCAA ATTACTCTGC
631 ATTTAAAATT GAATAAATCG ATTAAGATTT GGTGTGGATT TCTACAAAAA AAAAAAAAAA AAAAAAAAAA
701 AAAAAAAAAA AAAAAAAAAA AAAA
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Putative amino acid sequence of EmILP1a
1 MCERGFTCSP SSSSLLFSPF EMDKRNNFSD PRRIMCGYQL IVNLKMQCGD RGTYSPYERG PRIKRGLRLG
71 RPAPLYSPLK SRGRKHDDFC SIYLRYEPYT IVTECCCRGC TRRFLEQFCA KG
EmILP1b
Full length cDNA sequence of emilp1b
1 ACTTGACCGA GGTTCCTGTC TTCGAGAATG CATAGTCCCT TCCACCCATC CGTGGCTGAC CCACCCACCA
71 TCTTTCCCCA TTCGACGGTT ACCACCAACC CCGCTTCCCC GCATCTACTC ATTCTTGCGA TGTTAATGAC
141 CTTTTCACTA GTGAATTCCT CGCCTCTGCC AAGCGATCTC GAGAGCGGTG TGAATTATGT AGACCAGAAA
211 ACAATATTTG TTCCTAGTTT TGAGATGGAT AAACGCAACA ATTTCTCCGA TCCACGACGA ATCATGTGCG
281 GCTATCAGTT GATCGTCAAC CTCAAAATGC AGTGCGGAGA TAGAGGGACG TATTCGCCCT ACGAACGGGG
351 TCCGCGTATC AAGCGAGGTC TTCGATTGGG TCGACCAGCT CCGTTATACA GTCCGTTGAA GAGTCGAGGA
421 AGAAAGCATG ATGATTTTTG CTCCATTTAC CTTCGCTACG AGCCTTACAC CATCGTCACG GAATGCTGCT
491 GTCGTGGCTG TACTCGTCGG TTTTTGGAGC AGTTCTGTGC AAAAGGCTGA ACCGATGTCT CGACCTCCTC
561 TTCCACCCTC TCGCCCTCCT CCATCACCTT CTCCTATCAT CAATCTTTAT TTTTGTAAAA GCCGTATTCA
631 GCAACTATTT TCCTCCCCCC ACTCCTTAAT CCATCAGGCA TTTGTATAGA TCTCGACTGA TCCCTTTGTG
701 TAAAAAGCCT TGTCGATTAA TTGGCCAAAT TACTCTGCAT TTAAAATTGA ATAAATCGAT TAAGATTTGG
771 TGTGGATTTC TACAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AA
Putative amino acid sequence of EmILP1b
1 MHSPFHPSVA DPPTIFPHST VTTNPASPHL LILAMLMTFS LVNSSPLPSD LESGVNYVDQ KTIFVPSFEM
71 DKRNNFSDPR RIMCGYQLIV NLKMQCGDRG TYSPYERGPR IKRGLRLGRP APLYSPLKSR GRKHDDFCSI
141 YLRYEPYTIV TECCCRGCTR RFLEQFCAKG
EmILP2a
Full length cDNA sequence of emilp2a
1 GGTCAAACGT CAACGCCAAC AAGTACAGCA ATGTCTTCCC CAAGTCATTA TATTCCCGTA TTCCTACTAT
71 TAAACATATT TTTTCTCATT TCTGGCGGTT GTGCGGTATC ACCTCTTCAT GACTGGGAGG AGGAAGGCGA
141 CGCTCTATCA GAGGACAGTC TAAGCATGAT GAAACGAGCG AATACTGAAT ACGCAACAAC AGAAGTAGAT
211 CGTCCGCGTA TTCTTTGTGG CCAGTCGCTG ATTCACACCC TAAAGGAGCA GTGTGGACAA CGCGGAACAT
281 TCTCACCCTA CCACAAGCGC GCAGTTCGTG AGCTCATCAG AGTGGCTAGA GGGCTTCCTG TCAAATCCAC
351 TTGCACAAAC GATACGACGA TATCTGTGAA GTGTACTTGC GATACGAACC CGATAGTCCA CTTTCTCAAT
421 GCTGTTGTTT AGGCTGTACA AGAGCCTACT TGGAGAACTT TTGCGCTGAG GCTTAAAAAG TAAAGCAGGC
491 AAGTGGAGAC ATTCCAAATC TCCAATTCTT CCGCTCCCTC CCTACCTCAC CCCACTTTTG TCAGATCTTC
561 TATCCGCGTC GTCGGAAGAT CTGGGTCCTA CATACCACGT GTAAGTTCTC CCCTTCCACT CACCCACTCA
631 CTCAGTCCGT CGCAAGGCAT TCTTTCACCT TAATGTCCTG CCCGTCTCAA TCCCCCTCTG ACTTTGTTCG
701 CGTTCCACAC CTACACACTT TTTCATGCGA AAAGGCTCCT GTTTATAAAG AAGTCAGTGG ATATTGCAAA
771 AAAAAAAAAA AAAAAAAAAA AA
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Putative amino acid sequence of EmILP2a
1 MSSPSHYIPV FLLLNIFFLI SGGCAVSPLH DWEEEGDALS EDSLSMMKRA NTEYATTEVD RPRILCGQSL
71 IHTLKEQCGQ RGTFSPYHKR AVRELIRVAR GLPVKSTCTN DTTISVKCTC DTNPIVHFLN AVV
EmILP2b
Full length cDNA sequence of emilp2b
1 GGTCAAACGT CAACGCCAAC AAGTACAGCA ATGTCTTCCC CAAGTCATTA TATTCCCGTA TTCCTACTAT
71 TAAACATATT TTTTCTCATT TCTGGCGGTT GTGCGGTATC ACCTCTTCAT GACTGGGAGG AGGAAGGCGA
141 CGCTCTATCA GAGGACAGTC TAAGCATGAT GAAACGAGCG AATACTGAAT ACGCAACAAC AGAAGTAGAT
211 CGTCCGCGTA TTCTTTGTGG CCAGTCGCTG ATTCACACCC TAAAGGAGCA GTGTGGACAA CGCGGAACAT
281 TCTCACCCTA CCACAAGCGC GCAGTTCGTG AGCTCATCAG AGTGGCTAGA GGGCTTCCTG ACATATCAGA
351 TTTTGTTGAT AGTCAAATCC ACTTGCACAA ACGATACGAC GATATCTGTG AAGTGTACTT GCGATACGAA
421 CCCGATAGTC CACTTTCTCA ATGCTGTTGT TTAGGCTGTA CAAGAGCCTA CTTGGAGAAC TTTTGCGCTG
491 AGGCTTAAAA AGTAAAGCAG GCAAGTGGAG ACATTCCAAA TCTCCAATTC TTCCGCTCCC TCCCTACCTC
561 ACCCCACTTT TGTCAGATCT TCTATCCGCG TCGTCGGAAG ATCTGGGTCC TACATACCAC GTGTAAGTTC
631 TCCCCTTCCA CTCACCCACT CACTCAGTCC GTCGCAAGGC ATTCTTTCAC CTTAATGTCC TGCCCGTCTC
701 AATCCCCCTC TGACTTTGTT CGCGTTCCAC ACCTACACAC TTTTTCATGC GAAAAGGCTC CTGTTTATAA
771 AGAAGTCAGT GGATATTGCA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA
Putative amino acid sequence of EmILP2b
1 MSSPSHYIPV FLLLNIFFLI SGGCAVSPLH DWEEEGDALS EDSLSMMKRA NTEYATTEVD RPRILCGQSL
71 IHTLKEQCGQ RGTFSPYHKR AVRELIRVAR GLPDISDFVD SQIHLHKRYD DICEVYLRYE PDSPLSQCCC
141 LGCTRAYLEN FCAEA
EmPI3K
Full length cDNA sequence of empi3k
1 GCCTGATTGG TCGCAGTTCA TGCCAGGTTT CCTGTCCTTA TTGCATGATG CCTAGTCCCA GTATTTATTT
71 TCGACGGGAT TTATTTACCA TATTTTTTAC TTGTTCACTG ATTATGTACA TCTCTGCGTG CCTATCCTTA
141 CCTCATTCCT TCATTCTATG TTGAAAATTA GGTTAAAGAC ATATCAATGT CGTTATTGTA ATTTCTTGTT
211 AAAGTAGCGT AAATTCATGG GAAATTCATA TGACATTAGT GTCCTGCGTT GAAGTGTGTA TGGCTTGCTA
281 AATAGTGTGA AATTGGTGCT GGAGTATTCC ATTAATAATT TCGCTCCTAT AGCGGGTCTC CCGTTTTCGA
351 TTTAGTTCTT CCCGCCTTTT TCTGTACCGA TTTGCGCATT AGGCGTTTAT CGCAGTCACA CAGCTTCCAT
421 TTATAATGCT AATATAAGTC AATTTTGGGT AATAATGAAC AGGTGCAAAT AATAATCCAT GTTTAATTCC
491 TTGTTTAGTA ATGCCAGGAT GCCTCCAACC ACATTGGAGA GTTCGGACCA CATGTTCCAA CATTGCTCGT
561 CGATGAAACA TGACTTTTTA ATGCCTAACG GTATTGTCCT AACCTTGAAG CCCGACCCGG ATATTAGTTT
631 GGCGGATCTG AAGGCTCACC TCTGGGATTT GGCTTCTGCC GAACCCCTTT ACGAATGTCT GGGTCCTCCA
701 AATGACTACC TCTTCCAGGG TATTTCATCA CCCAAGGCTG AGGAGGAGGA ATTTTACGAT GAGCAATGCA
771 AATTTGCTGG TCTTCAGCTT TTCCTTCCTT TCATGCGTCT GGAAAAAGTT TCCGACGACG CTCAGATAAT
841 TGAGCAGAAG CGCAATGCCA TGATTGCCAA AATATCCACC ATATCTCAGG CTCACCTCAA GGCAGCAGAA
911 GGGGGCAACC CAGAGCTAGC TTGGGCTCGC CAGTGCCTCC TCGAGATGTC TGAAGCCAAT ATGAGGCGTC
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981 TGGAGGCAGG AGGGCCCGTT TCCATGGCGC ATTACCTCAC AGCCGCTTCA CTTCAACCGA AGCTGAATAC
1051 AGCACTGCAG CGACGTCTGC AACGCCTACC TTACCTTACC ATCTCGGCAG TTTGTGTAGA CTGCTACAGT
1121 CCGCCAACCC AGCACCTCCT CAAACTGAAT CTTCCTAAGT CAATCACTGT GGCGGCGGCG ATTAAGGAGA
1191 TCATTGATGA GCAGAGGCGA CTTGTGCAGG GTGATGTTAG TTGCCATGAT GTGGATCCAG CCCCTCAGTA
1261 CCTTCTCAAA GTGTGTTGTT CTCAAGAGTA TTTATTTGAA CAAGAGAGTG CACTGGTCCA CTACGCTTAC
1331 GTACAGGAGT GTCTTCAACG CGACGACATT CCACGCCTCA CTCCAGTCCT TCTCAAAGAT GTCCTAGAAT
1401 GCCTCGGCTT GCCAGTGCCG GAGGTGGTAA ACTGTGAGGG TTGCACACCA GCATACCCCT CCCCTGCAGT
1471 CGTCTCTAAC GCCGCTCCCC TCCCTTCTGT TATCGATCTC TACGGGGTGA AGGAAGAGGA TGAGGATGAA
1541 GGCGATGAGG CGATGGAGGC AAGCGTAGAT TTGTGGGACT TACGGGACTA CTTCTCTCTT ACTGTCCGCG
1611 CTGCTCAAAA ACTCACCACC CTGACGCAAA ATCCCTCAAC GGAGCAATTG GATACCGGTT TATTCTTCAC
1681 AGGCTCCTCT AGTTTCAGTG ATCTCACCAC GGATGTGACG TCATCGCTGG GTGGCAGTGA GAGTAGCGGC
1751 AGTGGCGGGG GGGGAGGAGC GTCAGCCTCC ACCACCCCAC TATCGGCTTC GTCGGCCTCA AGTCTTGATG
1821 CCTCATCGGG TAGTGTGGTG AACTACATTG TTCGAGTGGG ATTGGCTCAT GGTGGACAAC TGCTTGCGAA
1891 GTACCAGAAC ACACGAGGTG CAATAATCGT AATGGGTGGC AATTCGGCCC TTCAATGGAA CCAATCACTT
1961 AACTTTCGCC TAATCTACTC CAACCTGCCA CTCGCCACCA GGGTCTGTGT TGTCTTACTC CAAGTGAAAC
2031 GACGTCCTGG CCGAATCATG GAGTTCCCGG TAGGCTGGGC GAATATGAAC CTCTTTGATG AGAGGGGCTA
2101 CCTTGTTACG GGTCGCCGCT CTCTTCCCCT GTGGCGCAGC AGCTTCACCT CACCAGAAAC TGAAACCACC
2171 CACCAACTCA ATCTCGCCGG CACTGTGGCC GAGAATCCCG ATCCCGAGTT CACTCTTGTG CTGAATTTCT
2241 GTCATCCTAG CAACCAAAAG GCCCGTATCC GCTTTCCTAT CTCCCGTTTC ATCACCACCG TGCGCGGCGC
2311 CTCCCCTAAT ACGCCCACTG CTACCATCGT CCCTTCGCTC CATTCCAGCG ACTCCGACAT CCGTGTGATC
2381 CGTGATCTCA TACACCGGGA CCCCTTCTAC GAGTTATCAG AGCAGGACAA GGCTCTTCTC TGGCGCATCC
2451 GCGACTCATG CTGCCGTAGA CTTTACCCTG CTGAATCGTT GCCTTGGCTT GTGCAGGCTG TGGCCTGGGA
2521 AAGACGCGAG TTGGTGGAGG AGTTCTACCG CCTCCTTGCT GTTTGGCCAC GACCCCTACC CGTGGAAACC
2591 TGTCTCCAAC TCCTGGGTGT GGCAGGCCTT GCTGGTTCCG CTGCCGCCGA AGGGACGTTT GGAGAGGGTG
2661 GTGGGGGCAG TTATGTGATG GCCGGGGGGC GCACGACCGG TGTAGCGGAC CCTCTGGTTC GCGATATTGC
2731 GGTGCAAGGG CTGCAGGCGA GACTTTCAAA TGCGGATCTA GCTGACTATT TGCTTCAACT GGTACAGGTG
2801 GTACGAACCG AAGCCTTCTT GGTAAACCCA CTGACCTGTT TCCTTCTTCA ACGAGCCCTC GACTGTCCCA
2871 CACTGATCGG GGTTCGGTTG TGCTGGCATC TGCGCTCCCA ACTAGACAAT CCGGATGCCC GCCTTCGTTT
2941 TGGTCTGATT CTGGACGCCC TCTGTCGCGG TTTTGGACCT CGGCTCCTAC TCTTCGTCCA TGAACAAGTC
3011 AATGCACTTC ATCGACTTAC GGATCTTGCC ATCTCTGTCA AGCGTATCGC AGAGGATGAG GAACAGCGAG
3081 CCCGGTTCAA GTTTGAGCTA CATCGCAGTG AAGTTCGACG CGATCTTGAG GGCATCCTCT CCCCCTTACG
3151 TTTCTCTATC AAACTCGGTC CAGTGGTAGA ACAGCAATGT ACCGTGAAAC GCTCTAAAAA GCGTCCTCTT
3221 TGGATAGTCT GGGCCAATCC AGACAATCTC GGATTTCACC ACCACAAAAT TCATCAACTC CTCTTCAAGC
3291 ACGGTGATGA TCTGCGGCAG GATATGCTCA CTCTCCAGAT CCTCAAAGTG ATGGATCACA TCTGGAAGGA
3361 CGAGGGACTC AATCTCGATC TCACCACCTA CGACTGCCTT GCCACAGGCG ACGAGATGGG CCTGATTGAG
3431 GTGGTGCGCA ACTCTCAGAC CATCATGTCC ATTCAGGGAC AGCGAGTGCG CTCTGCAATG CAGATTGACT
3501 CCTCCCAACT ACATAAGTGG TTTTTGCAGA AGAAGGCTCC TCCACTGGGC TCGGAGGAGG CCTATGAGTC
3571 GGCCATCCGG CGGTTCACGA ACAGCTGCGC AGGCTACTGT GTGGCTACCT TTGTGTTAGG TATTCGCGAC
3641 CGGCACAATG ACAACATTAT GGTGGATGAT TCGGGTCGTC TATTTCATAT TGATTTTGGC CACATTCTAA
3711 ATAACAAGAA GAAGAAGTTT GGCATCACGA GAGAACGTGT GCCGTTCGTG CTGACAAGTG ACTTTGCCTG
3781 TGTGATCGCT CGAGGGGAAG AGAAGCCCTA CCGAAGCAAG GGGTTCATGG ATTTTACACG GCTGTGCGAG
3851 GATGCCTACC GCATTCTGCG ACGGCATTCC AACCTTCTCC TCACCCTTCT CGCCATGATG GTACCCTCCG
3921 GTCTGCCCGA ACTCACTTGC GCCAGCGATC TGGAATACGT GCGCAAGACC CTGGCTGTGG AGCTGCGTGA
3991 CGAGGAGGAG GCGCTAAACT ACTTCAACGC CAAGTTTAAT GAGGCCTACA ATGGTGCGTG GACTACGAAA
4061 ATCGATTGGT TCGCCCACTG GGTCCGCCGA TGATCAACAG AGTACCGACA GAGAGACCTG CACTTTTATT
4131 TACTCTATAT GTGATAATAC
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Putative amino acid sequence of EmPI3K
1 MPPTTLESSD HMFQHCSSMK HDFLMPNGIV LTLKPDPDIS LADLKAHLWD LASAEPLYEC LGPPNDYLFQ
71 GISSPKAEEE EFYDEQCKFA GLQLFLPFMR LEKVSDDAQI IEQKRNAMIA KISTISQAHL KAAEGGNPEL
141 AWARQCLLEM SEANMRRLEA GGPVSMAHYL TAASLQPKLN TALQRRLQRL PYLTISAVCV DCYSPPTQHL
211 LKLNLPKSIT VAAAIKEIID EQRRLVQGDV SCHDVDPAPQ YLLKVCCSQE YLFEQESALV HYAYVQECLQ
281 RDDIPRLTPV LLKDVLECLG LPVPEVVNCE GCTPAYPSPA VVSNAAPLPS VIDLYGVKEE DEDEGDEAME
351 ASVDLWDLRD YFSLTVRAAQ KLTTLTQNPS TEQLDTGLFF TGSSSFSDLT TDVTSSLGGS ESSGSGGGGG
421 ASASTTPLSA SSASSLDASS GSVVNYIVRV GLAHGGQLLA KYQNTRGAII VMGGNSALQW NQSLNFRLIY
491 SNLPLATRVC VVLLQVKRRP GRIMEFPVGW ANMNLFDERG YLVTGRRSLP LWRSSFTSPE TETTHQLNLA
561 GTVAENPDPE FTLVLNFCHP SNQKARIRFP ISRFITTVRG ASPNTPTATI VPSLHSSDSD IRVIRDLIHR
631 DPFYELSEQD KALLWRIRDS CCRRLYPAES LPWLVQAVAW ERRELVEEFY RLLAVWPRPL PVETCLQLLG
701 VAGLAGSAAA EGTFGEGGGG SYVMAGGRTT GVADPLVRDI AVQGLQARLS NADLADYLLQ LVQVVRTEAF
771 LVNPLTCFLL QRALDCPTLI GVRLCWHLRS QLDNPDARLR FGLILDALCR GFGPRLLLFV HEQVNALHRL
841 TDLAISVKRI AEDEEQRARF KFELHRSEVR RDLEGILSPL RFSIKLGPVV EQQCTVKRSK KRPLWIVWAN
911 PDNLGFHHHK IHQLLFKHGD DLRQDMLTLQ ILKVMDHIWK DEGLNLDLTT YDCLATGDEM GLIEVVRNSQ
981 TIMSIQGQRV RSAMQIDSSQ LHKWFLQKKA PPLGSEEAYE SAIRRFTNSC AGYCVATFVL GIRDRHNDNI
1051 MVDDSGRLFH IDFGHILNNK KKKFGITRER VPFVLTSDFA CVIARGEEKP YRSKGFMDFT RLCEDAYRIL
1121 RRHSNLLLTL LAMMVPSGLP ELTCASDLEY VRKTLAVELR DEEEALNYFN AKFNEAYNGA WTTKIDWFAH
1191 WVRR
EmTK6
Full length cDNA sequence of emtk6
1 CCCAGCCATT CATGCTTTCA TGAACTCAAA GTTGCACAAT GGGGAATTGT TTTACTTGCC ACGACCACAA
71 AGAAAATCTT CAGTGCCATG GAGACAATGG CATGACGCCG ATGGGTGCAA ATTCCCAAGG GGGTGGCCAG
141 GGACTAGGGC AAGCCCCATT CGGTCGTCAC TATGGTCCTT CAGGTGACGC TGCATCGGTC GGTGCCAATC
211 AGTCCGCCAT TGTGCCTGCT TCGCGTGGTG CACATCAACC CTCCCAACAG TACTCCGTGA ATCTTTACGG
281 CATGCAGAAT GGACCACAAC AGAGTGCATC CTACGCCTAC AGTCTCGCCC AACCTCCCGC GACTCTTGAC
351 CAGCAGCTGG CAGAGCAGTC ACCTCGAGTT GTCCGTGTTC ACGCTTTATA CACTTACGTT GCGCAAAACG
421 CTGATGATCT GAGCTTCCAG AAGGGTGATG TCATGCTAGT CGAGTCGGGC TTATCCGAAG CCTGGTGGTT
491 GGCGCGTCAC TTGAGGACCG GGCAACAGGG CTACATACCC AGTAACTATG TGACTGTAGA AAATGGTCTC
561 TCTACACAAA TGGAAGCCTG GTATGACATT ACACGTAAAG ATGCCGAGAG AATGCTTTTG ATGCCCGGGT
631 TGCCTCAAGG GACTTACATT TTACGCCCCT GTTCCGATTC CCGAAGTTAT GCTCTCTCCA TCCGGTTCGA
701 AATTGAGAGG AATATGTATG CAATAAAGCA CTACAAGATC CGAACTCGCG ATAACGGTGC CGGCTTCTAC
771 ATCACCAATC GAACCAACTT TGCTTCTGTC GCCGATCTCA TCTCTCACTA TCAGTCCACT AGCGATGGGC
841 TGTGCTGTCG CCTATCGCAG CCGTGTCCGC GGAAGTATAC CCCGCCGGTG CAGTTCCGTG ACATCGAGGC
911 AAATCGGCGG AGCCTGGAAT TCATCTGCGA GCTAGGCAAC GGCAGCTTCG GCATGGTTTA CCGGGCTCGG
981 TGGAACAAGA CCTTCGACGT GGCGGTGAAG AAGCGCCTCG CTACCACGGA CCGCGCACTT TTCATTGAGG
1051 AAGCGAAAGT GATGCACAAA TTGCATCACC GCCGTATCGT TCGCCTCCTC GGTGTCTGCA CCGAGCCGGC
1121 TGATGAGCCT GTTTTCATCA TCACAGAGTT GCTAGAGAAG GGTGCTCTGC GCAACTTCCT CAGCAGCGAA
1191 GAGGGCCGCC AACTCTTCCT CAGTGACCTT ATCGATATGA TTGCTCAGAT TGCCGAAGGA ATGGCATACC
1261 TGGAGGAGAT GAATTTCGTC CACCGAGACC TTCGAGCCGC CAACATCCTT GTGGATCGCG ACAACTCCGT
1331 CAAGGTAGCT GATTTCGGAC TTGCAAAAAT GCTTGATTCG GATGTTCAAA ATGATGGCGT CATTAAATTC
1401 CCCATCAAGT GGACCGCGCC AGAGGCGGCT CTTCCCGACC ACCATTTCAG TATAAAGTCG GACGTCTGGT
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1471 CCTTCGGTGT GCTCATGTAC GAAATCGTCA CTTACGGTGG CACTCCCTAC CCCCGCTTCA CTAATCGGGA
1541 GACGGTACAG CAGGTAGAGC GCGGCTATCG AATGCCAAAT CCGAATACAC CGACACAGCC GTGTCCGGAC
1611 GACCTCTACG ACATCATGAT GCAGTGTTGG TCAGCACGAC CCGAGGATCG ACCTACCTTC CACAACCTCT
1681 ACGACATCTT TGAGAACTGG GCCGTCCAGA CGGAGGGTCA GTACATCTCG GATGGAGCGC AAAACACTTG
1751 AATCAGTCAC CGCAGCCGCC GCCACCTCTA CAAAGACCGC GTGTGATTGT CGTTTATCCA TCCACCCGAT
1821 CTCTCCGCGC TGCATTTGAC TTCATCAATT CAATCCACCC TATCCCCTTT CCCTCCTCTC AACTGACTCC
1891 TTCATGTCGA TTTTTTGACG CCTTGGCTTT CTCTTCTCTC GTGTTCTTTT GCTAAGATTA ACACCGTCCC
1961 AATAAGACTC GTGGCTTGCA ATGGCTGCAG GGAACGGGAA TTCGTTTTTC GAAAGTGGAA TCTGGCAGTG
2031 GTTTTAGATG TCAAGTCCTG GGCGGGGAAG CTCGACGAAG ATGGGCTCAG GGGCTTACAT GGCATGCCCG
2101 TTTGTTGAGT CTCACTTTAT TCTGTTTTTC TTTTTTTTTC GTCCTGGTTT GTCTTCATTC TATTTTGCTG
2171 GAATTAAAAA AAAAAAAAAA AAAA
Putative amino acid sequence of EmTK6
1 MGNCFTCHDH KENLQCHGDN GMTPMGANSQ GGGQGLGQAP FGRHYGPSGD AASVGANQSA IVPASRGAHQ
71 PSQQYSVNLY GMQNGPQQSA SYAYSLAQPP ATLDQQLAEQ SPRVVRVHAL YTYVAQNADD LSFQKGDVML
141 VESGLSEAWW LARHLRTGQQ GYIPSNYVTV ENGLSTQMEA WYDITRKDAE RMLLMPGLPQ GTYILRPCSD
211 SRSYALSIRF EIERNMYAIK HYKIRTRDNG AGFYITNRTN FASVADLISH YQSTSDGLCC RLSQPCPRKY
281 TPPVQFRDIE ANRRSLEFIC ELGNGSFGMV YRARWNKTFD VAVKKRLATT DRALFIEEAK VMHKLHHRRI
351 VRLLGVCTEP ADEPVFIITE LLEKGALRNF LSSEEGRQLF LSDLIDMIAQ IAEGMAYLEE MNFVHRDLRA
421 ANILVDRDNS VKVADFGLAK MLDSDVQNDG VIKFPIKWTA PEAALPDHHF SIKSDVWSFG VLMYEIVTYG
491 GTPYPRFTNR ETVQQVERGY RMPNPNTPTQ PCPDDLYDIM MQCWSARPED RPTFHNLYDI FENWAVQTEG
561 QYISDGAQNT
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B List of Abbreviations
B List of Abbreviations
4E-BP Eukaryotic translation initiation factor 4E binding protein
aa Amino acids
ABZ Albendazole
AD Gal4 activation domain
AE Alveolar Echinococcosis
AS AS601245
BD Gal4 binding domain
bp Base pairs
C. elegans Caenorhabditis elegans
CML chronic myelogenous leukemia
Ctrl Control
D. melanogaster Drosophila melanogster
EmIR Echinococcus multilocularis insulin-like receptor
HE haematoxylin/ eosin staining
E. multilocularis Echinococcus multilocularis
H microstoma Hymenolepis microstoma
HMN HNMPA(AM)3
IGF Insulin like growth factor
Ins Insulin
ILP Insulin-like peptide
K11 K11777
LBD Ligand binding domain
LY Ly294002
Mc Metacestode vesicles
MAP Mitogen-activated protein
MAPK mitogen activated protein kinase
M. vogae Mesocestoides vogae
Na3VO4 Sodium orthovanadate
nt Nucleotides
ORF Open reading frame
Pc Primary cells
PI3K Phosphoinositide-3-kinase
PDGFR Platelet-derived growth factor receptor
PS+ Activated protoscoleces
Ps- Nonactivated protoscoleces
S. japonicum Schistosoma japonicum
S. mansoni Schistosoma mansoni
T. crassiceps Taenia crassiceps
T. solium Taenia solium
Y2H Yeast two hybrid
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